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ABSTRACT 
 Approximately one-third of the world’s population is currently infected with 
Mycobacterium tuberculosis (Mtb), the bacillus that causes tuberculosis. Globally, it is 
the second leading cause of death by a single infectious agent. An effective vaccine is 
needed to stop this ongoing pandemic, but efforts to design one are hampered by our 
limited understanding of host immunity to this pathogen.   
CD8+ T cells are elicited during tuberculosis and are required for optimum host 
resistance. They produce cytokines such as IFN-γ and can directly lyse infected cells. 
During infection, the expansion and differentiation of effector CD8+ T cells is a 
dynamically regulated process that is influenced by the inflammatory milieu of the 
infected host. Currently, the signals governing CD8+ T cell responses during 
tuberculosis are not well characterized. 
Utilizing a mouse model of disease, we address the effects of key cytokines on 
CD8+ T cells, beginning with IL-12, type 1 interferons (IFN), and IL-27. All three of these 
cytokines are produced by innate immune cells during tuberculosis and have profound 
effects on host resistance. IL-12 proves most essential for robust CD8+ T cell expansion 
and IFN-γ production and also drives the terminal differentiation of short-lived effector 
cells. However, IL-12 is not acting alone, and type 1 IFN and IL-27 each have non-
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redundant roles supporting expansion in infected lungs. Thus, CD8+ T cells reflect the 
inflammatory environment of the host, responding in different degrees to each cytokine 
present. 
We next examine the role of IL-21, a cytokine produced by activated CD4+ T 
cells. In the absence of IL-21 signaling, CD8+ T cell expansion and effector functions 
are severely compromised. IL-21 is also essential to prevent CD8+ T cell exhaustion at 
later time points during disease. These observations are the first to describe an 
essential role for IL-21 in the host immune response to Mtb.  
Together, these studies establish IL-12 and IL-21 as essential regulators of CD8+ 
T cells during tuberculosis, and indicate type 1 IFN and IL-27 support expansion in the 
lungs. We believe these observations have implications for future immunotherapies and 
rational vaccine design. 
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Introductory note 
 The work presented here centers on understanding the regulation of CD8+ T cells 
during infection with Mycobacterium tuberculosis (Mtb). Chapter 1 contains an overview 
of the pathogenesis of Mtb and focuses on the events leading up to the priming of the 
adaptive immune response. The roles of both CD4+ and CD8+ T cells are reviewed and 
several gaps in our understanding of adaptive immunity during tuberculosis are 
highlighted. The chapter concludes by raising several key questions regarding the 
regulation of CD8+ T cells in response to Mtb.  
 Chapter 2 addresses the impact of IL-12, type 1 interferons (IFN), and IL-27 on 
the CD8+ T cell response. These cytokines were chosen for two important reasons. 
First, they differentially regulate susceptibility to tuberculosis. Second, they profoundly 
influence CD8+ T cell responses in other infections. This chapter begins with a literature 
review detailing how these cytokines influence host resistance to Mtb and discusses the 
effects they have on CD8+ T cells in other contexts. The results and implication of our 
studies in tuberculosis are then presented.  
 Chapter 3 starts with a review of the biology of IL-21, a relatively new cytokine 
that is essential for CD8+ T cell responses during chronic viral infections. Currently, the 
role of IL-21 signaling during tuberculosis is relatively unexplored. Data are presented 
detailing the effects of IL-21 on the CD8+ T cell response during tuberculosis, and 
preliminary results are presented that indicate IL-21 is a major mediator of susceptibility. 
Chapter 4 briefly summarizes the findings presented in chapters 2 and 3, and 
discusses some of the implications of this work. 
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 Appendix 1 contains work that indicates cyclooxygenase-2 (COX-2) affects 
resistance to tuberculosis. Though not directly related to CD8+ T cell biology, the data 
provide insight into the role of eicosanoids in the host response to Mtb. The appendix 
begins with a review of our current understanding of these vital signaling molecules and 
their roles in tuberculosis. The experiments presented indicate that COX-2 is required 
for host resistance and highlight a role for nonhematopoietic cells in limiting pathology. 
 
Chapter 1: 
 
 
Introduction 
 
 
 
*Portions of the text were adapted from the author’s own writing published in: 
 
Behar SM, Carpenter SM, Booty MG, Barber DL, Jayaraman P. 
Orchestration of pulmonary T cell immunity during Mycobacterium tuberculosis 
infection: immunity interruptus. Seminars in Immunology 2014;26:559–77. 
 
Nunes-Alves C, Booty MG, Carpenter SM, Jayaraman P, Rothchild AC, Behar SM. 
In search of a new paradigm for protective immunity to TB. Nature Reviews 
Microbiology 2014;12:289–99. 
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Tuberculosis, a continued global health burden 
An estimated 9 million new cases of tuberculosis occurred worldwide in 2013 
along with 1.5 million deaths (1). Currently, nearly one-third of the world’s population is 
infected with Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis, 
with roughly 1 in 10 infected individuals developing active disease in their lifetime (2). 
The majority of infected individuals remain in a state of clinically asymptomatic latent 
tuberculosis (3), suggesting the immune system is capable of controlling, but not 
sterilizing the infection. Since 1990, TB mortality rates fell by an estimated 45%, 
indicating public health efforts are making substantial progress (1); however, the impact 
of tuberculosis is compounded by the AIDS epidemic and the continued spread of drug-
resistant strains of Mtb. In 2013 alone, an estimated 480,000 people developed multi-
drug resistant tuberculosis (MDR-TB) and 9% of those patients had extensively drug 
resistant tuberculosis (XDR-TB) (1). Current treatment regimens take several months to 
complete, thus an effective vaccine would greatly accelerate the control of tuberculosis 
and break the cycle of transmission (4). Bacillus Calmette-Guérin (BCG) was introduced 
as a vaccine almost a century ago, but it’s efficacy against pulmonary tuberculosis is 
highly variable between different populations (5). There are now over a dozen candidate 
vaccines being tested in clinical trials; however, many preliminary results have been 
disappointing (4,6-8). There are still large gaps in our understanding of the host’s 
response to tuberculosis, and we lack reliable correlates of protective immunity. Thus, a 
better understanding of the host’s immune response will be essential to designing a 
successful vaccine.  
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The intracellular pathogenesis of Mtb 
 Mtb is a facultative intracellular pathogen that primarily resides in macrophages 
and other phagocytes, where it is able to survive and replicate despite the hostile 
conditions within these cells. Mtb enters the host’s airways via aerosolized droplets and 
is subsequently phagocytosed by alveolar macrophages. Phagocytosis of Mtb is 
triggered through a number of mechanisms, including engagement of pattern 
recognition receptors (PRRs), C-type lectin receptors, complement receptors (CRs), 
and Fcγ receptors (FcγRs) (9-11). Recent data suggests Mtb masks its surface 
pathogen-associated molecular patterns (PAMPs) with lipids, specifically pthiocerol 
dimycoceroserate (PDIM), in an effort to avoid recruiting highly microbicidal 
macrophages (12,13).  
Once inside the cell, Mtb is capable of blocking phagosome maturation as a 
means of preventing it’s own destruction (14). Phagosome arrest is also postulated to 
facilitate the evasion of the adaptive immune response by limiting the presentation of 
antigens on major histocompatibility complex (MHC) class II (15,16). Numerous 
mycobacterial lipids and proteins are implicated in preventing the acquisition of late 
endosomal/lysosomal markers as well as blocking the acidification of the phagosome 
(17). Mycobacteria are thought to replicate within the immature phagosome and are 
hypothesized to obtain nutrients through interactions with early endosomes (18,19). 
Stimulation with interferon gamma (IFN-γ) enhances the killing of mycobacteria, in part 
by promoting the fusion of the mycobacterial phagosome with late 
endosomes/lysosomes via autophagy (20).   
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Though Mtb is generally thought to reside and replicate within the phagosome, 
several groups have observed bacteria in the cytosol (21-26), and it was suggested that 
Mtb replicates in the cytosol of infected DCs (23). In these systems, escape is only 
observed with virulent strains and is dependent on the “region of difference 1” (RD1) 
locus, a major virulence determinant (27). The RD1 locus encodes a novel secretion 
system, and one of its multiple substrate proteins, ESAT6, can cause membrane 
damage (28,29). Furthermore, the destabilization of phagosomal membranes likely 
facilitates the sensing of mycobacterial components by host cytosolic receptors, 
including nucleotide-binding oligomerization domain (NOD) proteins (10,30). Thus, 
phagosome destabilization and escape have important implications for the host’s 
response to Mtb.  
 
Cell death and immunity to Mtb  
It is becoming increasingly apparent that cell death is a pivotal axis regulating the 
outcome of Mtb infections. Virulent strains of Mtb, including H37Rv, primarily induce 
necrosis in infected macrophages, while H37Ra, an avirulent strain, induces apoptosis 
(31-33). The direct inhibition of apoptosis contributes to virulence, and Mtb actively 
blocks apoptosis through multiple mechanisms (34,35). Infection with avirulent bacteria 
induces the formation of the apoptotic envelope, an insoluble membrane sheath on the 
cell surface (36), and apoptosis limits the spread of bacteria while enhancing bacterial 
killing (37-40). Recently, Martin et al. linked apoptosis to bactericidal activity through a 
mechanism known as efferocytosis (41). In this process, uninfected macrophages 
engulf apoptotic cells containing Mtb and destroy the bacteria through phagolysosome 
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fusion.  Conversely, necrosis is detrimental to the host, as it facilitates the escape of 
Mtb from the infected macrophage and promotes the spread of bacteria into new cells. 
This is corroborated by the identification of the “super-susceptibility to tuberculosis 1” 
(sst1) locus in mice. Mice carrying the susceptible allele at this locus succumb to 
infection earlier due to the increased necrosis of macrophages (42).  
In addition to a role in innate immunity, the modality of cell death directly 
influences the adaptive immune response. Apoptosis of infected macrophages can 
facilitate the priming of CD8+ T cells in a process known as the “Detour Pathway” (43-
45). In this pathway, dendritic cells (DCs) phagocytose apoptotic blebs from infected 
cells and present mycobacterial antigens on CD1 and MHC Class I. The finding that a 
proapoptotic mutant of Mtb more efficiently primes CD8+ T cells in vivo provides clear 
support of this model (46). Additionally, manipulation of the host macrophage to 
preferentially undergo apoptosis accelerates CD8+ T cell priming in vivo (47). Based on 
these observations, the induction of necrosis by virulent Mtb likely delays the adaptive 
immune response by limiting the efficient presentation of MHC Class I and CD1-
restricted antigens.  
 
The initiation of the adaptive immune response 
T cell priming is considerably delayed following infection with Mtb, and there is 
evidence this delay correlates with host susceptibility (48,49). The factors controlling the 
initiation of the adaptive immune response are incompletely understood, but to some 
extent, the host influences the process. For example, resistant C57BL/6 mice prime T 
cells sooner in the lymph node and mount a faster adaptive immune response when 
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compared to more susceptible C3H mice (48). In mouse studies, aerosol infections are 
typically done with few bacteria (<200), thus limited amounts of antigen may also 
influence the generation of the adaptive immune response. However, increasing the 
inoculum size fails to significantly accelerate T cell priming in the lymph node, 
suggesting antigen availability is not the limiting factor (50). As mentioned above, Mtb 
impacts adaptive immunity by inhibiting apoptosis, but it also directly delays priming by 
inhibiting the maturation of infected DCs (51,52).  
Following infection, bacteria must be transferred from the lungs to the draining 
mediastinal lymph to prime naïve T cells (48,53-56), though priming can occur directly in 
the lungs under certain circumstances (57).  The process of dissemination to the lymph 
node takes approximately 9-11 days in the mouse model, and a variety of myeloid cells 
are involved in trafficking the bacteria. CCR2+ monocytes are important for delivering 
Mtb to the lymph node, though these cells still rely on lymph node resident DCs to prime 
T cells (58). Dendritic cells infected in vitro can also carry Mtb to the draining lymph 
node and, once there, are capable of transferring antigen to uninfected resident DCs 
(59). Additionally, neutrophils play a role in facilitating dissemination, as the depletion of 
lung neutrophils further delays the accumulation of Mtb in the lymph node (60). 
Interestingly, enhanced neutrophil apoptosis accelerates the priming of naïve T cells, 
suggesting that the trafficking of bacteria may be initiated when antigen presenting cells 
engulf infected apoptotic neutrophils (61). The transfer of antigen from infected to non-
infected cells is commonly observed in studies of priming, likely because directly 
infected DCs have a diminished ability to prime naïve T cells (52,59). Once bacteria 
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reach the LN, naïve CD4+ and CD8+ T cells begin to expand and subsequently migrate 
to the lung to exert their effector functions. 
Because priming is delayed following aerosol infection, approximately two weeks 
pass before effector T cells begin to accumulate in the lungs. This lag is detrimental to 
the host, as the replication of Mtb is relatively unrestricted during this time. Once 
activated, T cells halt Mtb growth, and bacterial burden switches from increasing 
exponentially to a plateau phase (48,54). In resistant strains of mice, this plateau phase 
is maintained for several months with effector T cells continuing to restrain but not 
reduce bacteria. The requirement for the adaptive immune response to control the 
growth of Mtb is best illustrated in RAG knockout (KO) mice, which lack B and T cells. In 
these mice, Mtb continues to grow exponentially and this plateau phase is never 
reached (62,63). Shortening the time it takes for effector T cells to reach the lung and 
inhibit bacterial growth is a major goal of vaccination. 
 
The role of CD4+ T cells  
 CD4+ T cells are considered the major mediators of protective immunity during 
tuberculosis, and IFN-γ-producing TH1 cells are the most prevalent CD4+ subset (64-
67). Though far less common, TH17 cells and regulatory T cells (Tregs) are also present 
during infection. In particular, TH17 cells have protective effects during the initial 
response to Mtb in the lung but become pathogenic if left unchecked (68-71). Overall, 
the requirement for CD4+ T cells in host protection is most evident in animal models 
where CD4+ T cells can be selectively depleted. In multiple mouse and primate studies, 
the loss of CD4+ T cells dramatically increases bacterial burden and worsens disease 
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(72-76). In humans, HIV induced depletion of CD4+ T cells is one of the greatest risk 
factors for developing active pulmonary tuberculosis (77). 
 During infection, CD4+ T cells are a major source of IFN-γ, and data in both mice 
and humans indicate IFN-γ is essential for protection against Mtb (78-82). Thus, it is 
assumed CD4+ T cells primarily mediate protection through IFN-γ; however, there is 
little direct evidence to support this. A recent study demonstrated that CD4+ T cell-
derived IFN-γ prolongs survival in infected mice, but even IFN-γ-/- CD4+ T confer a level 
of protection (83). Indeed, several studies indicate effector CD4+ T cells can mediate 
protection through IFN-γ-independent mechanisms (83-85). Gallegos and colleagues 
evaluated the cytokines required by CD4+ T cells using transgenic T cells specific for 
the MHC class II-restricted epitope of the Mtb antigen ESAT6. Surprisingly, antigen-
specific CD4+ T cells control bacterial growth even when they lacked IFN-γ, TNF, 
perforin, or FasL (85). Even cells lacking both IFN-γ and TNF reduced bacterial burden. 
It is possible that many of these effector functions are redundant for CD4+ T cell-
mediated protection, but the data suggest additional effector mechanisms exist to 
control bacterial growth. Jayaraman et al. recently identified a novel mechanism in 
which Tim-3, a molecule expressed on the surface of TH1 cells, directly interacts with 
macrophages to promote their activation and stimulate bactericidal activity (86). There 
are likely many effector mechanisms yet to be discovered in T cells.  
In addition to their antimicrobial functions, CD4+ T cells play important roles in 
dampening inflammation and preventing immunopathology. This aspect of the immune 
response is critical during Mtb infection, and a correlation between host susceptibility 
and immunopathology has long been observed. Though IFN-γ is one of the major pro-
	   9	  
inflammatory cytokines produced by both CD4+ and CD8+ T cells, it also serves to limit 
inflammation through multiple distinct mechanisms. IFN-γ inhibits CD4+ T cell 
production of IL-17, a cytokine that drives inflammation in part by regulating the 
recruitment of neutrophils (87). Additionally, IFN-γ directly inhibits the accumulation of 
neutrophils and impairs their survival (84,88). The production of nitric oxide (NO) by the 
inducible form of nitric oxide synthase (iNOS) is one of the main antimicrobial effectors 
stimulated by IFN-γ. In addition to controlling bacterial growth, NO inhibits the assembly 
of the NLRP3 inflammasome and curtails the production of pro-inflammatory IL-1β (89). 
These examples underscore how a single molecule can have pleiotropic effects in the 
course of an infection and illustrate how T cells can simultaneously support bactericidal 
activity while limiting inflammation. 
CD4+ T cells are also key sources of other anti-inflammatory meditators. In 
particular, regulatory T cells (Tregs) are a specially equipped population of cells capable 
of suppressing inflammation and limiting immune responses. Tregs produce the 
immunosuppressive cytokines IL-10 and TGF-β and can further suppress immune 
responses through direct cell-mediated interactions (90). During tuberculosis, Tregs are 
actually associated with limiting protective immunity and increasing bacterial burden 
(91-93). However, Tregs can control local tissue damage in other infections (94), and 
their role in regulating immunopathology during tuberculosis has never been directly 
addressed.  
Both CD4+ and CD8+ T cells are elicited during Mtb infection, and comparatively, 
CD4+ T cells are considered more protective. Mogues et al. performed the clearest 
studies supporting this claim by selectively depleting either CD4+ or CD8+ T cells in 
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thymectomized mice and monitoring survival. Both groups of mice succumb early to 
aerosol infection, but the loss of CD4+ T cells has a far greater impact on survival (95). 
Of note, the greatest reduction in survival was observed when both CD4+ and CD8+ T 
cells were depleted, indicating both cell types are required for optimal resistance. Based 
on these observations, it appears CD4+ T cells have a dominant role during infection; 
however, these data should be interpreted with some caution. During viral infections, 
CD4+ T cells are essential to promote and maintain a robust CD8+ T cell response (96-
103). During tuberculosis, it is known that CD4+ T cells enhance CD8+ T cell IFN-γ 
production and cytolytic activity (83,104,105). Thus, one important CD4+ T cell function 
is to support the CD8+ T cell response. It is undeniable that CD4+ T cells are essential 
for resistance to tuberculosis, but we are only beginning to understand all of the 
mechanisms involved in protection.  
 
 
The role of CD8+ T cells 
 
 
Antigen processing 
 
 CD4+ T cells typically recognize antigens processed by lysosomal proteolysis in 
endocytic and phagocytic pathways and presented by professional antigen presenting 
cells (APCs) (106). In contrast, CD8+ T cells recognize cytosolic antigens that can be 
processed and presented by almost all cell types. In this process, self and foreign 
proteins that enter the cytosol are cleaved by the proteasome into short peptides (8-10 
amino acids) and transported into the endoplasmic reticulum (ER) by the transporter 
associated with antigen processing (TAP). Once in the ER, the peptide assembles with 
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class I MHC heavy chain and β2-microglobulin (β2m) and is transported to the cell 
surface (107). Exogenous antigens obtained by endocytosis and phagocytosis can 
enter the MHC class 1 pathway in a process known as cross-presentation. Initially, the 
impression that CD4+ T cells are more important than CD8+ T cells was reinforced by 
the differences in class I and class II antigen presentation.  Because Mtb was thought to 
reside exclusively in the phagosome, it seemed logical that the MHC class II pathway 
would be the dominant form of antigen presentation during infection. Based on our 
current understanding, we know that CD8+ T cells are primed during tuberculosis and 
can begin to speculate on the mechanisms involved in the cross-presentation of Mtb 
antigens.   
 Secreted Mtb proteins are the primary targets of both CD4+ and CD8+ T cells 
during tuberculosis (108,109). In particular, ESAT-6 related proteins secreted by 
specialized type VII secretion systems are prominent CD8+ T cell antigens in both 
humans and mice (110-119), and their secretion is absolutely required to prime CD8+ T 
cells (120,121). Following low-dose aerosol infection of C57BL/6 mice, approximately 
30-50% of CD8+ T cells in the lungs respond to an epitope in the secreted ESAT-6 
related protein TB10.4 (EsxH) (47,117,122). The reasons why CD8+ T cells 
preferentially recognize secreted antigens are not entirely clear. It is possible that the 
research is biased simply because secreted antigens are easier to obtain in purified 
form. However, the immunodominance of many of these antigens is remarkable, and 
suggests some biological mechanism is at work. Our current understanding of the 
intracellular pathogenesis of Mtb may offer some clues regarding the prominence of 
secreted antigens. As previously discussed, there is increasing evidence that Mtb 
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damages phagosomal membranes and possibly escapes into the cytosol. Destabilizing 
the phagosome would allow secreted proteins to enter the cytosol where they can be 
processed for MCH class I presentation. Of course, there are other pathways of cross-
presentation, and regardless of the precise mechanism, CD8+ T cells are clearly primed 
during infection. 
 
CD8+ T cells are required for optimal resistance to tuberculosis 
 The first data to indicate a protective role for CD8+ T cells came from studies in 
the mouse model. In 1987, Ian Orme demonstrated that purified CD4+ or CD8+ T cells 
from the spleens of infected mice conferred protection when transferred into recipients. 
Specifically, immune CD8+ T cells reduced bacterial burden when transferred into sub-
lethally irradiated mice prior to IV infection (123). In the same year, Müller et al. 
demonstrated that the absence of CD8+ T cells increases susceptibility to Mtb. They 
observed that the depletion of CD8+ T cells in thymectomized mice reduced their ability 
to control bacterial growth in the spleen following IV infection (124).  
Studies in knockout mice eventually provided the clearest evidence linking CD8+ 
T cells to resistance. In 1992, Flynn et al. demonstrated that mice lacking β2-
microglobulin (β2m-/-) succumb rapidly to IV infection with Mtb (125). In β2m-/- mice, 
MHC class I does not traffic to the cell surface, and consequently, CD8+ T cells fail to be 
positively selected during thymic development. Thus, the susceptibility of β2m-/- mice 
was attributed to the absence of CD8+ T cells; however, other antigen presenting 
molecules, including CD1, also require β2m. Behar and colleagues resolved this by 
examining the susceptibility of CD1d-/- mice and TAP-1-/- mice (defective in MHC class I 
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presentation) (126). These experiments demonstrated that antigen presentation by 
MHC class I was essential for protection, while the loss of CD1d had little impact on 
host susceptibility in the mouse model. The requirement for CD8+ T cells has since 
been confirmed using CD8-/- mice and the class I MHC heavy chain knockout (95,127-
129). In addition to the use of knockout mice, numerous studies utilizing the adoptive 
transfer of cells as well as vaccination strategies have demonstrated protective roles for 
CD8+ T cells (reviewed in (130)).  
CD8+ T cells are also critical for immunity in both non-human primate and bovine 
models of tuberculosis (131-133). In early studies with human samples, CD8+ T cells 
were identified as a major component of granulomas, and Ag-specific CD8+ T cells were 
cloned from the pleural fluid of patients with tuberculosis (134,135). Currently, there is 
no data that directly demonstrates CD8+ T cells are essential for immunity in humans. 
However, there is considerable evidence that infected people generate Ag-specific 
CD8+ T cells that express effector functions and are cable of controlling bacterial growth 
(115,136-140). These observations coupled with studies in animal models indicate that 
CD8+ T cells are important mediators of immunity to Mtb. 
 
CD8+ T cell effector functions 
 As previously mentioned, IFN-γ is essential for resistance to tuberculosis (78-82). 
Though CD4+ T cells are considered a major source of IFN-γ during infection, Mtb-
specific CD8+ T cells from mice and humans also produce this important cytokine 
(110,112,113,141-144). However, it is difficult to demonstrate that IFN-γ from CD8+ T 
cells is essential for immunity to Mtb. CD8+ T cells require IFN-γ to mediate protection 
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when transferred into T cell deficient recipients, thus they are capable of supporting 
IFN-γ-driven protection in vivo (145). We recently demonstrated that TB10.4-specific 
CD8+ T cells require IFN-γ to protect sublethally irradiated mice from aerosol infection 
(Nunes-Alves et al., in press). This protection was dependent on TAP1 expression in 
the host, indicating that TB10.4-specific CD8+ T cells produced IFN-γ in response to 
antigen stimulation. Still, IFN-γ-producing CD8+ T cells cannot fully compensate for the 
protection mediated by CD4+ T cells. CD8+ T cells maintain high levels of IFN-γ in the 
lungs of CD4-/- mice following IV infection, yet these animals still succumb early to 
disease (146). In addition to IFN-γ, CD8+ T cells also produce TNF and GM-CSF in 
response to infection (111,144), but little is known about the role of these cytokines in 
CD8+ T cell-mediated protection. Though CD8+ T cells clearly make important 
cytokines, their relative contribution to protective cytokine production remains unclear 
during the course of natural infection. 
 One of the most important effector functions of CD8+ T cells is the ability to kill 
infected cells, and this killing is typically dependent on the TCR. CD8+ T cells that 
acquire the ability to specifically lyse targets are referred to as cytotoxic T lymphocytes 
(CTLs). During tuberculosis, CTLs are elicited both in humans and in animal models 
and have the ability lyse targets in vitro and in vivo (110,114,147). There are three main 
pathways that mediate CTL activity: cytotoxic granule exocytosis; Fas/FasL; and TNF 
secretion (64). Fas-/-, FasL-/-, and perforin-/- mice are all more susceptible to 
tuberculosis, suggesting cytolysis is an important mechanism of protection. (127,148).  
During cytotoxic granule exocytosis, perforin is essential to allow granzymes to 
enter the target cell and trigger apoptosis (149), and this molecule is an important 
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mediator of CD8+ T cell function during tuberculosis.  Stimulated CD8+ T cells from the 
lungs of Mtb-infected mice can lyse infected macrophages in vitro in a manner 
dependent on granule exocytosis (150).  In vivo, CTL activity can be directly assessed 
by transferring groups of fluorescently labeled splenocytes into infected animals. These 
splenocyte populations are pulsed with CD8+ T cell antigens (e.g. TB10.4) or left 
unpulsed as controls. By comparing the ratio of pulsed to unpulsed splenocytes over 
time, the specific killing of these cells can be measured. In mice, Ag-specific CTL 
activity can be detected four weeks after aerosol infection with Mtb and persists for 
months. Using this system, Woodworth et al. demonstrated that perforin is essential for 
CTL activity in vivo during tuberculosis (151). Furthermore, perforin-/- CD8+ T cells are 
unable to protect sublethally irradiated mice from aerosol infection. In the absence 
perforin, residual cytolytic activity is observed and is largely dependent on FasL and 
TNF signaling. Currently, perforin is the only essential molecule known for CD8+ T cell-
mediated cytolysis in the mouse model.  
Numerous Mtb-specific human CD8+ T cell lines have cytolytic activity in vitro 
(115,140,152). Similar to mice, human CD8+ T cells require granule exocytosis to 
control Mtb growth in infected macrophages, and perforin is also an important effector 
molecule (153). Additionally, human CD8+ T cells can mediate bacterial control with 
granulysin, a molecule that has direct antimicrobial effects (153). There is no known 
murine orthologue of granulysin, suggesting mouse and human CD8+ T cells differ 
somewhat in terms of their effector functions.  
All CD8+ T cell cytolytic pathways result in the target cell undergoing apoptosis, 
and apoptosis is associated with reduced bacterial burden (154). We hypothesize that 
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apoptosis leads to bacterial control through efferocytosis, which directly mediates 
bacterial killings (41). Therefore, CD8+ T cells may promote bacterial control by inducing 
apoptosis and initiating the process of efferocytosis. This hypothesis remains to be 
tested, and we are only beginning to understand CD8+ T cell effector functions during 
tuberculosis. 
 
Unanswered questions 
 The evidence highlighted in this chapter indicates that CD8+ T cells are important 
for immunity to Mtb. In particular, animal studies indicate that these cells are required 
for optimal resistance during tuberculosis. Understanding the role of CD8+ T cells in 
host immunity will be essential for effective vaccine design, and multiple groups are 
already targeting CD8+ T cells in vaccine strategies. However, we still know very little 
about the protective roles of CD8+ T cells and have almost no data on the factors 
governing CD8+ T cell responses during tuberculosis. In the following chapters, we 
investigate the regulation of CD8+ T cells, and seek to address several questions: 
1. Which cytokine(s) regulate the priming of CD8+ T cells during tuberculosis? 
2. Which cytokine(s) expand and maintain CD8+ T cells in the lungs? 
3. Which cytokine(s) promote effector functions, including cytokine production and 
cytolytic activity? 
4. Which cytokine(s) regulate CD8+ T cell differentiation and the potential for 
transition into memory? 
5. In what ways do CD4+ T cells support the CD8+ T cell response? 
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These questions are broad in scope, but we begin by evaluating several key cytokines 
known to influence CD8+ T cell responses during other infections.  We believe that 
answering these questions will significantly advance our understanding of CD8+ T cells 
during tuberculosis, and this knowledge has implications for augmenting CD8+ T cell 
responses during infection, be it by vaccination or other means.  
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Abstract 
 
The differentiation of effector and memory CD8+ T cells is a dynamically 
regulated process that varies considerably during different infections and is influenced 
by the inflammatory milieu of the host. Here, we define three signals regulating CD8+ T 
cell responses during tuberculosis by focusing on cytokines known to impact disease 
outcome: IL-12, type 1 interferons (IFN), and IL-27.  
IL-12, type 1 IFN, and IL-27 are all elicited during tuberculosis and have profound 
effects on host resistance. IL-12 is required for resistance in mice and humans, and has 
an essential role in promoting CD4+ T cell expansion and IFN-γ production. In contrast, 
IL-27 acts as an immunoregulatory cytokine and can dampen CD4+ T cell responses. 
Type 1 IFN has multiple effects during infection, but its overproduction is detrimental to 
the host. The increased resistance of IFNAR-/- mice underscores this fact. In other 
infections, all three of these cytokines can profoundly affect CD8+ T cell expansion and 
function; however, their effect on CD8+ T cells during tuberculosis is largely unknown. 
Using mixed bone marrow chimeras, we compared wild type and receptor 
knockout CD8+ T cells within the same mouse following aerosol infection with M. 
tuberculosis (Mtb). Four weeks post-infection, all three cytokines were required for 
efficient CD8+ T cell expansion in the lungs, with IL-12 showing the greatest 
contribution. We next determined if these cytokines directly promote priming or are 
required only for expansion in the lungs. Utilizing retrogenic CD8+ T cells that express a 
T cell receptor specific for the Mtb antigen TB10.4, we observed that IL-12 is the 
dominant cytokine driving CD8+ T cell priming in the lymph node and expansion in the 
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lungs. Type 1 interferons and IL-27 appear to have non-redundant roles in supporting 
pulmonary CD8+ T cell expansion. 
In addition to expansion, these cytokines regulate the differentiation and function 
of CD8+ T cells during tuberculosis. All three cytokines were necessary for the induction 
of granzyme B; however, cells still retained a high degree of cytolytic ability. IL-12 was 
the only cytokine necessary for the differentiation of short-lived effector cells (SLECs) 
and IFN-γ production. These data demonstrate distinct and overlapping roles for each of 
the cytokines examined and underscore the complexities of CD8+ T cell regulation 
during tuberculosis.	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Introduction 
 
In this chapter, we examine the regulation of CD8+ T cells during tuberculosis by 
focusing on three key cytokines: IL-12, type 1 IFN, and IL-27. There are two main 
reasons why we chose these particular cytokines. First, all three dramatically influence 
susceptibility to tuberculosis. This chapter begins with a review of these cytokines and 
explains their impact on immunity to Mtb. The second reason for examining these 
cytokines is that they are profoundly important for regulating CD8+ T cells during other 
infections. In particular, IL-12 and type 1 IFN are known as “Signal 3” cytokines, 
because they provide a third signal necessary for CD8+ T cell priming in many systems. 
The introduction ends with a review of signal 3 cytokines and their roles in other 
infections.  
 
The IL-12 family of cytokines 
Interleukin 12 (IL-12) was first identified in the supernatant of Epstein-Bar virus 
(EBV)-transformed B cell lines and was shown to enhance IFN-γ production, 
cytotoxicity, and proliferation in NK cells (1,2). Following this discovery, IL-12 production 
by innate immune cells, including macrophages and dendritic cells (DCs), was revealed 
to drive the TH1 polarization of naïve CD4+ T cells (3-8). The hallmark of TH1 
polarization is the production of IFN-γ, making IL-12 an important regulator of immune 
responses to intracellular bacteria and protozoa. Intriguingly, the avirulent M. 
tuberculosis (Mtb) strain H37Ra was one of the earliest stimulants shown to induce IL-
12 in peripheral blood mononuclear cells (PBMCs) (6).  
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Historically, IL-12 is the first cytokine to connect innate and adaptive immunity, 
and it’s discovery supports a central paradigm in which innate cells direct the 
development of adaptive immune responses. Years later, IL-23 and IL-27 were 
identified based on homology searches, becoming members of what is now the IL-12 
family of cytokines (9,10). Like IL-12, macrophages and DCs can produce IL-23 and IL-
27 in response to infection, and these cytokines influence T cell function.  IL-35 is the 
newest member of this family and is unique in that it is a potent inhibitory cytokine 
primarily secreted by regulatory T cells (Tregs) (11). 
The IL-12 family is the only heterodimeric cytokine family, and chain sharing is a 
common attribute of both the cytokines and their receptors (12,13). IL-12 and IL-23 are 
disulfide-linked heterodimers consisting of p35/p40 and p19/p40, respectively. IL-27 and 
IL-35 lack the disulfide linkage and are comprised of p28/Ebi3 and p35/Ebi3, 
respectively. Interpreting the various functions of IL-12 family members can prove 
challenging, because multiple cytokines share the same chains (e.g. IL-12 and IL-23 
share the same β-chain, p40). This added complexity continues with the cytokine 
receptors, which also consist of two chains. IL-12 signals through IL-12Rβ1 and IL-
12Rβ2, and IL-23 uses IL-12Rβ1 and IL-23R. IL-27 interacts with IL-27Rα (WSX-1) and 
gp130, and IL-35 utilizes IL-12Rβ2 and gp130. The precise biological reason for this 
promiscuity in the use of cytokine and receptor chains is unclear, but this novel feature 
has implications for the coordinated regulation of this family of cytokines (13). This is 
especially interesting considering that these cytokines can have opposing effects during 
an immune response. Broadly, IL-12 and IL-23 are proinflammatory and IL-27 and IL-35 
have immunoregulatory functions (13-16).   
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IL-12 and host resistance to tuberculosis 
IL-12 is key mediator of resistance during tuberculosis and is required to promote 
a protective TH1 response. One striking example of its importance is a group of genetic 
disorders characterized by a predisposition to infection with mycobacteria known as 
Mendelian susceptibility to mycobacterial disease (MSMD).  Patients with MSMD 
frequently exhibit disease in early childhood caused by typically non-pathogenic 
mycobacteria and often as a result of bacillus Calmette-Guérin (BCG) vaccination (17). 
MSMD can arise from a variety of genetic mutations, but the most common cause is 
autosomal recessive complete deficiency of IL-12Rβ1 (18,19). These patients are 
unresponsive to IL-12 and IL-23 signaling, have blunted IFN-γ production, and often 
suffer from mycobacterial infections (17,20). Surprisingly, tuberculosis is not particularly 
common in MSMD patients; however people with IL12RB1 mutations are the most likely 
MSDM patients to contract severe forms of tuberculosis (21-24). These finding 
underscore the protective role of IL-12 family members during mycobacterial infections, 
including tuberculosis.  
In mice, the induction and protective effects of IL-12 are well characterized during 
tuberculosis. Mtb can directly stimulate IL-12 production by macrophages and DCs in a 
manner dependent on TLR2 and TLR9 signaling (25-27). This is a key first step in 
generating a TH1 response and controlling bacterial growth. Mice lacking MyD88, a 
major adaptor for TLR signaling, are highly susceptible to Mtb (i.e. higher bacterial 
burden and decreased survival) and have diminished levels of IL-12p40 and IFN-γ 
(28,29). Knocking out single TLRs fails to recapitulate the dramatic survival defect seen 
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in MyD88-/- mice, suggesting some redundancy in signaling. Mice deficient for TLR2, 
TLR4, or TLR6 are not particularly susceptible to low dose aerosol infection and IL-
12p40 production is uncompromised (25,26,30,31). Mice singly deficient for TLR9 have 
reduced levels of IL-12p40 following aerosol infection; however, dramatic survival 
defects and increased bacterial burden are only observed when both TLR2 and TLR9 
are knocked out (26). In addition to TLR signaling, MyD88 serves as an adaptor for 
downstream signaling of the IL-1 and IL-18 receptors. IL-18-/- mice show reduced serum 
levels of IL-12p40 following IV infection with Mtb Erdman (32), and IL-1R-/- 
macrophages produce less IL-12p40 after H37Rv infection (33). Overall, TLR9 appears 
to be largely responsible for IL-12p40 production during tuberculosis; however, multiple 
redundant pathways augment IL-12 levels. 
 Early studies indicated that exogenous administration of IL-12 reduced bacterial 
burden and extended survival in mice infected with Mtb (34,35). In these experiments, 
the protective effect of IL-12 was largely dependent on IFN-γ production, as mice 
incapable of making IFN-γ were not protected by exogenous IL-12 (36). Studies using 
knockout mice confirmed the importance of IL-12 in controlling bacterial growth in vivo. 
Following IV infection, mice lacking the β-chain of IL-12, IL-12p40-/-, have increased 
bacterial burden and are incapable of Ag-specific IFN-γ production (37). Later studies 
demonstrated that infected IL-12p40-/- mice have dramatically reduced numbers of CD4+ 
T cells producing IFN-γ (38). The effects of IL-12 on CD8+ T cells have never been 
directly addressed during tuberculosis. 
  Of course, IL-12p40 is required to generate both IL-12 and IL-23, and it can form 
a functional homodimer (IL-12(p40)2) that has both agonistic and antagonistic effects on 
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IL-12 signaling (39-42). A direct role for IL-23 in contributing to the IFN-γ response was 
examined in IL-23p19-/- mice. Following aerosol infection, IL-23p19-/- mice mount a 
robust CD4+ T cell response, produce normal levels of IFN-γ, and show no increase in 
bacterial burden at early time points (43).  This experiment demonstrates that IL-23 
does not contribute to TH1 expansion when IL-12 is present.  
 
IL-23 and host resistance to tuberculosis 
IL-23 is induced following Mtb infection in a manner largely dependent on TLR2 
signaling (44). Though not strictly required for early protective immunity to Mtb, IL-23 
can compensate for the loss of IL-12. Mice deficient in the α-chain of IL-12, IL-12p35-/-, 
have increased bacterial burden and decreased survival compared to WT controls; 
however, they are not as susceptible as IL-12p40-/- mice (38,45). Unlike IL-12p40-/- 
mice, IL-12p35-/- mice still make IL-23, generate a modest CD4+ T cell response, and 
produce some IFN-γ (38). Thus, IL-23 is capable of supporting a modest TH1 response 
in the absence of IL-12 and confers some protection. The susceptibility of the IL-12p40-/- 
mice is only recreated when mice lack both IL-23p19 and IL-12p35, and are again 
incapable of producing IL-23 and IL-12 (43). Other models have confirmed the ability of 
IL-23 to support CD4+ T cell function in the absence of IL-12. In IL-12p40-/- mice, co-
administration of a plasmid expressing IL-23 can restore the generation of protective 
IFN-γ-producing T cells in response to DNA vaccination (46).  
IL-23 also has independent effects on the immune response during tuberculosis. 
IL-23 mediates the protective effects of ESAT6-vaccination by inducing a population of 
IL-17-producing memory cells (47). In fact, eliciting IL-17-producing CD4+ T cells (TH17 
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cells) in response to Mtb appears to be a major function of IL-23 (43,44). TH17 cells are 
important for recruiting cells such as neutrophils to sites of infection. During 
tuberculosis, they can be protective early on but generate immunopathology if left 
unchecked (48-51). In this way, IL-23 can have a deleterious effect on the outcome of 
infection by supporting IL-17-driven immunopathology (48). There is also evidence 
supporting a protective role for IL-23 during chronic tuberculosis. IL-23p19-/- mice are 
unable to restrict bacterial growth at later time points during tuberculosis (>150 days), 
despite maintaining consistent IFN-γ levels (52). The mechanism of this protection is 
unclear, but the observation illustrates that IL-23 has multiple, often contradictory, 
effects on susceptibility. 
 
IL-27 and host resistance to tuberculosis 
Depending on the context, IL-27 can have both pro- and anti-inflammatory 
effects, though most recent research has focused on its immunoregulatory functions. In 
many infections, IL-27 functions to limit immunopathology (16,53). This was first 
demonstrated in Toxoplasma gondii infection, where IL-27 dampens TH1 responses. IL-
27Rα-/- mice succumb early to T. gondii infection due to immunopathology as result of a 
heightened CD4+ T cell response (54). Following Mtb infection, macrophages produce 
IL-27 and it is also detected in the lungs of infected mice (55,56). During tuberculosis, 
IL-27Rα-/- mice have reduced bacterial burdens in the lungs associated with the 
increased recruitment of activated CD4+ T cells (55,56). Hölscher et al. observed 
increased levels of IL-12p40 and IFN-γ in the lungs of infected IL-27Rα-/- mice and 
demonstrated that infected IL-27Rα-/- macrophages produce increased amounts IL-
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12p40 and TNF (56). Thus, the absence of IL-27 signaling can enhance the immune 
response to Mtb. Though bacterial growth is better controlled, IL-27Rα-/- mice exhibit 
extensive immunopathology by 250 days post-infection and die sooner than WT 
controls (56). This illustrates an essential balance that must be maintained between 
protective host responses and immunopathology.  
IL-12 and IL-27 mediate susceptibility during tuberculosis and form an import axis 
regulating TH1 responses. IL-12 is essential for host protection in both mice and 
humans and promotes a protective CD4+ T cell response. IL-27 serves to dampen this 
TH1 response and, in turn, limits immunopathology. It is worth noting that in almost all of 
the studies described, CD8+ T cells were left unexamined. In IL-27Rα-/- mice, there is 
increased recruitment of CD8+ T cells to the lungs during tuberculosis, suggesting IL-27 
also inhibits CD8+ T cell function (56). However, it is possible that this effect is indirect 
and results from the lack of CD4+ T cell help.  In other infections, direct IL-27 signaling 
can enhance CD8+ T proliferation and the acquisition of effector functions (57-60). Thus, 
the full impact of IL-12 and IL-27 on CD8+ T cells during tuberculosis remains to be 
examined.  
 
Type 1 Interferons  
 Interferons were discovered in 1957 by Isaacs and Lindenmann and are 
considered the first cytokine to be identified (61,62). Their name is derived from the 
initial observation that they “interfere” with viral replication in mammalian cells. Today, 
there are three interferon (IFN) families: Type 1, Type 2, and Type 3. There are multiple 
type 1 IFN family members, but the most studied are the IFNα subtypes (14 in humans 
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and 13 in mice) and the single IFNβ. The lone member of the type 2 family is IFN-γ, and 
the type 3 family consists of IL-28A, and IL-28B, and IL-29. Nearly every cell in the body 
can produce type 1 IFN. This is in stark contrast to type 2 IFN (IFN-γ), which is primarily 
secreted by T cells and NK cells.  
The production of type 1 IFN is triggered by a number of pattern recognition 
receptors (PRRs) found in the cytosol that recognize nucleic acids and other pathogen 
associated molecular patters (PAMPs) (63-66). Additionally, TLR3, TLR4, TLR7, TLR8, 
and TLR9 can induce type 1 IFN (63,67). All type 1 IFN family members signal through 
a ubiquitously expressed heterodimeric receptor consisting of IFNAR1 and IFNAR2 
(68). Because most cells can produce and respond to type 1 IFN, this family of 
cytokines is an especially important in defending against pathogens.  However, the 
effects of type 1 IFN are complex and have both positive and negative effects on host 
resistance, depending on the pathogen. 
 
Type 1 IFN and susceptibility to tuberculosis 
 Mtb can trigger type 1 IFN production in infected macrophages through the 
activation of the cytosolic sensor nucleotide-binding oligomerization domain containing 
2 (Nod2) and IFN-β mRNA is detected in mice as soon as 24 hours after IV infection 
(69,70). During tuberculosis, type 1 IFN is considered detrimental to host resistance, but 
the precise mechanisms for this negative effect are incompletely understood. Knockout 
mice lacking a negative regulator of type 1 IFN production, TPL2, have higher bacterial 
burdens following aerosol infection (71). Mice deficient in the IFNα/β receptor, IFNAR-/-, 
are one of the few knockout strains that better control bacterial growth (70,72,73). 
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Additionally, IFNAR-/- mice have a survival advantage when infected with hypervirulent 
clinical isolates (70,72,73). In WT mice, these hypervirulent clinical isolates induce 
greater amounts of type 1 IFN during infection, and this is associated with a dampened 
TH1 response (72-74) 
Additional evidence for these negative effects can be found in studies that 
increase type 1 IFN levels during infection. In short, any factor that augments type 1 IFN 
production exacerbates disease. Direct administration of either intranasal type 1 IFN or 
Poly-IC, a potent inducer of type 1 IFN, reduces survival in WT mice (74,75). In a more 
physiological version of this experiment, co-infection with Mtb and influenza A results in 
unrestricted Mtb growth, and this phenotype is not observed in co-infected IFNAR-/- 
mice (76). Decreases TH1 immunity is a likely mechanism for the negative impact of 
type 1 IFN; however it is not a universally observed phenomenon in the mouse model 
(75). 
In humans, increased type 1 IFN signaling is associated with active tuberculosis. 
In a large patient cohort, a 393-gene signature was identified in whole blood that 
distinguished latent from active disease, and this transcriptional profile diminished as 
patients underwent antibiotic treatment (77). Pathway analysis revealed that genes 
downstream of type 1 IFN were overrepresented in this transcriptional signature, thus 
associating type 1 IFN with an active disease state. Similar associations were made in 
additional cohorts of patients, confirming this observation (78). Whether increased type 
1 IFN is a cause or a result of active disease remains to be determined. 
 Defining a clear mechanism behind all of these observations is challenging, and 
it is likely that type 1 IFN exacerbates disease through a number of mechanisms. Early 
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mouse studies associated a dampened TH1 response with type 1 IFN overproduction, 
but it is unclear which cell types are being affected to reduce T cell activation (72,74). 
Infected macrophages and monocytes respond to increased type 1 IFN by reducing the 
production of inflammatory cytokines, including IL-12, and simultaneously increase the 
production of the immunosuppressive cytokine IL-10 (71,79-81). This influence on IL-12 
levels has the potential to affect CD4+ T cell expansion and the production of IFN-γ.  
In addition to affecting cytokine production, type 1 IFN directly modulates the 
antimicrobial activity of infected cells in part by diminishing the response to IFN-γ. Type 
1 IFN downregulates IFN-γR1 expression on monocytes in addition to inhibiting 
downstream IFN-γR1 signal transduction (80). In macrophages, IFN-γ-mediated 
bacterial killing is significantly enhanced when cells lack IFNAR (81). A possible 
mechanism for this reduction in killing was identified in studies with Mycobacterium 
leprae. In infected macrophages, M. leprae inhibits the production of IFN-γ-induced 
antimicrobial peptides through IFNβ-driven IL-10 production (82). Thus, type 1 IFN 
directly interferes with the macrophage’s ability to kill Mtb. In total, these observations 
suggest type 1 IFN counters both the production and the cellular response to IFN-γ. 
Finally, type 1 IFN can affect disease by influencing the recruitment of innate immune 
cells to the lung. Administration of intranasal Poly-IC during tuberculosis results in the 
recruitment of a monocyte population (CD11b+Gr1int) that is highly permissive to 
bacterial growth (75).  
 Type 1 IFN clearly has the potential to influence adaptive immunity based its 
ability to suppress IL-12 production. However, no studies have addressed the direct 
effects of type 1 IFN on CD4+ and CD8+ T cells during tuberculosis. Depending on the 
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context, type 1 IFN can stimulate or inhibit CD4+ and CD8+ T cell proliferation and 
effector functions (63). In response to some pathogens, type 1 IFN is a key signal 
promoting CD8+ T cells expansion, function, and eventual memory formation (discussed 
in detail below). For this this reason, the effect of type 1 IFN on the CD8+ T cell 
response to tuberculosis should be examined.  
  
CD8+ T cells require three signals for activation 
Classically, the activation of naïve CD4+ and CD8+ T cells is thought to require 
two signals. The first signal comes from interaction of the T cell receptor (TCR) with its 
cognate antigen. This antigen must be presented to the naïve T cell in the context of an 
antigen-presenting molecule on the surface of an APC.  In addition to TCR stimulation 
(signal 1), naïve T cells require signals from a variety of co-stimulatory receptors to 
efficiently expand and acquire effector functions. CD28 is the prototypical co-stimulatory 
receptor and is constitutively expressed on both naïve CD4+ and CD8+ T cells. Its 
ligands, B7.1 and B7.2, are expressed on the surface of APCs and are upregulated 
upon activation of these cells. While mice lacking either B7.1 or B7.2 alone have no 
phenotype following Mtb infection, mice lacking both co-stimulatory ligands show 
delayed T cell priming and have fewer CD4+ and CD8+ T cells producing IFN-γ in their 
lungs (83,84). These mice are still capable of mounting a modest T cell response, 
suggesting that other co-stimulatory signals may exist during tuberculosis. 
Intriguingly, there is evidence suggesting some microbial products directly co-
stimulate T cells.  The Mtb lipoprotein LprG can serve as a co-stimulatory signal for 
human CD4+ T cells in a manner dependent on TLR1 and TLR2 (85), and the TLR2 
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agonist P3CSK4 is sufficient to co-stimulate transgenic CD4+ T cells specific for Ag85B 
(86).  Rv2468c, a protein primarily found in the Mtb cell wall, can also serve as a co-
stimulatory molecule by interacting with the integrin VLA-5 (α5β1) on CD4+ T cells (87). 
A role for direct costimulation of CD8+ T cells during tuberculosis has not been 
examined. Co-stimulatory receptors and ligands have a profound influence on T cell 
biology, and we are only beginning to address the roles these molecules play during 
tuberculosis.   
More recently, the two-signal model of T cell activation has expanded for CD8+ T 
cells to include a necessary third signal (Figure 2-1). The requirement for this third 
signal was first demonstrated using artificial APCs (aAPCs). These aAPCs are created 
by incorporating co-stimulatory B7 ligands along with peptide/major histocompatibility 
complexes (MHC) on the surface of microspheres. This experimental tool has the 
advantage of minimizing the potential signals delivered to naïve CD8+ T cells. Work with 
aAPCs in vitro revealed that CD8+ T cells require input from inflammatory cytokines in 
addition to TCR engagement, co-stimulation, and IL-2 during priming (88). The 
predominant “signal 3” cytokines are IL-12 and type 1 IFN, and they have pivotal roles 
in influencing CD8+ T cell expansion, differentiation, effector functions, and memory 
formation (88,89). These effector functions include the production of IFN-γ and the 
ability to lyse target cells. In the absence of signal 3 cytokines, primed CD8+ T cells can 
proliferate but fail to develop effector functions and become tolerant to antigen 
stimulation (90). The first clear in vivo examples of a signal 3 came from studies using 
peptide vaccination in mice. When combined with peptide, IL-12 and type 1 IFN can act 
in place of an adjuvant to elicit productive CD8+ T cell responses (91-93). This finding  
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Figure 2-1. IL-12 and Type 1 IFN provide a third signal necessary for efficient 
CD8+ T cell priming. 
 
In addition to TCR ligation (signal 1), and signals from cell surface co-stimulatory 
receptors (signal 2), CD8+ T cells require a third signal in the form of an inflammatory 
cytokine. The predominant signal 3 cytokines are IL-12 and type 1 interferon (type 1 
IFN).	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suggests that eliciting signal 3 cytokines is an additional component of adjuvant 
function.  
 
Signal 3 cytokines during infection 
The first studies demonstrating a role for signal 3 cytokines during infection were 
done by transferring naïve TCR transgenic P14 CD8+ T cells into mice and infecting 
with lymphocytic choriomeningitis virus (LCMV). IFNAR-/- CD8+ cells expand poorly in 
response to LCMV and can be reduced by as much as 99% relative to WT P14 CD8+ T 
cells (94,95). In many of these early studies, IFNAR-/- CD8+ T cells initially proliferated 
following exposure to antigen but ultimately failed to expand as a population (94-96). 
Recent data have shed light on this phenomenon by demonstrating that signal three 
cytokines sustain expression of the high-affinity IL-2 receptor, CD25, on primed CD8+ T 
cells (97). This sustained IL-2 signaling supports a transcriptional program that 
promotes cell cycle progression genes and facilitates CD8+ T cell expansion. 
The requirement for different signal 3 cytokines can differ greatly between 
pathogens. Direct type 1 IFN signaling is essential for the CD8+ T cell response to 
LCMV, and IL-12 is unnecessary (96,98). In contrast, IL-12 is essential for CD8+ T cells 
to acquire effector functions in response to vaccination with an attenuated strain of T. 
gondii (99). To date, Listeria monocytogenes (LM) is the only bacterial pathogen 
examined, and CD8+ T cell expansion is largely dependent on IL-12 production 
(96,98,100). However, type 1 IFN signaling still supports a small degree of expansion 
when cells lack IL-12R, indicating that multiple signal 3 cytokines can affect CD8+ T 
cells in a single infection (98). Though IL-12R-/- CD8+ T cells expand poorly in response 
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to L. monocytogenes, IFN-γ production and cytolytic activity are only significantly 
compromised when both IL-12R and IFNAR are absent (98). This suggests that IL-12 
and type 1 IFN can compensate for each other to promote effector function.  
The relative importance of IL-12 or type 1 IFN during an infection may simply be 
a matter of the particular cytokines elicited by the pathogen. Keppler and colleagues 
performed an extensive analysis of IL-12 and type 1 IFN during infections with vaccinia 
virus (VV), vesicular stomatitis virus (VSV), LCMV, and L. monocytogenes (98). Overall, 
the timing and relative amounts of IL-12 and type 1 IFN elicited during CD8+ T cell 
expansion correlated with their role as signal 3 cytokines. For example, L. 
monocytogenes induces an initial burst of IL-12 that gives way to increased levels of 
type 1 IFN. Thus, IL-12 has the biggest impact on CD8+ T cells, while type 1 IFN has a 
supporting role. During L. monocytogenes infection, CD8+ T cell expansion is only fully 
abrogated when both IL-12R and IFNAR are absent from the CD8+ T cell. It is unclear if 
a single CD8+ T cell responds to both IL-12 and Type 1 IFN or if there are distinct 
populations of cells responding to a single cytokine during infection. It should be noted 
that some pathogens elicit strong CD8+ T cell response without a known signal 3. The 
CD8+ T cell response to VV is unaltered even in the absence of both IL-12R and IFNAR 
(98,101). This is surprising given that VV elicits IL-12 production and suggests that 
additional sources of signal 3 exist.  
 
Signal 3 cytokines regulate the differentiation of effector CD8+ T cells. 
Beyond promoting expansion and effector function, signal 3 cytokines are 
important regulators of CD8+ T cell differentiation during infection. Following priming, 
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CD8+ T cells can adopt several phenotypes that ultimately determine which cells will 
progress to form a memory population. This was first demonstrated in L. 
monocytogenes infection, where long-lived memory cells are preferentially derived from 
a small subset of effector cells expressing the IL-7 receptor subunit α (CD127) (102-
104). These CD127hi cells are now termed memory precursor effector cells (MPECs). 
The majority of CD127lo effectors cells are shorter lived and much of this population dies 
following the clearance of infection. These short-lived effector cells (SLECs) express 
high amounts of killer cell lectin-like receptor G1 (KLRG1). Cells that express neither 
KLRG1 or CD127 are early effector cells (EECs) and have yet to adopt a SLEC or 
MPEC phenotype (105-108).  
KLRG1 and CD127 can be useful markers to identify SLECs (KLRG1hi CD127lo) 
and MPECs (KLRG1lo CD127hi); however, they are not absolute determinants of a cell’s 
memory potential. For example, some KLRG1hi cells survive to become memory cells 
and can mount highly protective secondary responses (107,109). Additionally, KLRG1hi 
CD127hi  (termed double positive effector cells – DPECs) exist during most infections 
and have a survival half-life between SLECs and MPECs (107). An individual CD8+ T 
cell can show remarkable heterogeneity in its ability to form each of these populations 
(EEC, SLEC, DPEC, and MPEC), and we are only beginning to understand the factors 
involved in these cell fate decisions. It appears that the inflammatory milieu elicited by 
different pathogens plays some role in determining the relative proportion of these 
effector populations (108,110).  
In general, signal 3 cytokines drive the terminal differentiation of CD8+ T cells 
and promote KLRG1 expression. This is especially true of IL-12 which drives SLEC 
	  	   51	  
differentiation by promoting the expression of the transcription factor T-bet (103). This 
increased formation of SLECs occurs at the expense of MPEC generation, suggesting 
that heightened inflammation undermines memory formation by promoting the terminal 
differentiation of cells. Indeed, some studies show that limiting inflammation during 
infection can enhance memory formation (111). Similarly, blocking signal 3 during 
infection can promote the formation of MPECs. IL-12R-/- CD8+ T cells overwhelming 
adopt an MPEC phenotype following L. monocytogenes infection, and similar 
observations have been made with other pathogens (96,98). However, it is unclear if 
these IL-12R-/- MPECs are functional memory cells. Constitutive expression of CD127 is 
insufficient to support memory cell formation, suggesting that CD127 alone cannot 
define true memory potential (112).  
There is substantial evidence that signal 3 cytokines are required for the 
formation of memory cells.  CD8+ T cells stimulated in vitro with aAPCs and then 
transferred into mice only survive to form a memory population when IL-12 is included 
with the initial stimulation (100). Studies of memory recall responses have also 
demonstrated a clear requirement for signal 3 cytokines (113). Signal 3 cytokines 
control a balance between SLEC and MPEC phenotypes by favoring SLEC 
differentiation; however, functional memory cannot be formed in the absence of signal 
three.  
 
IL-27 as an alternative signal 3 cytokine 
Though it has never been directly associated with signal 3 activity, IL-27 can 
affect CD8+ T cell function in ways similar to IL-12 and type 1 IFN. Obar and colleagues 
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demonstrated that IL-27 is important for the accumulation of SLECs during VSV 
infection, and cells are more likely to adopt an MPEC phenotype in its absence (108). 
Surprisingly, CD8+ T cell expansion was not affected by the loss of IL-27 in this system. 
This ability to promote SLEC differentiation likely results from IL-27 inducing T-bet 
expression (57). IL-27 is also associated with promoting CD8+ T cell function. IL-27 is 
required to promote IFN-γ expression during both T. gondii and influenza virus infection 
(58). In vitro, IL-27 augments the expression of effector molecules such as granzyme B 
and perforin in naïve CD8+ T cells stimulated with anti-CD3 and anti-CD28 (57,59). 
Recently, the role of IL-27 was examined in a peptide vaccination model using Poly-IC 
and anti-CD40 as adjuvants. In this model, CD8+ T cells required IL-27 for both primary 
expansion and recall responses (114).  Furthermore, the transfer of vaccine-elicited IL-
27R-/- CD8+ T cells was unable to protect against L. monocytogenes infection. These 
observations suggest IL-27 has an important role in augmenting CD8+ T cells response 
during infection, and other groups have speculated that it may be an alternative signal 3 
cytokine (98). 
 
Summary 
IL-12, type 1 IFN, and IL-27 are all elicited during tuberculosis and have profound 
effects on disease outcome. IL-12 is required for host resistance in mice and humans, 
and has an essential role in promoting CD4+ T cell responses. In contrast, IL-27 acts as 
an immunoregulatory cytokine and can dampen CD4+ T cell responses. During 
tuberculosis, IL-27 limits the control of bacterial growth but is necessary to prevent 
immunopathology during chronic disease. Type 1 IFN has a variety of effects during 
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infection, and its overproduction is detrimental to host resistance. The increased 
resistance of IFNAR-/- mice to Mtb infection underscores this fact. A similar association 
exists in humans, where type 1 IFN signaling is linked to active disease.  
In other infections, all three of these cytokines directly regulate CD8+ T cells and 
can act as essential signals promoting CD8+ T cell expansion and effector function. 
However, the effects of these cytokine on CD8+ T cells during tuberculosis are 
uncharacterized. In fact, little is known about the inflammatory signals governing CD8+ T 
function during tuberculosis. Here, we seek to identify the cytokines that augment or 
potentially inhibit CD8+ T cells, and begin by addressing the roles of IL-12, type 1 IFN, 
and IL-27. Given the important role of IL-12 in promoting CD4+ T cell responses during 
tuberculosis, we hypothesized IL-12 will also be a dominant signal for CD8+ T cell 
expansion and function. The roles of type 1 IFN and IL-27 are more challenging to 
predict, and they potentially have a variety of effects.  
Using 1:1 mixed bone marrow chimeras, we demonstrate that IL-12 is essential 
to promote CD8+ expansion and the acquisition of effector function. However, type 1 
IFN and IL-27 are not dispensable and also augment the expansion of effector cells. 
These findings support a model in which each cytokine influences CD8+ T cell 
expansion in a non-redundant way. Using bone marrow chimeras, we interrogate the 
cytolytic ability of IL-12R-/-, IFNAR-/-, and IL-27R-/- CD8+ T cell in vivo. Overall specific 
killing is reduced in the absence of IL-12; however, even IL-12R-/- CD8+ T cells remain 
highly cytolytic. This surprising finding indicates that cytolysis is a robust effector 
function during tuberculosis and is likely promoted and executed through redundant 
mechanisms.  
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Using the adoptive transfer of retrogenic Ag-specific CD8+ T cells, we directly 
examine priming following low-dose aerosol infection. These studies reveal that IL-12 is 
necessary to prime CD8+ T cells in the lymph node and to continue their expansion in 
the lungs. For this reason, IL-12 is the dominant signal 3 cytokine during tuberculosis. In 
total, IL-12 promotes CD8+ T cell priming, expansion, SLEC differentiation, and IFN-γ 
production, while type 1 IFN and IL-27 support expansion in the lungs. To date, this is 
the most comprehensive study of CD8+ T cell regulation during tuberculosis. We believe 
such understanding has potential implications for rational vaccine design and the 
development of immunotherapies.  
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Results 
 
CD8+ T cells express the receptors for IL-12, type 1 IFN, and IL-27 throughout Mtb 
infection. 
 To determine the expression of IL-12R, IFNAR, and IL-27R on CD8+ T cells 
during Mtb infection, we used a method based on the protocol set forth by the 
Immunological Genome Project (115). Briefly, magnetic bead purified T cells were 
pooled from the lungs of naïve or infected mice and sorted by FACS to obtain a 
population of 99% pure CD3+ CD8+ cells. Gene expression profiling was done using the 
Affymetrix Mouse Gene 1.0ST array and relative expression values were normalized 
across all the samples in the experiment. Here, we are interested in the relative 
expression of the subunits for the IL-12 receptor (Il12rb1 and Il12rb2) the interferon-α/β 
receptor (Ifnar1 and Ifnar2) and the IL-27 receptor (Il27ra and Il6st). IL12rb1 transcripts 
were marginally detectable in cells from uninfected mice (time 0) and IL12rb2 was 
undetectable (Figure 2-2A). Following infection, transcription of both IL-12 receptor 
subunits increased and remained detectable throughout the experiment (Figure 2-2A). 
Expression of the interferon-α/β and IL-27 receptor subunits remained relatively high in 
CD8+ T cells in both uninfected and infected mice (Figure 2-2A). IL-12p40 and IL-27 
levels were also quantified in lung homogenates from mice infected for 0, 1, 2, and 4 
weeks (Figure 2-2B). IL-12p40 was undetectable in the lungs of uninfected mice and 
steadily increased through the first four weeks of infection. IL-27 was detectable in 
uninfected mice and began to rise 2 weeks after infection. IFNβ is detectable in 
bronchoalveolar lavage fluid from the lungs of infected mice and was previously  
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Figure 2-2. CD8+ T cells express the receptors for IL-12, type 1 IFN, and IL-27 
throughout Mtb infection. 
 
(A) Relative expression of the indicated cytokine receptor subunits on sorted CD8+ T 
cells purified from the lungs of uninfected mice (time 0) as well as 4, 16, and 46 
weeks after low dose aerosol infection. At each time point, lung homogenates were 
pooled from three mice prior to magnetic bead purification and cell sorting. Replicates 
reflect three independent infections, each with three pooled mice. (B) Cytokine array 
data from lung homogenates of infected mice. N=5 mice per time point. For relative 
expression, values >120 have a 95% probability or greater of true expression and 
values <47 have 95% probability or greater of being silent. 
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reported (116). Together, these findings suggest that CD8+ T cells are capable of 
responding to all three cytokines throughout infection. 
  
IL-12, type 1 IFN, and IL-27 augment the magnitude of the CD8+ T cell response during 
tuberculosis.  
Previous studies examined the roles of IL-12, type 1 IFN, and IL-27 during 
tuberculosis by directly infecting knockout mice lacking either the functional cytokines or 
the relevant receptors. The inflammatory response and degree of susceptibility to Mtb 
varies substantially between these various knockout strains thus confounding a direct 
comparison of these experiments. To determine the effects of IL-12, type 1 IFN, and IL-
27 on CD8+ T cell responses during tuberculosis, we utilized 1:1 mixed bone marrow 
chimeras in an aerosol infection model, which allowed for the direct comparison of wild-
type (WT) and receptor knock-out (KO) CD8+ T cells within the same host mouse. This 
experimental system has the key advantage of exposing both WT and KO CD8+ T cells 
to the same inflammatory environment and bacterial burden throughout the infection.  
To generate chimeric mice, congenically marked recipients (CD90.1+) were 
lethally irradiated and reconstituted with equal ratios of WT (CD45.1+) bone marrow and 
bone marrow from one of the receptor knockout strains (CD45.2+) (Figure 2-3A). The 
donor knockout mice lacked one of following cytokine receptors: IL-12 receptor beta 2 
(IL-12R-/-), interferon-α/β receptor 1 (IFNAR-/-), or IL-27 receptor alpha (IL-27R-/-). After 
reconstitution, the resulting chimeras had equivalent ratios of WT and KO CD4+ and 
CD8+ T cells in the peripheral blood, lungs, and spleen (Figure 2-3B and 2-3C, and data 
not shown). This suggests that the absence of the individual cytokine receptors did not  
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Figure 2-3. IL-12, type 1 IFN, and IL-27 augment CD8+ T cell expansion following 
Mtb infection. 
 
(A) Overview of 1:1 mixed bone marrow chimera generation. The WT:KO 
combinations are: WT:IL-12R-/-; WT:IFNAR-/-; and WT:IL-27R-/-.  (B) Representative 
flow cytometry plots of CD3+ CD8+ T cells from the blood of the same chimeric 
mouse before and four weeks after infection with Mtb. (C) The ratio of WT to KO 
CD8+ T cells in the indicated 1:1 chimeric mice before and after infection (n = 9-10 
mice per group). **P < 0.01, ***P < 0.001, ****P < 0.0001 (paired Student’s t-test). 
Data are representative of three independent experiments. 
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significantly alter T cell development and homeostasis in uninfected mice. Once 
baseline reconstitution was assessed, the chimeras were infected via the aerosol route 
and examined four weeks later at the peak of the adaptive immune response. In control 
experiments, we generated 1:1 mixed bone marrow chimeras with a mixture of WT 
CD45.1+ and WT CD45.2+ bone marrow. These control mice maintained an equal ratio 
of CD45.1+ and CD45.2+ CD8+ T cells in the blood and lungs four weeks following 
infection with Mtb (Figure 2-4), confirming that both groups of donor-derived cells 
respond to infection. 
By determining the ratio of WT and KO CD8+ T cells in the blood, we tracked the 
proportions of WT and KO CD8+ T cells in the same mice before and after infection with 
Mtb. Four weeks after infection, IL-12R-/-, IFNAR-/-, and IL-27R-/- CD8+ T cells were 
underrepresented in the blood relative to WT cells (Figure 2-3B and 2-3C). This was 
also true in the lungs of infected mice, where the percentage and number of IL-12R-/-, 
IFNAR-/-, and IL-27R-/- CD8+ T cells were reduced relative to their WT counterparts in 
the same mouse (Figure 2-5A and 2-5B). Tetramer staining of CD8+ T cells specific for 
the immunodominant antigen TB10.44-11 (ESXH) revealed the same requirement for all 
three cytokines in maintaining antigen specific cells in the lungs, and KO CD8+ T cells 
comprised a significantly smaller percentage of the antigen-specific population (Figure 
2-5C). Overall, these data indicate that all three cytokines (IL-12, type 1 IFN, and IL-27) 
are necessary for the accumulation of CD8+ T cells in the lungs during tuberculosis. Of 
these cytokines, IL-12 appears to have the greatest impact, as IL-12R-/- CD8+ T cells 
demonstrated the most dramatic reduction in cell numbers. However, type 1 IFN and IL-
27 clearly have roles augmenting the magnitude of the CD8+ T cell response.  
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Figure 2-4. Both groups of donor bone marrow can contribute to the immune 
response following Mtb infection in 1:1 mixed bone marrow chimeras. 
 
Here, a control group of bone marrow chimeras was generated using a 1:1 mixture of 
WT CD45.1+ and WT CD45.2+ bone marrow. (A) The ratio of CD45.1+ to CD45.2+ 
CD8+ T cells after 6 and 12 weeks of reconstitution in uninfected mice. (B) The ratio 
of CD45.1+ to CD45.2+ CD8+ T cells before and four weeks after Mtb infection. (C) 
The percentage of antigen-specific CD8+ T cells positive for CD45.1 or CD45.2 in the 
blood. (D) The percentage CD8+ T cells positive for CD45.1 or CD45.2 in the lungs 
before and after infection. (E) Total number CD45.1+ and CD45.2+ CD8+ T cells in the 
lungs of uninfected mice and mice 4 weeks post-infection. (F) The percentage of 
antigen-specific CD8+ T cells positive for CD45.1 or CD45.2 in the lungs of infected 
chimeras. The tetramer used to determine antigen-specific CD8+ T cells contains the 
immunodominant epitope TB10.44-11. Each bar represents the mean ± SEM (n = 4-5 
mice per group). N.S. = not significant (paired Student’s t-test). Data are 
representative of two independent experiments.  
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Figure 2-5. IL-12, type 1 IFN, and IL-27 are required for the efficient 
accumulation of CD8+ T cells in the lungs following Mtb infection. 
 
(A) Representative flow cytometry plots of CD3+ CD8+ T cells from the lungs of the 
indicated chimeric mice 4 weeks after infection. (B) Total number of WT (CD45.1+) or 
KO (CD45.2+) CD8+ T cells in the lungs of uninfected chimeric mice and mice 4 
weeks post-infection. (C) The percentage of TB10.4-specific CD8+ T cells that are 
WT or KO in the lungs of infected chimeras. Each bar represents the mean ± SEM (n 
= 4-5 mice per group for the uninfected groups and n = 8-10 mice per group for the 
infected groups) **P < 0.01, ***P < 0.001, ****P < 0.0001 (paired Student’s t-test). 
Data are representative of three independent experiments for the infected groups 
and two independent experiments for the uninfected. 
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Both IL-12 and IL-27 influence the differentiation of effector CD8+ T cells during 
tuberculosis. 
 Following priming, CD8+ T cells can differentiate into several distinct effector 
subpopulations that are distinguishable by their expression of the cell surface markers 
killer cell lectin-like receptor subfamily G, member 1 (KLRG1) and interleukin-7 receptor 
(CD127) (103,104). Recently primed effector cells lack expression of both KLRG1 and 
CD127 and are known as early effector cells (EECs) (108). These cells then give rise to 
the two main effector subpopulations: short-lived effector cells (SLEC – KLRG1Hi 
CD127Lo) and memory precursor effector cells (MPEC – KLRG1Lo CD127Hi). MPECs 
are the population that will eventually give rise to long-lived memory cells. A fourth 
subpopulation exits that expresses both KLRG1 and CD127 (DPEC – double positive 
effector cell); however, the functional relevance of these cells remains unclear.  
The inflammatory environment elicited by the pathogen influences these cell fate 
decisions, and IL-12, type 1 IFN and IL-27 all have differing roles in CD8+ T cell 
differentiation during different infections (98,110). We examined the role of these 
cytokines in CD8+ T cell differentiation during tuberculosis using the 1:1 mixed bone 
marrow chimera model. Four weeks post infection, antigen-specific cells were 
determined by staining with TB10.44-11 tetramers, and the expression of KLRG1 and 
CD127 was then evaluated in the WT and receptor knockout populations. Following Mtb 
infection, WT CD8+ T cells primarily adopt a SLEC and EEC phenotype with few cells 
expressing CD127 (Figure 2-6A and 2-6B). Loss of IL-12 signaling severely skewed the 
differentiation of effector cells, resulting in a substantial decrease in terminally 
differentiated SLECs and a subsequent increase in both EECs and MPECs  
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Figure 2-6. IL-12 and IL-27 influence the differentiation of effector CD8+ T cells 
during tuberculosis. 
 
(A) Representative flow cytometry plots of lung CD8+ TB10.4+ T cells of the indicated 
genotype 4 weeks after infection in 1:1 mixed bone marrow chimeras. (B) Phenotypic 
analysis of CD8+ TB10.4+ cells based on KLRG1 and CD127 staining (EEC – Early 
Effector Cells; SLEC – Short-Lived Effector Cells; DPEC – Double Positive Effector 
Cell; MPEC – Memory Precursor Effector Cell) Each bar represents the mean ± SEM 
(n = 9-10 mice per group) **P < 0.01, ***P < 0.001, ‡P < 0.0001 (paired Student’s t-
test). Data are representative of three independent experiments. 
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(Figure 2-6A and 2-6B). Loss of type 1 IFN signaling had no impact on the relative 
proportion of effector subpopulations (Figure 2-6A and 2-6B). The absence of IL-27 
signaling lead to increased expression of CD127 accompanied by a mild decrease in 
EECs (Figure 2-6A and 2-6B). Frequently, an increase in MPECs is accompanied by 
decreased SLEC generation (98,108); however, SLECs accumulated normally without 
IL-27R. Of the cytokines examined, IL-12 appears to be a main determinant of CD8+ T 
cell differentiation during tuberculosis, as its absence resulted in the most substantial 
skewing of effector subpopulations. 
 
IL-12, type 1 IFN, and IL-27 have distinct and overlapping effects on CD8+ T cell 
function during tuberculosis.  
 IL-12, type 1 IFN, and IL-27 can all impact the acquisition of effector functions by 
CD8+ T cells, but their effects on CD8+ T cell function during tuberculosis has not been 
examined. Interferon gamma (IFN-γ) is a particularly important cytokine during 
tuberculosis, and CD8+ T cells are a source of this protective cytokine. We stimulated 
lung cells from 1:1 mixed bone marrow chimeras ex vivo with the immunodominant 
TB10.44-11 peptide and performed intracellular cytokine staining to assess the 
percentage of cells producing IFN-γ. As controls, lung cells were also left unstimulated 
or stimulated with anti-CD3 and anti-CD28. Significant levels of cytokine production 
were not observed in the unstimulated samples (data not shown). Of the three 
cytokines, IL-12 was the only one essential for IFN-γ production by lung CD8+ T cells 
four weeks after infection (Figure 2-7A and 2-7B). Compared to WT IFN-γ+ CD8+ T 
cells, the IL-12R-/- IFN-γ+ CD8+ T cells also had a significantly reduced MFI, indicating  
	  	   65	  
Figure 2-7. IL-12 promotes CD8+ T cell derived IFN-γ production. 
 
(A) Representative flow cytometry plots of lung CD8+ T cells of the indicated 
genotype 4 weeks after infection. Lung homogenates were stimulated ex vivo with 
TB10.4 peptide prior to IFN-γ ICS. (B) The percentage of WT and KO CD8+ T cells 
positive for IFN-γ as determined by ICS. Lung cells were stimulated ex vivo with 
either TB10.4 peptide or αCD3 and αCD28. (C) IFN-γ MFI of the IFN-γ+ populations 
from lung homogenates stimulated ex vivo with TB10.4 peptide (same samples as 
panel B). Each bar represents the mean ± SEM (n = 9-10 mice per group) N.S. = Not 
Significant, **P < 0.01, ***P < 0.001, ****P < 0.0001 (paired Student’s t-test). Data are 
representative of three independent experiments. 
 
Figure panels on following page. 
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Figure 2-7 (Continued). IL-12 promotes CD8+ T cell derived IFN-γ production. 
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that IFN-γ+ cells were making less cytokine in the absence of IL-12 signaling (Figure 2-
7C). Surprisingly, IL-27R-/- IFN-γ+ CD8+ T cells had a significantly higher MFI, 
suggesting that IL-27R-/- CD8+ T cells may produce more IFN-γ on a per cell basis. 
(Figure 2-7C). This may be analogous to the increase in IFN-γ production observed in 
CD4+ T cells from IL-27R-/- mice following Mtb infection (56). 
 In addition to cytokine production, IL-12, type 1 IFN, and IL-27 can alter the 
cytolytic capacity of CD8+ T cells. To address the role of these cytokines in inducing 
cytolytic function, we analyzed granzyme B levels in CD8+ T cells from the lungs of 1:1 
mixed bone marrow chimeras. Surprisingly, the loss of receptor signaling for all three 
cytokines resulted in decreased levels of granzyme B by both percentage and overall 
MFI (Figure 2-8A and 2-8B). These findings lead us to hypothesize that all three 
cytokines are required for optimal cytolytic function.  
 
Following Mtb infection, elicited CD8+ T cells remain cytolytic in the absence of IL-12, 
type 1 IFN, or IL-27 signaling.  
 With the goal of examining cytolytic function, we adopted a new strategy to 
generate bone marrow chimeras in which all the CD8+ T cells lacked the cytokine 
receptors of interest (Figure 2-9A). Briefly, TCRα-/- mice were lethally irradiated and 
reconstituted with a mixture of donor cells consisting of 80% CD8α-/- bone marrow and 
20% of either WT or receptor knockout bone marrow (IL-12R-/-, IFNAR-/-, or IL-27R-/-). In 
the resulting “4:1” chimeric mice, CD8+ T cells can only be derived from either the donor 
WT or receptor knockout bone marrow, depending on the experimental group. CD8+ T 
cells developed normally in these mice and responded robustly to aerosol infection with  
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Figure 2-8. Multiple cytokines augment granzyme B production. 
 
(A) Representative flow cytometry plots of lung CD8+ T cells of the indicated 
genotype 4 weeks after infection. Lung homogenates were stimulated ex vivo with 
TB10.4 peptide prior to intracellular staining for granzyme B. (B) The percentage of 
WT and KO CD8+ T cells positive for intracellular granzyme B staining from lung cells 
stimulated ex vivo with TB10.4 peptide. (C) MFI of total granzyme B staining in WT 
and KO CD8+ T cells from lung cells stimulated ex vivo with TB10.4 peptide (same 
samples as panel B). Each bar represents the mean ± SEM (n = 9-10 mice per 
group) *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (paired Student’s t-test). 
Data are representative of three independent experiments. 
 
Figure panels on following page. 
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Figure 2-8 (Continued). Multiple cytokines augment granzyme B production. 
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Figure 2-9. The “4:1” mixed bone marrow chimera system: A different approach 
to studying the role of IL-12R, IFNAR, and IL-27R on CD8+ T cells.  
 
(A) Overview of 4:1 mixed bone marrow chimera generation. Briefly, TCRα-/- mice 
were irradiated and reconstituted with a mixture of donor cells consisting of 80% 
CD8α-/- bone marrow and 20% of either WT or receptor knockout bone marrow (IL-
12R-/-, IFNAR-/-, or IL-27R-/-). (B) Total number CD8+ T cells in the lungs of uninfected 
mice and mice 6 weeks post-infection. (C) Total number CD8+ TB10.4+ T cells in the 
lungs of mice 6 weeks post-infection. (n = 4-5 mice per group). *P < 0.05, **P < 0.01 
(unpaired Student’s t-test). Data are representative of two independent experiments.  
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Mtb (Fig 2-9B and data not shown). After six weeks of infection, the chimeras with IL-
12R-/-, IFNAR-/-, or IL-27R-/- CD8+ T cells had the same bacterial burden as control 
chimeras with WT CD8+ T cells and all chimeras survived (data not shown).  
As a model, the 4:1 chimeras recapitulated many of the phenotypes observed in 
the 1:1 mixed bone marrow chimeras, and the loss of IL-12 signaling again had the 
largest effect on CD8+ T cell expansion in the lungs following infection (Figure 2-9B and 
2-9C). Compared to the 1:1 mixed bone marrow chimeras, this defect in IL-12R-/- CD8+ 
T cell expansion was less dramatic. In the 4:1 chimera model, type 1 IFN signaling also 
had a less dramatic effect on CD8+ T cell expansion, and the loss of IL-27R did not 
impact CD8+ T cell numbers during infection. This underscores the value of the 1:1 
mixed bone marrow chimera model where WT and KO cells can be directly compared in 
the same host environment. It is possible that the effect of type 1 IFN and IL-27 on 
CD8+ T cell expansion is only evident when KO cells are in direct competition with the 
WT response. Overall, this data supports the observation that type 1 IFN and IL-27 play 
a smaller role in supporting expansion. Beyond expansion, CD8+ T cell differentiation 
and function were also affected in the 4:1 chimera system. Again, only IL-12 and IL-27 
influenced the differentiation of effector cells (Figure 2-10). IL-12 was required for 
efficient IFN-γ production (Figure 2-11A), and granzyme B levels were reduced in IL-
12R-/-, IFNAR-/-, and IL-27R-/- CD8+ T cells (Figure 2-11B).  
An in vivo cytotoxicity assay was performed with the 4:1 chimeras by assessing 
the specific killing of fluorescently labeled target splenocytes loaded with TB10.44-11. We 
observed the killing of target cells in the both the lungs and spleens of infected mice, 
and only IL-12R-/- CD8+ T cells demonstrated diminished specific killing  
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Figure 2-10. IL-12 and IL-27 influence effector CD8+ T cells differentiation in the 
4:1 chimera model.  
 
Phenotypic analysis of CD8+ TB10.4+ cells based on KLRG1 and CD127 staining 
(EEC – Early Effector Cells; SLEC – Short-Lived Effector Cells; DPEC – Double 
Positive Effector Cell; MPEC – Memory Precursor Effector Cell) Each bar represents 
the mean ± SEM (n = 4-5 mice per group) *P < 0.05, **P < 0.01, ***P < 0.001, ‡P < 
0.0001 (unpaired Student’s t-test). Data are representative of two independent 
experiments. 
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Figure 2-11. Only IL-12 is required for IFN-γ production, but IL-12, type 1 IFN, 
and IL-27 all enhance granzyme B levels.  
 
(A) The percentage of WT and KO CD8+ T cells positive for IFN-γ as determined by 
ICS. Lung cells from 4:1 chimeras were stimulated ex vivo with either TB10.4 peptide 
or αCD3 and αCD28. (B) The percentage of CD8+ T cells positive for intracellular 
granzyme B staining in the lung. Each bar represents the mean ± SEM (n = 4-5 mice 
per group) *P < 0.05, **P < 0.01 (unpaired Student’s t-test). Data are representative 
of two independent experiments. 
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(Figure 2-12A and 2-12B). Given that IL-12R-/- CD8+ T cells have a profound defect in 
the expansion of antigen-specific cells (Figure 2-9B and 2-9C), it was important to 
determine if the reduced level of specific killing resulted from fewer antigen-specific cells 
or actually reflected the functional capacity of the cytotoxic lymphocytes. By plotting the 
absolute number of TB10.4-specifc CD8+ cells in the spleen versus specific killing, it 
was apparent that cell number had the greatest impact on the percentage of target cells 
lysed (Figure 2-13). This correlation was most robust in the spleens where a higher 
number of target cells were recovered, but similar results were observed in the lungs 
(data not shown). These findings suggest that cytolytic cells are still generated in the 
absence of IL-12, type 1 IFN, or IL-27 signaling, despite an overall reduction in 
granzyme B levels. Multiple molecules and several different pathways contribute to 
cytolysis (117,118), thus it is likely that the loss of individual cytokine receptors does not 
have a substantial impact this effector function.  
 
IL-12 mediates CD8+ T cell priming in the lung draining lymph node, while type 1 IFN 
and IL-27 exert the majority of their effects in the lungs. 
 IL-12, type 1 IFN, or a combination of the two are known to provide a necessary 
third signal for priming CD8+ T cells in multiple infections, but their role as “signal 3” 
cytokines during tuberculosis is unknown. At present, IL-27 is not considered a signal 3 
cytokine, but it has several of the same attributes. IL-27 can support CD8+ T cell 
expansion, the induction of cytolytic activity, and it influences CD8+ T cell differentiation. 
Because IL-12, type 1 IFN, and IL-27 all influence the magnitude of the CD8+ T cell 
response during tuberculosis, we examined if these effects are mediated at the onset of 
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Figure 2-12. IL-12R-/- CD8+ T cells exhibit reduced specific killing in an in vivo 
cytotoxicity assay.  
 
In vivo cytolytic activity of TB10.4-specific CD8+ T cells in the lungs (A) and spleens 
(B) of infected 4:1 chimeras. Here, target cells were pulsed with 100 nM of TB10.4 
peptide. Specific killing was calculated as described in the Materials and Methods. 
Each bar represents the mean ± SEM (n = 4-5 mice per group) N.S. = Not 
Significant, *P < 0.05, **P < 0.01, ***P < 0.001 (unpaired Student’s t-test). Data are 
representative of two independent experiments. 
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Figure 2-13. The reduced specific killing by IL-12R-/- CD8+ T cells is the result of 
diminished CD8+ T cell numbers.  
 
(A) The total number CD8+ TB10.4+ T cells in the spleens of mice 6 weeks post-
infection. (B) Nonlinear regression analysis of TB10.4-specific CD8+ T cell number 
vs. specific killing for each group of 4:1 chimeras. In every experiment, the data is 
best fit by a single curve. Each bar represents the mean ± SEM (n = 4-5 mice per 
group) *P < 0.05, **P < 0.01, ***P < 0.001 (unpaired Student’s t-test). Data are 
representative of two independent experiments. 
	  	   77	  
priming or occur later in the lungs.  
 To address this question, we utilized a retrogenic mouse model in which a high 
percentage of CD8+ T cells are specific for the immunodominant antigen TB10.44-11. 
One of the key advantages of retrogenic mice is that naïve antigen-specific CD8+ T cells 
can be generated on nearly any genetic background, thus providing a source of naïve 
TB10.44-11-specific IL-12R-/-, IFNAR-/-, and IL-27R-/- CD8+ T cells. Our lab has recently 
validated this system as a means of obtaining large numbers of functional TB10.44-11-
specific CD8+ T cells, and upon adoptive transfer, these cells are primed in the draining 
lymph node approximately 11 days following aerosol infection (Nunes-Alves et al., in 
press). This delay in T cell priming results from the delayed transfer of Mtb from the lung 
to the draining lymph node (119). In these priming experiments, equal numbers of 
congenically marked WT and receptor KO retrogenic (Rg) TB10.44-11-specific CD8+ T 
cells were transferred into recipient mice 7 days after low-dose aerosol infection, and 
the ratio of WT and KO Rg CD8+ T cells was assessed at days 8, 11, 13, and 15.  
 At day 8, the ratio of WT and receptor KO Rg CD8+ T cells was unaltered from 
the ratio of cells injected at day 7 and no group of cells diluted proliferation dye (Figure 
2-14A and data not shown). By day 11 in the mediastinal lymph node, IL-12R-/- Rg CD8+ 
T cells were underrepresented relative to WT cells and continued to lag behind through 
days 13 and 15 (Figure 2-14A). Throughout the experiment, IFNAR-/- and IL-27R-/- Rg 
CD8+ T cells maintained a consistent ratio with WT cells in the lymph node, indicating 
that type 1 IFN and IL-27 are dispensable for CD8+ T cell priming following Mtb infection 
(Figure 2-14A). Overall, the expansion of IFNAR-/- and IL-27R-/- CD8+ T cells was 
equivalent to WT cells in the lymph node at all the time points (Figure 2-14B).  
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Figure 2-14. IL-12 acts as a Signal 3 cytokine during tuberculosis and promotes 
CD8+ T cell priming in the lung draining lymph node. 
 
Equal numbers of retrogenic (Rg) TB10.4-specific CD8+ T cells were transferred into 
mice 7 days after low-dose aerosol infection with Mtb. (A) The percentage of total 
retrogenic (Rg) cells that were WT or KO for the indicated cytokine receptor in the 
mediastinal lymph node at days 8, 11, 13 and 15 following infection. (B) Total number 
of WT and KO Rg cells detected in the lymph node at the indicated time points. (C) 
Histograms depicting the dilution of the proliferation dye efluor 450 in Rg cells in 
lymph node at day 11. Each group of samples (WT or KO) was concatenated into a 
single histogram. Each bar or point represents the mean ± SEM (n = 4-5 mice per 
group) ‡P < 0.0001 (Holm-Šídák multiple comparisons testing following two-way 
ANOVA). Data are representative of two independent experiments. 
 
Figure panels on following page. 
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Figure 2-14 (Continued). IL-12 acts as a Signal 3 cytokine during tuberculosis 
and promotes CD8+ T cell priming in the lung draining lymph node. 
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Surprisingly, IL-12R-/- Rg CD8+ T cells still expanded significantly in the lymph node, 
though they did lag behind WT cells (Figure 2-14B). Indeed, IL-12R-/- Rg CD8+ T cells in 
the lymph node substantially diluted their proliferation dye by day 11 post-transfer, 
though not as efficiently as WT cells (Figure 2-14C). These observations indicate that 
additional signals present in the lymph node facilitate CD8+ T cell priming and suggest 
that an additional signal 3 cytokine may exist. Additionally, type 1 IFN or IL-27 may be 
able to support priming in the absence of IL-12. IFNAR-/- and IL-27R-/- Rg CD8+ T cells 
diluted their proliferation dye equivalent to WT cells by day 11, reinforcing that these 
signals are not needed to prime cells in the lymph node when IL-12 is present (Figure 2-
14C).  
 In the same priming experiments, the expansion of the transferred cells was 
monitored in the lungs of recipient mice. Similar to the observations in the lymph node, 
IL-12R-/- Rg CD8+ T cells continued to expand over the course of the experiment; 
however, they underperformed relative to WT cells (Figure 2-15A and 2-15B). This 
suggests that IL-12 is necessary for the efficient priming of CD8+ T cells in the lymph as 
well as their continued expansion in the lungs. Though type 1 IFN and IL-27 are 
dispensable for CD8+ T cell priming, their influence on CD8+ T cell expansion in the 
lungs was observable at 13 days post infection, and the percentage of IFNAR-/- and IL-
27R-/- Rg CD8+ T cells decreased relative to their WT counterparts at days 13 and 15 
(Figure 2-15A and 2-15B). These data suggest that type 1 IFN and IL-27 primarily 
influence the accumulation of CD8+ T cells in the periphery after priming has occurred.  
 
	  	   81	  
 
Figure 2-15. IL-12, type 1 IFN, and IL-27 augment the expansion of CD8+ T cells 
in the lungs during tuberculosis. 
 
Equal numbers of retrogenic (Rg) TB10.4-specific CD8+ T cells were transferred into 
mice 7 days after low-dose aerosol infection with Mtb. (A) The percentage of total 
retrogenic (Rg) cells that were WT or KO for the indicated cytokine receptor in the 
lungs at days 8, 11, 13 and 15 following infection. (B) Total number of WT and KO Rg 
cells detected in the lungs at the indicated time points. Each bar or point represents 
the mean ± SEM (n = 4-5 mice per group) ‡P < 0.0001  (Holm-Šídák multiple 
comparisons testing following two-way ANOVA). Data are representative of two 
independent experiments. 
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Discussion 
 Infection with Mtb elicits a complex inflammatory milieu that shapes the adaptive 
immune response. Here, we examined the impact of inflammation on CD8+ T cell 
function by focusing on three cytokines known to influence host resistance. Using 1:1 
mixed bone marrow chimeras and the transfer of naïve Ag-specific CD8+ T cells, we 
show that IL-12 is a major regulator of the CD8+ T cell response during tuberculosis. 
Following aerosol infection, IL-12 is essential for efficient CD8+ T cell priming in the 
lymph node and subsequent expansion in the lungs. IL-12 also promotes the terminal 
differentiation of SLECs and enhances IFN-γ production. For these reasons, IL-12 is the 
dominant signal 3 cytokine during tuberculosis.  
 However, IL-12 is not acting alone in the infected host. We demonstrate a 
supporting role for both type 1 IFN and IL-27 in expansion. These effects are not 
observed in the lymph node during the priming of naïve CD8+ T cells and only become 
evident in the infected lungs. Because they are dispensable for priming, we argue type 
1 IFN and IL-27 are not acting as signal 3 cytokines. Comparatively, IL-12 has the most 
dramatic impact on CD8+ T cell numbers, likely because it influences expansion in both 
the lymph node and the lungs. Though less pronounced, type 1 IFN and IL-27 each 
have a non-redundant role augmenting the magnitude of the CD8+ T cell response in 
the lungs. This is most evident in the 1:1 mixed bone marrow chimeras, where WT and 
KO cells are in direct competition within the same inflammatory environment. This 
complex involvement of multiple inflammatory cytokines is similar to other infections, 
where IL-12 and type 1 IFN both support CD8+ T cell expansion (98). In this way, CD8+ 
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T cells reflect the inflammatory environment of the host, responding in different degrees 
to each cytokine present. 
 Type 1 IFN negatively impacts host immunity to Mtb through a number of 
mechanisms, but a direct effect on T cells has not been examined. In 1:1 mixed bone 
marrow chimeras, type 1 IFN supported CD8+ T cell expansion and had no impact on 
CD4+ T cell numbers (data not shown). Based on these findings, type 1 IFN does not 
have a directly negative effect on T cells and instead boosts the expansion of CD8+ T 
cells in the lungs. Beyond this effect, type 1 IFN was not required for CD8+ T cell 
differentiation or function in our experiments.  
We were surprised to discover IL-27 had no impact on effector functions. IL-27 is 
a critical promoter of IFN-γ production by CD8+ T cells in other infections (58); but we 
did not observe this during tuberculosis. It is possible that the strong effect of IL-12 
masks a role for IL-27; however, this seems unlikely. During T. gondii infection, IL-27 is 
necessary for IFN-γ production, while IL-12 levels drive the generation of effector CD8+ 
T cells (58,99,120). Thus in other infections, IL-27 is capable of driving IFN-γ-production 
even in the presence of high IL-12. The effects of IL-27 on CD8+ T cell-derived IFN-γ 
are likely pathogen-specific, and it is clearly unnecessary during tuberculosis. The loss 
of IL-27 signaling does influence CD8+ T cell differentiation. It is dispensable for SLEC 
generation, but limits CD127 expression. Thus, IL-27R-/- cells were more likely to 
become DPECs and MPECs. Based on this observation, it is tempting to speculate that 
IL-27 limits the formation of memory during tuberculosis; however, such a possibility 
cannot be addressed with our current data.  
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IL-12, type 1 IFN, and IL-27 all promote granzyme B production following Mtb 
infection, but no loss in in vivo cytolytic activity is observed. Mice with IL-12R-/- CD8+ T 
cells show reduced specific killing; however, out data indicate this results from reduced 
CD8+ T cell numbers not cytolytic function. In fact, IL-12R-/- CD8+ T cells were highly 
capable of lysing targets cells in vivo. This observation is likely due to redundancy in 
regulating cytolysis. For example, multiple cytokines may support cytolytic activity, 
therefore, the loss of a single cytokine fails to perturb specific killing. Additionally, there 
are multiple molecules and mechanisms involved in cytolysis during tuberculosis 
(117,118), thus a reduction in granzyme B levels alone may have a marginal impact 
overall. In particular, perforin is critical for cytolysis during tuberculosis (117). However, 
a reliable method for perforin staining in murine cells has only recently become 
available (121), thus we did not assess perforin expression in these experiments. 
Nonetheless, cells retain a high degree of cytolytic activity even in the absence of IL-12. 
This suggests that cytolysis is a robust effector mechanism found even in dysfunctional 
cells, such as IL-12R-/- CD8+ T cells.  
Using adoptively transferred retrogenic cells, we tracked CD8+ T cell priming in 
the lung draining lymph. IL-12 was critical for supporting priming, however, naïve IL-
12R-/- CD8+ T cells still expanded in all of our experiments. This implies other signals 
support CD8+ T cell priming in the absence of IL-12. During tuberculosis, IL-23 can 
compensate for the absence of IL-12 to promote CD4+ T cell responses. We used IL-
12Rβ2-/- cells in all our experiments, thus IL-23 signaling remained intact. It is possible 
that IL-23 supported CD8+ T cell expansion; however, in vitro experiments have failed to 
associate IL-23 with signal 3 activity, making it an unlikely candidate (100). Though type 
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1 IFN and IL-27 are dispensable for priming, it is possible they promote it in the absence 
of IL-12. We have recently acquired IL-12R/IFNAR double knockout mice and will soon 
test the priming ability of these cells. During vaccinia virus infection, neither IL-12 nor 
type 1 IFN are required to generate a CD8+ T cell response, thus unknown sources of 
signal 3 must exist.  IL-21 is a potential candidate, and it acts as a signal 3 cytokine in 
vitro (discussed in Chapter 3) (122). Such a scenario would be somewhat 
unconventional, because activated CD4+ T cells produce IL-21, not DCs.  
Our current understanding of CD8+ T cell responses during tuberculosis is 
limited. These data illuminate a portion of the cytokine network regulating these cells 
and illustrate the complex ways in which inflammation shapes the adaptive immune 
response. CD8+ T cells are similar to CD4+ T cells in their requirement for IL-12, but 
have the opposite response to IL-27 signaling. It is intriguing to consider that IL-27 
functions to limit a pathological CD4+ T cell response while simultaneously supporting 
the expansion of CD8+ T cells. In this way, IL-27 can possibly achieve a balance of IFN-
γ-producing cells in the lungs. Relationships such as these must be understood if we 
hope to design better vaccination strategies in the future.  
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Materials and methods 
 
Mice  
C57BL/6 (WT), CD45.1 (B6.SJL-PtprcaPepcb/BoyJ), CD90.1 (B6.PL-Thy1a/CyJ), 
TCRα-/- (B6.129S2-Tcratm1Mom/J), CD8α-/- (B6.129S2-Cd8atm1Mak/J), IL-12 receptor beta 
2 deficient (IL-12R-/-: B6.129S1-Il12rb2tm1Jm/J), and IL-27 receptor alpha deficient (IL-
27R-/-: B6N.129P2-Il27ratm1Mak/J) mice were purchased from Jackson Laboratories (Bar 
Harbor, ME). Interferon-α/β receptor deficient mice (IFNAR-/-) were obtained from Dr. 
Raymond M. Welsh and were previously described (123,124). Mice were 6 to 10 weeks 
old at the start of all experiments. All animal experiments were performed in accordance 
with National and European Commission guidelines for the care and handling of 
laboratory animals and were approved by the National Veterinary Directorate and by the 
local Animal Ethical Committee or Institutional Animal Care and Use Committee (Animal 
Welfare Assurance no. A3023-01 [DFCI] or A3306-01 [UMMS]), under Public Health 
Service assurance of Office of Laboratory Animal Welfare guidelines). Mice infected 
with M. tuberculosis were housed in a biosafety level 3 facility under specific pathogen-
free conditions at DFCI or at UMMS. 
 
Generation of mouse bone marrow chimeras 
1:1 mixed bone barrow chimeras were made by lethally irradiating CD90.1+ 
recipients (2 doses of 600 rads separated by three hours). Bone marrow was flushed 
from the femurs, tibia, and humeri of donor mice and RBC lysed. Bone marrow cells 
were then enumerated and groups were combined in a 1:1 ratio. Each recipient mouse 
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received a total of 107 bone marrow cells (5×106 of WT and 5×106 of KO) via lateral tail 
vein injection and was kept on antibiotic-treated water for 5 weeks following irradiation. 
Mice were checked for reconstitution by retro-orbital bleeding to assess the ratio of 
donor cells in the peripheral blood by flow cytometry. Bone marrow chimeras were 
infected with Mtb 8-10 weeks after transfer of the bone marrow cells. For 4:1 chimeras, 
TCRα-/- mice were given a lower dose of radiation (2 doses of 500 rads separated by 
three hours). The ratio of donor cells in these chimeras was 80% CD8α-/- and 20% of 
the indicate KO bone marrow.  
 
Generation of retrogenic mice  
TCR retroviral constructs were generated as 2A-linked single open reading 
frames using PCR and cloned into a murine stem cell virus-based retroviral vector with 
a GFP marker as previously described (125). Details of cloning strategies and primer 
sequences are available upon request (Samuel.behar@umassmed.edu). Retroviral-
mediated stem cell gene transfer was performed as previously described (125). 
 
Experimental infection and bacterial quantification 
Infection with M. tuberculosis (Erdman strain) was performed via the aerosol 
route, and mice received a day 1 inoculum of 50-200 CFU. A bacterial aliquot was 
thawed, sonicated twice for 10 seconds in a cup horn sonicator, and then diluted in 
0.9% NaCl–0.02% Tween 80. A 15 ml suspension of M. tuberculosis was loaded into a 
nebulizer (MiniHEART nebulizer; Vortran Medical Technologies) and mice were infected 
using a nose-only exposure unit (Intox Products). Alternatively, the bacterial aliquot was 
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diluted in a final volume of 5ml, and mice were infected using a Glas-Col aerosol-
generation device. At different times post-infection, mice were euthanized by carbon 
dioxide inhalation, organs were aseptically removed, individually homogenized and 
viable bacteria were enumerated by plating 10-fold serial dilutions of organ 
homogenates onto 7H11 agar plates. Plates were incubated at 37ºC and M. 
tuberculosis colonies were counted after 21 days. 
 
FACS analysis 
Cell suspensions from lung, spleen and lymph nodes were prepared by gentle 
disruption of the organs through a 70µm nylon strainer (Fisher) or using the GentleMacs 
apparatus (Miltenyi Biotec, Germany) according to the manufacturer’s instructions. For 
lung preparations, tissue was digested for 30-60 min at 37°C in cRPMI with 300U/ml 
collagenase (Sigma) prior to straining. Erythrocytes were lysed using a hemolytic 
solution (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM sodium EDTA pH 7.2) and, after 
washing, cells were resuspended in supplemented RPMI (cRPMI - 10% heat inactivated 
FCS, 10 mM HEPES, 1 mM sodium pyruvate, 2 mM L-glutamine, 50 mg/ml 
streptomycin and 50 U/ml penicillin, all from Invitrogen) or MACS buffer (Miltenyi Biotec, 
Germany). Cells were enumerated in 4% trypan blue on a hemocytometer or using a 
MACSQuant flow cytometer (Miltenyi Biotec, Germany). Surface staining was 
performed with antibodies specific for mouse CD3 (clone 17A2), CD3ε (clone 145-
2C11), CD4 (clone GK1.5), CD8 (clone 53-6.7), CD19 (clone 6D5), CD44 (clone IM7), 
CD62L (clone MEL-14), CD45.1 (clone A20), CD45.2 (clone 104), CD90.1 (clone OX-7), 
CD90.2 (clone 53-2.1), CD127 (clone A7R34), KLRG1 (clone 2F1/KLRG1) and Va2 
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(clone B20.1), (from Biolegend, CA, USA, or from BD Pharmingen, CA, USA). The 
tetramers of TB10.44–11-loaded H-2 Kb were obtained from the National Institutes of 
Health Tetramer Core Facility (Emory University Vaccine Center, Atlanta, GA, USA). All 
staining was performed for 20 min at 4°C and, unless otherwise stated, cells were fixed 
before acquisition with 1% formaldehyde in PBS for 30-60 min. Cell analysis was 
performed on a FACS Canto (Becton Dickinson, NJ, USA) or on a MACSQuant flow 
cytometer (Miltenyi Biotec, Germany). Data were analyzed using FlowJo Software (Tree 
Star, OR, USA). For FACS analysis, single-lymphocyte events were gated by forward 
scatter versus height and side scatter for size and granularity. 
 
Intracellular cytokine staining 
5×105-1×106 cells were plated in each well of a round bottom 96-well plate and 
incubated in the presence of TB10.44-11 peptide (10 µM; New England Peptide). 
Incubation in the presence of αCD3/αCD28 (1 µg/mL; BioLegend) or in the absence of 
stimuli were used as positive and negative controls, respectively. Cells were incubated 
for 1 hour at 37ºC, at which point GolgiPlug solution (BD Pharmingen, CA, USA) was 
added to each well for the remaining 4 hours. Cells were collected after the 5 hours 
stimulation and then surface stained with the antibodies described above, followed by 
intracellular staining for IFN-γ (clone XMG1.2), TNF (clone MPX6-T22), or granzyme B 
(clone gb11) using the BD Permwash Kit (BD Pharmingen, CA, USA) as per 
manufacturer’s instructions. 
 
In vivo cytotoxicity assay 
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In vivo cytotoxicity was determined using peptide-coated splenocytes 
differentially labeled with the fluorescent dyes CFSE and efluor 450 (eBiosciences) as 
previously described (12, 31)(117). All target cells were obtained from uninfected mice. 
Target cells were labeled in PBS for either 20 minutes (efluor 450) or 10 minutes 
(CFSE) at room temperature, followed by extensive washing. Target cell populations 
were pulsed with 10-0.01 µM of the TB10.44-11 peptide at 37°C for 1 hour in complete 
medium or left unpulsed. Labeled populations were mixed at an equal cell ratio and 
injected IV into age-matched uninfected and infected recipient mice (2.5x106 of each 
labeled population per mouse). After 20 hours, recipient spleens and lungs were 
harvested and single-cell suspensions were made as described. Ratios of recovered 
CFSE- and efluor 450-labeled target lymphocyte populations were determined by flow 
cytometry. Percent specific killing was determined by the following formula: percent 
specific killing = 100 – (100 - (ratio in infected mice)/(ratio in uninfected mice)), where 
ratio = percent peptide-pulsed target cells/percent unpulsed target cells. 
 
Adoptive T cell transfer 
Single cell suspensions of pools of spleens and lymph nodes from naive 
retrogenic mice (6 to 12 weeks post reconstitution) were prepared. CD8+ T cells were 
purified from each suspension using the CD8+ T cell isolation kit and magnetic 
separation (STEMCELL Technologies Inc, Canada). After purification, cells were 
counted and transferred via the tail vein into congenically marked recipients (CD45.1 or 
CD90.1), which had been infected 7 days earlier with virulent Mtb (Erdman) via the 
aerosol route. For all experiments, 3×104 -5×104 cells of each group were transferred 
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into each recipient.  
 
Measurement of cell proliferation 
For analysis of cell proliferation of retrogenic cells after adoptive transfer, bead-
purified naïve Rg cells (see above) were labeled with 5 µM cell proliferation dye efluor 
450 (eBiosciences) in PBS for 20 min at room temperature, followed by extensive 
washing. 
 
Cell isolation and microarray analysis 
Female C57BL/6 mice were infected with Mtb Erdman as described above. At 
the indicated time points, mice were euthanized by cervical dislocation and lungs were 
harvested after perfusion with collagenase containing media. Lungs were allowed to 
digest in collagenase-containing media for 15 minutes before being homogenized into 
single cell suspensions. At this point, the lungs from 3 individual mice were combined 
into a single sample. T cells were then purified by negative magnetic bead selection 
(Miltenyi Biotec, Germany). Purified cells were stained to distinguish CD4+ and CD8+ T 
cells (CD19, CD3, CD4, CD8). For cell sorting, stained cells were suspended in MACS 
buffer (Miltenyi Biotec, Germany) and deposited in collection tubes using a BD Canto 
flow cytometer (Becton Dickinson, NJ, USA). 50,000 CD19-CD3+CD4+ or CD19-
CD3+CD8+ cells were sorted directly into TRIzol Reagent (Life Technologies, California) 
and immediately frozen. RNA extraction, microarray hybridization (Affymetrix MoGene 
1.0ST array) and data processing were done at the ImmGen Project processing center. 
Details of the data analysis and quality control can be found at (www.immgen.org). 
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Cytokine measurements 
 Flash frozen lung lobes from infected mice were thawed and lysed using the Bio-
Rad Bio-Plex Cell Lysis Kit (Bio-Rad Laboratories, Inc., CA, USA) and a FastPrep-24 
homogenizer (MP Biomedicals, CA, USA). Protein concentrations were quantified using 
the Pierce BCA protein assay kit (Life Technologies, CA, USA) and diluted to a 
concentration of 1.5 mg/mL in PBS containing BSA. Samples were analyzed using the 
Bio-Rad Bio-Plex Pro Mouse Ctyokine Immunoassay and a Bio-Rad Bio-Plex 200 
suspension array reader.  
 
Statistical analysis 
All data are represented as mean with SEM. Comparisons of two groups within 
1:1 mixed bone marrow chimeras were done with a paired student’s t-test. All other 
comparisons were done with an unpaired student’s t-test and are indicated in the figure 
legends. Comparisons of more than two groups were done using Holm-Šídák multiple 
comparisons testing following two-way ANOVA. Significance was represented by the 
following symbols: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, and ‡P < 0.0001. 
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Abstract 
  
 IL-21 is primarily produced by activated CD4+ T cells and is a mediator of CD4 
help to both CD8+ T cells and B cells. During chronic viral infections, IL-21 acts directly 
on CD8+ T cells to support expansion and cytokine production in addition to actively 
inhibiting CD8+ T cell exhaustion. Though IL-21 is essential during many chronic 
infections, it has never been closely examined during tuberculosis. Here, we define an 
essential role for IL-21 during the immune response to tuberculosis and establish it as a 
mediator of host resistance.  
 We address the impact of IL-21 on the immune response with the use of mixed 
bone marrow chimeras. These experiments indicate IL-21R is required on CD8+ T cells 
for efficient expansion and acquisition of effector functions during tuberculosis. Using 
the adoptive transfer of Ag-specific IL-21R-/- CD8+ T cells, we demonstrate that CD8+ T 
cells require IL-21 for expansion both in the lymph node during priming and in the lungs. 
This suggests IL-21 acts as “signal 3” cytokines and is required at all stages of the CD8+ 
T cell response. These observations highlight the vital role of CD4+ T cell help during 
tuberculosis, as CD4+ T cells are the primary source of IL-21.  
 We also show preliminary data examining the susceptibility of IL-21R-/- mice. 
Four weeks after aerosol infection, IL-21R-/- mice have reduced numbers of CD8+ T 
cells, but otherwise have an intact immune response. At later time points, CD8+ T cells 
show signs of exhaustion, including increased PD-1 expression and decreased TNF 
production. By sixteen weeks post-infection, IL-21R-/- mice failed to control bacterial 
growth and have reduced numbers of both CD4+ and CD8+ T cells in the lungs. These 
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data indicate IL-21R signaling supports resistance during chronic infection and is 
essential to maintain both CD4+ and CD8+ T cell responses. We are currently 
investigating the mechanism behind the decline in CD4+ T cell numbers observed in IL-
21R-/- mice.  During tuberculosis, IL-21 is essential for CD8+ T cell responses and it 
influences host resistance through multiple mechanisms.  
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Introduction 
 
Basic biology of IL-21 
The common receptor gamma-chain (γc) family of cytokines consist of IL-2, IL-7, 
IL-9, IL-15, and IL-21, and all members share the common gamma-chain (γc) as a 
component of their individual receptors (1). The γc was first cloned in 1992 as a 
component of the IL-2 receptor, thus IL-2 is the prototypical member of this cytokine 
family (2). Cytokines that signal through γc support the survival and function of a variety 
of immune cells, a fact that is highlighted by the human disease X-linked severe 
combined immunodeficiency (XSCID). Patients with XSCID lack T cells and NK cells 
and have nonfunctioning B cells as a result of mutations in the gene encoding γc 
(IL2RG) (3,4). In particular, many cytokines that utilize γc are important for CD8+ T cells. 
IL-2 can support CD8+ T cell expansion both during priming and memory recall (5-11). 
IL-7 is required for the homeostatic proliferation of naïve CD8+ T cells and supports the 
survival of memory cells (12,13). IL-15 is necessary for SLEC survival in addition to the 
proliferative maintenance of memory CD8+ T cells (14-19). Thus, IL-2 and IL-15 are 
essential for effector CD8+ T responses and IL-7 and IL-15 maintain memory 
populations.  
The IL-21 receptor (IL-21R) was first discovered in 2000, and the identification of 
its ligand, IL-21, soon followed (20,21). In 2001, γc was recognized as the other 
essential component for IL-21R signal transduction, placing IL-21 in the γc family of 
cytokines (22,23). IL-21R is predominantly expressed on B, CD4+ T, CD8+ T, NKT, and 
NK cells, though B cells express the highest amounts by far (24). Early studies suggest 
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IL-21R is expressed at relatively low levels on resting T cells and is upregulated upon 
TCR stimulation or IL-21 signaling (24-27). IL-21R expression has also been noted on 
DCs, macrophages, and some non-hematopoietic cells (28-30). IL-21 is mainly 
produced by CD4+ T and NKT cells, but studies have also noted production by CD8+ T 
and γδ T cells (21,24,31-36). Interestingly, NKT cells, but not CD4+ T cells, produce 
high amounts of IL-21 in response to activation with bacillus Calmette-Guérin (BCG) 
(32). Since it’s discovery, IL-21 has been ascribed important roles during infection, 
autoimmunity, and cancer (4,37). Largely, its effects are pro-inflammatory and primarily 
influence B, CD4+ T, and CD8+ T cell functions. 
 
IL-21 supports plasma cell generation and antibody production 
 In addition to lacking T and NK cells, XSCID patients have nonfunctional B cells. 
One mechanism behind this dysfunction was revealed with the discovery that IL-21R-/- 
mice have dramatically impaired Ag-specific IgG1 production in response to 
immunization and infection (38). IL-21 is not necessary for B cell development, but 
multiple studies have implicated a role for it in immunoglobulin production and plasma 
cell generation (38-42).  It is also important for the formation of germinal centers (GCs). 
GCs are sites of B cell expansion, somatic hypermutation, and affinity maturation. They 
are also necessary for the formation of memory B cells and plasma cells. IL-21 supports 
GC formation by acting directly on B cells to promote the expression of the transcription 
factor Bcl-6; however, GC formation can occur independently of IL-21 in some contexts 
(43-45). The source of IL-21 during GC formation is T follicular helper cells (Tfh), a 
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subset of CD4+ T cells that assist in forming and maintain GCs.  These cells, along with 
TH17 cells, are major producers of IL-21. 
 
IL-21 and CD4+ T cell subsets 
 Broadly, IL-21 influences CD4+ T cells by promoting TH2 polarization while also 
limiting TH1 polarization, but it is also affects other T helper subsets. (46-49). Tfh cells 
are important for B cell help and are among the greatest producers of IL-21 (37,50-52). 
Tfh cells also respond directly to IL-21, though its role in their development is somewhat 
controversial. IL-21 is not absolutely required for Tfh generation, but it synergizes with 
other cytokines, mainly IL-6, to promote Tfh differentiation and function (52-55). IL-21 
also affects both regulatory T cells (Tregs) and TH17 cells. It antagonizes the expansion 
of regulatory T cells (Tregs) through direct signaling and indirectly by suppressing IL-2 
levels (56,57). This ability to suppress Treg expansion inherently supports the 
generation of TH17 cells. Similar to Tfh cells, TH17 cells make and respond to IL-21. It is 
not required for TH17 development in vivo, but promotes the expansion of existing TH17 
cells (33,37,58-62). IL-21 assists in maintaining TH17 cells by inducing IL-23R 
expression, and IL-23 signaling subsequently preserves the TH17 phenotype (62). CD4+ 
T cells are the major sources of IL-21 during a variety of diseases states, thus they 
mediate much of its effects in vivo.  
 
IL-21 and CD8+ T cells 
 Similar to B cells, CD8+ T cells respond to IL-21 and are major targets of its 
effects (24). CD8+ T cells can produce IL-21 in some settings, and it may act in an 
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autocrine manner to promote effector function (63). However, the relevance of CD8+ T 
cell-derived IL-21 is poorly understood, and most studies implicate CD4+ T cells as the 
primary source of this cytokine. IL-21 is not essential for naïve CD8+ T cell 
development, but it can profoundly shape primary and, to some extent, memory 
responses. Indirectly, IL-21 supports CD8+ T cell proliferation and effector function by 
restricting the expansion of Tregs (57,64); however, its effects are largely mediated by 
direct signaling on CD8+ T cells. Numerous in vitro studies with both murine and human 
cells have demonstrated a direct stimulatory effect on CD8+ T cell expansion (65-68). 
IL-21 can synergize with IL-15, and to a lesser extent IL-7, to promote proliferation, and 
it independently supports cell survival (67,69-71). In experiments with artificial antigen 
presenting cells (aAPCs), IL-21 facilitated naïve CD8+ T cell priming and cytotoxic T 
lymphocyte (CTL) differentiation when combined with IL-2, TCR ligation, and co-
stimulation (72). Thus, IL-21 may act as a signal 3 cytokine; however, this has never 
been fully addressed in vivo. CD4+ T cell-derived IL-21 can also rescue the expansion 
of naïve CD8+ T cells under priming conditions where IL-2 is depleted, suggesting IL-21 
can stand-in for IL-2 in some contexts (73). In addition to its effects on primary 
expansion, IL-21 can support memory responses, though there are conflicting reports 
regarding its role in memory development. Following the clearance of certain acute 
strains of lymphocytic choriomeningitis virus (LCMV), memory IL-21R-/- CD8+ T cells 
expand poorly upon rechallenge (74). During vaccinia virus (VV) infection, IL-21R-/- 
CD8+ T cells are unable to survive the contraction phase and fail to form a memory pool 
(71). Still, other reports show IL-21 is dispensable for memory responses, and this role 
likely varies between pathogens (34).  
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 IL-21 augments effector function by promoting IFN-γ, granzyme B, and perforin 
production, and it also enhances cytotoxicity (65-67,75,76). In mouse models of tumor 
growth, IL-21 therapy potently limits tumor size in a manner dependent on CD8+ T cell-
mediated killing (66,67,77). T-bet is essential for the IL-21-driven differentiation of CTLs, 
and IL-21 directly induces T-bet expression (76). Overall, IL-21 aids in the expansion of 
CD8+ T cells and promotes their function. Given that CD4+ T cells are the major source 
of IL-21, this underscores the importance of CD4+ T cell help in generating potent 
effector CD8+ T cells.  
 
The role of IL-21 during infection 
 A dramatic role for IL-21 during infection was revealed when comparing acute 
and chronic viral clones. In the absence of IL-21, mice are capable of clearing acute 
strains of LCMV; however, they are unable to control chronic LCMV infection and 
develop high viral titers. (34,78,79). Further analysis revealed that the loss of IL-21 
severely diminishes the number of virus-specific CD8+ T cells at later time points during 
chronic infection. IL-21 is dispensable for the initial response to LCMV but is required to 
maintain CD8+ T cell numbers long term. Experiments with mixed bone marrow 
chimeras demonstrated that IL-21 acts directly on CD8+ T cells and appears to promote 
continuous proliferation throughout infection (34).  
In addition to maintaining CD8+ T cell numbers, IL-21 is required to prevent CD8+ 
T cell exhaustion. In the absence of IL-21, CD8+ T cells produced less IFN-γ and IL-2 
and express high amounts of the exhaustion marker programmed death 1, PD-1 
(34,79). Thus, IL-21 is essential to maintain CD8+ T cell numbers and prevent 
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exhaustion during chronic disease. CD4+ T cells are the major source of IL-21 during 
LCMV infection and produce it in an antigen specific-manner. When infected with 
LCMV, CD4-/- mice are also unable to control viral replication and develop severe CD8+ 
T cell exhaustion (80-82). Simply treating CD4-/- mice with exogenous IL-21 is enough to 
rescue CD8+ T cell expansion and cytokine production, subsequently reducing viral 
titers (79). This experiment illustrates the importance of CD4+ T cell help during infection 
and implicates IL-21 as an essential mediator of this help. 
 IL-21 has important roles in the adaptive immune response to a number of 
pathogens. Unlike acute LCMV, CD4+ T cell-derived IL-21 is essential for CD8+ T cells 
expansion and IFN-γ production during acute vaccinia virus infection (71). In this 
system, IL-21 was not needed to support the activation or proliferation of CD8+ T cells 
but instead promoted cell survival. This ability to support survival proved essential 
through the contraction phase, and a memory pool failed to form in the absence of IL-21 
(71). During chronic toxoplasmic encephalitis, IL-21 supports CD8+ T cell cytokine 
production and survival in the brain (83). Surprisingly, IL-21 is dispensable for CD8+ T 
cell responses during Listeria monocytogenes infection. IL-21-/- mice have unaltered 
CD8+ T cell expansion and overall IFN-γ-production (84). Furthermore, IL-21-/- mice 
have comparable bacterial burdens and generate protective memory responses. L. 
monocytogenes is an acute bacterial pathogen, thus it may be more analogous to acute 
LCMV infection where IL-21 is also unnecessary.  
 Loss of IL-21 often leads to B cell dysfunction during infection, and this is 
frequently associated with increased susceptibility. Plasma cell generation and IgG 
production are reduced in IL-21R-/- mice infected with the gut-dwelling roundworm 
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Heligmosomoides polygyrus (45). The loss of IL-21 in this system ultimately 
compromises protective immunity, and unlike WT mice, IL-21R-/- mice cannot control 
reinfection with this pathogen. Decreased IgG titers and reduced plasma cell numbers 
are also observed when IL-21R-/- mice are infected with LCMV, influenza, and vesicular 
stomatitis virus (VSV) (54). In these infections, IL-21R is required on both B cells and T 
cells for optimal antibody production. B cell dysfunction was also noted during chronic 
toxoplasmic encephalitis, and mice showed reduced IgG production and GC B cells 
(83). IL-21-/- mice ultimately succumb early to T. gondii infection, but the precise 
mechanism for this remains unclear. Finally, a recent study in malaria demonstrated a 
key role for IL-21 in limiting parasitemia during chronic infection, and this was again 
associated with reduced IgG levels (85). In this system, resistance depended on IL-21 
production by T cells as well as IL-21R expression on B cells. Thus, T cell-derived IL-21 
acted directly on B cells to promote IgG production. IL-21 was further necessary for 
chloroquine-cured mice to control parasitemia upon reinfection. In summary, IL-21 is 
most important during chronic infections and can mediate susceptibility by influencing 
both CD8+ T cells and B cells.  
 
Summary 
 IL-21 is an important cytokine during multiple chronic infections and can have 
broad impacts on the adaptive immune response. Currently, the role of IL-21 during 
chronic bacterial infections, including tuberculosis, is unknown. IL-21 mRNA is enriched 
in the lung lesions of patients with active tuberculosis, implicating it as a component of 
the local immune response to Mtb (86). Furthermore, plasma levels of IL-21 are 
	   114	  
differentially associated with active pulmonary tuberculosis in adult and pediatric 
patients. In children with active pulmonary tuberculosis, plasma IL-21 is increased 
relative to health controls (87). Adults with active disease have decreased levels of 
circulating IL-21 when compared to latently infected individuals (88), suggesting high IL-
21 is associated with controlled disease. There is a single published account of bacterial 
burden in IL-21-/- mice following aerosol infection with H37Rv (89). In this study, IL-21-/- 
mice controlled bacterial growth comparably to WT animals; however, there was no 
detailed analysis of their immune response.  
 Because IL-21 is essential for CD8+ T cell responses during chronic viral 
infection, we hypothesize that it is necessary to support CD8+ T cell expansion and 
function during tuberculosis. Previously, we demonstrated the importance of direct IL-12 
signaling on CD8+ T cells during Mtb infection (Chapter 2). Despite the critical role of IL-
12, CD8+ T cells can still be primed in its absence, suggesting there are additional 
signals supporting CD8+ T cell responses. We believe IL-21 is a strong candidate for 
this role. 
 We first address the impact of IL-21 on the immune response with the use of 
mixed bone marrow chimeras. These experiments indicate IL-21R is required on CD8+ 
T cells for efficient expansion and the acquisition of effector functions during 
tuberculosis. Using the adoptive transfer of naïve Ag-specific IL-21R-/- CD8+ T cells, we 
demonstrate that CD8+ T cells require IL-21 for expansion in both the lymph node and 
the lungs. This suggests IL-21 is similar to other signal 3 cytokines and is required at all 
stages of the CD8+ T cell response. As a signal 3 cytokine, IL-21 is comparable to IL-12 
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in its ability to promote expansion and effector function, underscoring the importance of 
IL-21 signaling.  
 Finally, we show preliminary data examining the susceptibility of IL-21R-/- mice. 
Following aerosol infection, IL-21R-/- mice initially have no immune defects beyond 
reduced CD8+ T cell numbers and have comparable bacterial burdens at week four 
post-infection. At week sixteen, we examined CD8+ T cells for signs of exhaustion and 
discovered a dramatic increase in PD-1 expression. This was accompanied by 
decreased TNF production, suggesting IL-21 is required to prevent CD8+ T cell 
exhaustion during tuberculosis. Additionally, IL-21R-/- mice failed to control bacterial 
growth at week 16 and had reduced numbers of both CD4+ and CD8+ T cells in the 
lungs. This indicates IL-21R supports resistance during chronic infection and is 
essential to maintain both CD4+ and CD8+ T cells. Overall, these findings detail the 
importance of IL-21 during chronic tuberculosis. In particular, we believe IL-21 has 
relevance for generating protective CD8+ T cells through vaccination.   
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Results 
 
CD4+ and CD8+ T cells constitutively express the IL-21 receptor, and CD4+ T cells 
increase IL-21 expression following Mtb infection. 
 Using the microarray gene expression analysis discussed in Chapter 2, we 
examined our dataset for the expression of IL-21 and it’s receptor in lung CD4+ and 
CD8+ T cells at multiple time points following Mtb infection. Detectable expression of the 
IL-21 receptor, I21r, was observed in both CD4+ and a CD8+ T cells throughout the 
experiment and was not influenced by Mtb infection (Figure 3-1). Some in vitro studies 
have suggested TCR stimulation increases IL-21R expression, but steady-state 
expression of IL-21R has been noted on CD4+ and CD8+ T cells during chronic T. gondii 
infection (83). Our transcriptional analysis was performed on bulk T cells, thus we 
cannot comment if IL-21R expression is altered on antigen specific-cells. The 
expression of the cytokine, IL21, was minimal in naïve CD4+ T cells and was 
upregulated following Mtb infection (Figure 3-1). IL21 expression remained detectable in 
CD4+ T cells throughout infection but was never induced to detectable levels in CD8+ T 
cells (Figure 3-1). These data indicate that CD4+ T cells are capable of producing IL-21 
during tuberculosis and that CD8+ T cells have the capacity to respond to this form of 
CD4+ T cell help.  
 
IL-21 augments CD8+ T cell expansion during tuberculosis.  
 To examine the role of IL-21R on CD8+ T cells, we generated 1:1 mixed bone 
marrow chimeras with WT (CD45.1+) and IL-21R-/- (CD45.2+) bone marrow. Following  
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Figure 3-1. CD4+ and CD8+ T cells constitutively express the IL-21 receptor, and 
CD4+ T cells increase IL-21 expression following Mtb infection. 
 
Relative expression of the indicated transcripts in sorted CD8+ (Left) and CD4+ 
(Right) T cells purified from the lungs of uninfected mice at time 0, as well as 4, 16, 
and 46 weeks after low dose aerosol infection. At each time point, lung homogenates 
were pooled from three mice prior to magnetic bead purification and cell sorting. 
Replicates reflect three independent infections, each with three pooled mice. For 
relative expression, values >120 have a 95% probability or greater of true expression 
and values <47 have 95% probability or greater of being silent. 
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reconstitution, mice had roughly equivalent amounts of WT and IL-21R-/- CD4+ and 
CD8+ T cells, indicating that IL-21R-/- T cells developed normally in uninfected mice 
(data not shown). CD8+ T cells were tracked before and after infection in the same 
mouse by measuring the ratio of WT to IL-21R-/- cells in the blood. By four weeks post 
infection, IL-21R-/- CD8+ T cells were reduced in the blood relative to WT cells (Figure 3-
2). During the same time frame, the ratio of WT to IL-21R-/- CD4+ T cells remained 
unaltered, suggesting that IL-21 signaling in dispensable for CD4+ T cell expansion 
during tuberculosis (data not show). In the lungs, IL-21R-/- CD8+ T cells accounted for 
less than 20% of the total CD8+ T cell response (Figure 3-3A and 3-3B). Tetramer 
staining for TB10.44-11-specific CD8+ T cells revealed that IL-21R-/- CD8+ T cells were 
equally underrepresented in this antigen-specific population (Figure 3-3C). These data 
are the first to implicate IL-21 as a major regulator of CD8+ T cell responses during 
tuberculosis, and this observation underscores the importance of CD4+ T cell help. 
 
IL-21 affects CD8+ T cell differentiation and the acquisition of effector functions. 
 Using the 1:1 mixed bone marrow chimera modal, we examined the role IL-21 in 
CD8+ T cell differentiation and function during tuberculosis. KLRG1 and CD127 were 
used as markers to assess the differentiation of TB10.44-11-specific CD8+ T cells from 
the lungs. Though some differences were observed, IL-21 did not have the dramatic 
impact on differentiation seen with IL-12 (Chapter 2). Antigen specific IL-21R-/- CD8+ T 
cells showed a small but consistent increase in the percentage of KLRG1Hi short-lived 
effector cells (SLEC) accompanied by a decrease in double negative early effector cells 
(EEC) (Figure 3-4). The functional relevance of a minor increase in the SLEC population  
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Figure 3-2. IL-21 augments CD8+ T cell expansion following Mtb infection. 
 
(A) Representative flow cytometry plots of CD3+ CD8+ T cells from the blood of the 
same 1:1 (WT:IL-21R-/-) mixed bone marrow chimera before and four weeks after 
infection with Mtb. (B) The ratio of WT to KO CD8+ T cells in the 1:1 chimeras before 
and after infection (n = 8 mice per group). ****P < 0.0001 (paired Student’s t-test). 
Data are representative of three independent experiments.	  
	   120	  
 
Figure 3-3. IL-21 signaling is required for the accumulation of antigen-specific 
CD8+ T cells in the lungs during Mtb infection. 
 
(A) Representative flow cytometry plots of CD3+ CD8+ T cells from the lungs of a 1:1 
mixed bone marrow chimera left uninfected or one four weeks post-infection. (B) The 
percentage of CD3+ CD8+ T cells that are WT (CD45.1+) or IL-21R-/- (CD45.2+) in the 
lungs of infected chimeras. (C) The percentage of TB10.4-specific CD3+ CD8+ T cells 
that are WT or IL-21R-/- in the lungs of infected chimeras. Each bar represents the 
mean ± SEM (n = 8 mice per group) ****P < 0.0001 (paired Student’s t-test). Data are 
representative of three independent experiments.	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Figure 3-4. An increased percentage of IL-21R-/- CD8+ T cells become terminally 
differentiated short-lived effect cells (SLECs). 
 
(A) Representative flow cytometry plots of lung CD8+ TB10.4+ T cells of the indicated 
genotype 4 weeks after infection. (B) Phenotypic analysis of CD8+ TB10.4+ cells 
based on KLRG1 and CD127 staining (EEC – Early Effector Cells; SLEC – Short-
Lived Effector Cell; DPEC – Double Positive Effector Cell; MPEC – Memory 
Precursor Effector Cell). Each bar represents the mean ± SEM (n = 10 mice per 
group) ***P < 0.001, ‡P < 0.0001 (paired Student’s t-test). Data are representative of 
two independent experiments. 
	   122	  
is challenging to interpret; however, this may suggest IL-21 has a minor role in inhibiting 
the terminal differentiation of CD8+ T cells. IL-12 and IL-27 were shown to drive CD8+ T 
cell expansion and increase SLEC formation (Chapter 2). In this way, IL-21 is unique in 
that it dramatically influences CD8+ T cell expansion without driving terminal 
differentiation. 
 Lung cells from 1:1 mixed bone marrow chimeras were stimulated ex vivo with 
the immunodominant TB10.44-11 peptide and intracellular cytokine staining was done to 
measure the percentage of CD8+ T cells making IFN-γ and TNF. As controls, lung cells 
were left unstimulated or stimulated with anti-CD3 and anti-CD28. Significant levels of 
cytokine production were not observed in the unstimulated samples (data not shown). 
Following TB10.44-11 peptide stimulation, fewer IL-21R-/- CD8+ T cells were positive for 
IFN-γ or double positive for IFN-γ and TNF (Figure 3-5A and 3-5B). In total, a smaller 
percentage of IL-21R-/- CD8+ T cells were positive for either IFN-γ or TNF following 
TB10.4 or anti-CD3/anti-CD28 stimulation (Figure 3-5C and 3-5D). To address cytolytic 
function, we performed intracellular staining for granzyme B, and IL-21R-/- CD8+ T cells 
showed reduced levels (Figure 3-5E). These findings support a role for IL-21 in 
promoting cytokine production and possibly cytolytic activity in CD8+ T cells during 
tuberculosis.  
 
IL-21 supports CD8+ T cell expansion in the lymph node and lungs.  
 Given the dramatic impact of IL-21 on CD8+ T cell expansion, we examined if IL-
21 is directly involved in CD8+ T cell priming following Mtb infection. In vitro, IL-21 can 
act as a signal 3 cytokine and is sufficient to prime naïve CD8+ T cells when combined  
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Figure 3-5. IL-21R-/- CD8+ T cells produce less IFN-γ, TNF, and granzyme B. 
 
(A) Representative flow cytometry plots of lung CD8+ T cells of the indicated 
genotype 4 weeks after infection. Lung homogenates were stimulated ex vivo with 
TB10.4 peptide prior to IFN-γ and TNF ICS. (B) The percentage of WT and KO CD8+ 
T cells positive for the indicated combinations of IFN-γ and TNF as determined by 
ICS. (C,D) The total percentage of IFN-γ+ (C) and TNF+ (D) CD8+ T cells of the 
indicated genotype following ex vivo TB10.4 or αCD3/αCD28 stimulation. (E) The 
percentage of WT and KO CD8+ T cells positive for intracellular granzyme B staining 
in the lungs. Each bar represents the mean ± SEM (n = 9 mice per group) *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001 (paired Student’s t-test). Data are 
representative of three independent experiments.	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with TCR engagement and costimulation (72). However, IL-21 has never been 
implicated in CD8+ T cell priming in vivo. To analyze priming, we generated retrogenic 
(Rg) CD8+ T cells specific for the immunodominant antigen TB10.44-11 on both WT and 
IL-21R-/- backgrounds. Equal numbers of congenically marked WT and IL-21R-/- Rg cells 
were transferred into recipient mice 7 days after low-dose aerosol infection, and the 
ratio of WT and KO Rg CD8+ T cells was assessed at days 8, 11, 13, and 15 in the 
lymph node. At the onset of priming, IL-21R-/- Rg cells expanded comparably to WT 
cells. The ratio of WT and IL-21R-/- Rg cells remained consistent from days 8 to 11 as 
the number of both WT and KO cells increased by over five fold (Figure 3-6A and 3-6B). 
The cells were labeled with a proliferation dye prior to transfer and both populations 
diluted the dye to the same degree by day 11, indicating that IL-21R-/- Rg cells were 
dividing comparably to WT Rg cells (Figure 3-6C).  
Despite initially expanding well, IL-21R-/- Rg cells started to lag behind WT Rg 
cells by day 13 and were underrepresented in the lymph node through day 15 (Figure 3-
6A and 3-6B). This pattern was mirrored in the lungs where the percentage and number 
of IL-21R-/- Rg cells began to decline after day 13 (Figure 3-7A and 3-7B). We tracked 
the transferred Rg cells through day 28 in the lungs and observed that the IL-21R-/- cells 
continued to decline (Figure 3-7A and 3-7B). These observations suggest that the initial 
cell divisions following priming can still occur in the absence of IL-21 signaling, but that 
IL-21 is required soon after priming for the robust expansion of CD8+ T cells. 
Furthermore, IL-21 is required in both the lymph node and the lungs to support 
expansion.   
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Figure 3-6. IL-21 supports the expansion of CD8+ T cells in the lung draining 
lymph node. 
 
Equal numbers of retrogenic (Rg) TB10.4-specific CD8+ T cells were transferred into 
mice 7 days after low-dose aerosol infection with Mtb. (A) The percentage of total 
retrogenic (Rg) cells that were WT or IL-21R-/- in the mediastinal lymph node at days 
8, 11, 13 and 15 following infection. (B) Total number of WT and IL-21R-/- Rg cells 
detected in the lymph node at the indicated time points. (C) Histograms depicting the 
dilution of the proliferation dye eflour 450 in Rg cells from the lymph node at day 11. 
Each group of samples (WT and IL-21R-/-) was concatenated into a single histogram. 
Each bar or point represents the mean ± SEM (n = 4-5 mice per group) *P < 0.05, 
***P < 0.001, ‡P < 0.0001 (Holm-Šídák multiple comparisons testing following two-
way ANOVA). Data are from a single experiment. 
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Figure 3-7. IL-21 is required for the continued expansion of CD8+ T cells in the 
lungs during tuberculosis. 
 
Equal numbers of retrogenic (Rg) TB10.4-specific CD8+ T cells were transferred into 
mice 7 days after low-dose aerosol infection with Mtb. (A) The percentage of total 
retrogenic (Rg) cells that were WT or IL-21R-/- in the lungs at days 8, 11, 13, 15, and 
28 following infection. (B) Total number of WT and IL-21R-/- Rg cells detected in the 
lungs at the indicated time points. Each bar or point represents the mean ± SEM (n = 
4-5 mice per group) *P < 0.05, ***P < 0.001, ‡P < 0.0001 (Holm-Šídák multiple 
comparisons testing following two-way ANOVA). Data are from a single experiment. 
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IL-21R-/- mice have a diminished CD8+ T cell response throughout Mtb infection.  
 To date, no studies have characterized the susceptibility of IL-21R-/- mice to 
tuberculosis, and we are currently examining the immune response and bacterial 
burden in these mice. As an initial assessment, female IL-21R-/- mice and age-matched 
C57BL/6J controls were infected via the aerosol route and time points were performed 
at weeks four and sixteen.  At week 4, IL-21R-/- mice had comparable percentages of 
CD4+ T cells and B cells in the lungs and spleens (data not show). Similar to our 
observations using the 1:1 mixed bone marrow chimeras, the overall number of CD8+ T 
cells was severely reduced in the lungs of IL-21R-/- mice, and this trend continued 
though week 16 (Figure 3-8A). In both WT and IL-21R-/- mice, approximately 30% of 
CD8+ T cells were specific for TB10.44-11 at week 4; however, TB10.44-11-specific cells 
were reduced due to the overall defect in CD8+ T expansion (Figure 3-8B and data not 
shown). IL-21R-/- mice had comparable numbers of CD8+ T cells in the spleen at week 
4, but IL-21R-/- CD8+ T numbers declined as the infection progressed (Figure 3-8C and 
3-8D). These observations confirm a substantial role for IL-21 in maintaining CD8+ T cell 
numbers during tuberculosis.  
 
Loss of IL-21R increases CD8+ T cell exhaustion. 
 During chronic viral infections, T cell exhaustion is partially related to the 
upregulation of a number of inhibitory receptors, including PD-1 and TIM-3 (90,91). IL-
21 is implicated in preventing CD8+ T cell exhaustion during LCMV infection (34,78,79), 
so we examined these exhaustion markers on TB10.44-11-specific CD8+ T cells. At week 
16, the majority of WT TB10.44-11-specific CD8+ T cells expressed high levels of Tim-3,  
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Figure 3-8. IL-21R-/- mice have a diminished CD8+ T cell response following Mtb 
infection. 
 
WT and IL-21R-/- mice were infected via the aerosol route and total CD8+ T cells 
enumerated in the lungs (A) and spleens (C) at 4 and 16 weeks post infection. The 
number of TB10.4-specific cells was also determined in the lungs (B) and spleen (D) 
based on tetramer staining. Each point represents the mean ± SEM (n = 5 mice per 
group) *P < 0.05, **P < 0.01, ***P < 0.001 (unpaired Student’s t-test). Data are from a 
single experiment. 
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but relatively low amounts of PD-1 (Figure 3-9A). TIM-3 expression was comparable 
between IL-21R-/- and WT cells but nearly all TIM-3+ IL-21R-/- cells were also PD-1+ 
(Figure 3-9A and 3-9B). Indeed, PD-1 expression was substantially increased on IL-
21R-/- CD8+ T cells by both percentage and intensity (Figure 3-9C and 3-9D). This 
dramatic increase in PD-1 expression suggests IL-21R-/- CD8+ T cells are exhausted 
and may be functioning poorly. 
 To functionally address exhaustion, we measured IFN-γ and TNF production by 
intracellular cytokine staining in lung cells stimulated ex vivo with the immunodominant 
TB10.44-11 peptide. IL-21R-/- CD8 T cells still produced significant amounts of cytokine in 
response to peptide stimulation; however, the percentage of cells producing both IFN-γ 
and TNF was reduced (Figure 3-10A and 3-10B). The total amount of IFN-γ production 
was comparable between the WT and IL-21R-/- groups and the defect in double positive 
cells was the result of diminished TNF production (Figure 3-10C and 3-10D). TNF 
productions is typically one of first effector functions lost as CD8+ T cell become 
exhausted, while IFN-γ production persists longer (92). Thus, this observation is in line 
with research done in other chronic infections. A decrease in granzyme B levels was 
also observed in IL-21R-/- CD8+ T cells, suggesting multiple effector functions are 
compromised in the absence of IL-21 (Figure 3-10E). It appears that the absence of IL-
21 leads to the accelerated exhaustion of CD8+ T cells during tuberculosis. 
 
IL-21R-/- mice are more susceptible to chronic Mtb infection. 
 Depleting CD8+ T cells during tuberculosis only results in a survival defect after 
200 days of infection (93).  Thus, a defect in CD8+ T cell function alone is not expected  
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Figure 3-9. IL-21R-/- CD8+ T cells express high levels of PD-1 by 16 weeks post-
infection. 
 
(A) Representative flow cytometry plots of lung CD8+ TB10.4+ T cells of the indicated 
genotype 16 week post-infection. (B) The percentage of WT or IL-21R-/- CD8+ 
TB10.4+ T cells positive for TIM-3 expression in the lungs.  (C) The percentage of WT 
or IL-21R-/- CD8+ TB10.4+ T cells positive for PD-1 expression in the lungs. (D) 
Histograms depicting PD-1 levels on lung CD8+ TB10.4+ T cells. Each group of 
samples (WT and IL-21R-/-) was concatenated into a single histogram.  Each bar 
represents the mean ± SEM (n = 5 mice per group) ****P < 0.0001 (unpaired 
Student’s t-test). Data are from a single experiment. 
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Figure 3-10. IL-21R-/- CD8+ T cells maintain IFN-γ production 16 weeks post-
infection but produce less TNF. 
 
(A) Representative flow cytometry plots of lung CD8+ T cells of the indicated 
genotype 16 weeks after infection. Lung homogenates were stimulated ex vivo with 
TB10.4 peptide prior to IFN-γ and TNF ICS. (B) The percentage of WT and KO CD8+ 
T cells positive for the indicated combinations of IFN-γ and TNF as determined by 
ICS. Here, IFN-γ+ and TNF+ indicates the percentage of the population producing 
only that cytokine. The total percentage of IFN-γ+ (C) and TNF+ (D) CD8+ T cells of 
the indicated genotype following ex vivo TB10.4 peptide stimulation. (E) The 
percentage of WT and KO CD8+ T cells positive for intracellular granzyme B staining 
in the lungs. Each bar represents the mean ± SEM (n = 9 mice per group) **P < 0.01, 
***P < 0.001, ****P < 0.0001 (unpaired Student’s t-test). Data are from a single 
experiment. 
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to cause an acute increase in susceptibility. For this reason, a potential survival defect 
in the IL-21R-/- mice is predicted to take a considerable amount of time to become 
evident. Consistent with this hypothesis, IL-21R-/- mice have survived past 125 days of 
infection without showing overt signs of illness (data not shown), and survival 
experiments are currently ongoing. At week four, bacterial burden was comparable 
between WT and IL-21R-/- mice in both the lungs and spleen (Figure 3-11A and 3-11B). 
This finding was expected, because the only observed defect in the immune response 
was a reduction in CD8+ T cells. By week 16, bacterial burden increased in the lungs of 
IL-21R-/- mice, indicating that they eventually fail to restrict bacterial growth (Figure 3-
11A). Bacterial burden in the spleens remained comparable between the WT and KO 
groups at all time points (Figure 3-11B).  
It is tempting to speculate that the dysfunctional CD8+ T cell response was 
contributing to this loss of bacterial control in IL-21R-/- mice; however, we observed 
additional alterations in the immune response by week 16. Though the amount of CD4+ 
T cells was unaltered at week 4, IL-21R-/- mice had reduced CD4+ T cell numbers by 
week 16 of infection (Figure 3-11C). Additionally, these mice had slightly increased 
number of neutrophils in the lungs (Figure 3-11D), though this may be a result of the 
increased bacterial burden. CD4+ T cells from IL-21R-/- mice produced comparable 
amounts of TNF and IFN-γ when stimulated ex vivo with ESAT6 peptide or anti-
CD3/anti-CD28 (Figure 3-12 and data not shown). This suggests that the remaining 
CD4+ T cells were functional and capable of responding to antigen. Based on the 
current data, we cannot know if CD4+ T cell functions are comprised in IL-21R-/- mice, 
but it is clear that CD4+ T cell numbers decline by week 16 of infection. For this reason,  
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Figure 3-11. IL-21R-/- mice fail to control bacterial growth by week 16 and have 
diminished CD4+ T cell numbers.  
 
Bacterial burden in the lungs (A) and spleens (B) at 4 and 16 weeks post infection. 
(C) The total number of CD4+ T cells was determined in the lungs at weeks 4 and 16 
post infection. (D). Total number of neutrophils (CD11b+ Ly6G+) in the lungs of 
infected mice at week 16. Each point with error bars represents the mean ± SEM. 
The points in (D) represent individual mice and the bars represents the mean. (n = 5 
mice per group) *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (unpaired 
Student’s t-test). Data are from a single experiment. 
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Figure 3-12. IL-21R-/- CD4+ T cell cytokine production is unaltered. 
 
Representative flow cytometry plots gated on lung CD4+ T cells of the indicated 
genotype 16 weeks after infection. ICS was performed for IFN-γ and TNF production 
by CD4+ T cells from lung homogenate stimulated ex vivo with ESAT6 peptide. 
Shown are representative plots from a group of 5 mice. Data are from a single 
experiment. 
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it is likely that the combined reduction of CD4+ and CD8+ T cells is contributing to 
increased bacterial burden. Overall, IL-21 appears to regulate host resistance during 
chronic infection with Mtb. 
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Discussion 
 During chronic viral infections, IL-21 is a major mediator of CD4+ T cell help and 
is essential to maintain a functional CD8+ T response. This cytokine not only supports 
CD8+ T cell numbers but also preserves cytokine production and prevents T cell 
exhaustion. Here, we demonstrate IL-21 is essential for the CD8+ T cell response to 
Mtb. Without this cytokine, CD8+ T cell numbers are dramatically reduced following 
aerosol infection and the remaining CD8+ T cell population eventually adopts an 
exhausted phenotype. Furthermore, IL-21R-/- mice ultimately fail to control bacterial 
growth; indicating IL-21 is a mediator of resistance during chronic infection.  
 Using 1:1 mixed bone marrow chimeras, we demonstrate IL-21R is directly 
required on CD8+ T cells during tuberculosis. This system offers the key advantage of 
directly comparing WT and IL-21R-/- CD8+ T cells in the same inflammatory environment 
in vivo. Four week following aerosol infection, IL-21R-/- CD8+ T cells are dramatically 
reduced in the blood and lungs relative to WT cells. Additionally, IL-21R-/- CD8+ T cells 
produce less IFN-γ, TNF, and granzyme B. These effects resemble experiments with IL-
12R-/- CD8+ T cells (Chapter 2). IL-12 is well characterized as an essential cytokine for 
CD4+ T cell responses during tuberculosis, and our data indicate it is also essential for 
CD8+ T cells. Together IL-12 and IL-21 are significant drivers of the CD8+ T cell 
response to Mtb.  
 Using the adoptive transfer of retrogenic Ag-specific CD8+ T cells, we tracked 
the priming of IL-21R-/- cells in the lung-draining lymph node following low-dose aerosol 
infection. Initially, IL-21R-/- CD8+ T cells respond comparably to WT cells and dilute their 
proliferation dye. However, IL-21R-/- cells lag behind WT cells as soon as 13 days post-
	   137	  
infection. Because IL-21 is required in the lymph node, we argue that it is a signal 3 
cytokine and facilitates priming. Our data indicate IL-21 is dispensable for the initial cell 
divisions following priming but is soon required to promote expansion. Similar 
observations were made with type 1 IFN and IL-12 during other infections, and current 
data suggests signal 3 cytokines support CD8 accumulation by maintaining cell cycle 
progression several days after priming (94-96). Typically, APCs produce signal 3 
cytokines, making IL-21 unique. Because Ag-specific CD4+ T cells are the likely source 
IL-21, these findings have implications for the coordinated priming of naïve CD4+ and 
CD8+ T cells during infection.  
 Similar to the findings in the lymph node, IL-21R-/- CD8+ T cells initially expand 
well in the lungs but begin to recede in number by day 15. From days 15 to 28, the 
number of IL-21R-/- CD8+ T cells continues to decline, suggesting an increase in cell 
death. IL-21 has been associated both with promoting CD8+ T cell division and cell 
survival, depending on the pathogen (34,83). Based on the current data, we cannot 
address the roles of cell death versus continued proliferation in maintaining cell number 
in the lungs. Future experiments will be designed to address these possibilities. 
 In addition to examining the effects of IL-21 on CD8+ T cells, we characterized 
the susceptibility of IL-21R-/- mice to tuberculosis. Four weeks following aerosol 
infection, IL-21R-/- mice had normal amounts of B and CD4+ T cells, but severely 
reduced numbers of CD8+ T cells. This observation supports our findings in the 1:1 
mixed bone marrow chimeras and suggests IL-21 acts primarily on CD8+ T cells at early 
time points. At sixteen weeks post infection, CD8+ T cell numbers remain diminished 
and cells have increased expression of the inhibitory receptor PD-1. This was 
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accompanied by deceased production of TNF and granzyme B, indicating CD8+ T cells 
were exhausted in the absence of IL-21 signaling. CD8+ T cell exhaustion is common 
during chronic infections, but the role of exhaustion during tuberculosis is not clearly 
understood (90). Higher frequencies of PD-1+ T cells are observed in patients with 
active pulmonary tuberculosis and PD-1 blockade in vitro can enhance Mtb-specific 
IFN-γ production (97). Thus, it is possible T cell exhaustion limits bacterial killing during 
chronic tuberculosis. Currently, we have no data on the kinetics of IL-21 production in 
the lungs of WT mice infected with Mtb. It will be interesting to determine if IL-21 levels 
remain consistent throughout disease and potentially correlate IL-21 concentrations with 
CD8+ T cell exhaustion. 
 By week sixteen, IL-21R-/- mice fail to control bacterial growth in the lungs. This 
observation conflicts with a previous report examining bacterial burden in IL-21-/- mice 
(89). This study failed to identify a difference in bacterial control between WT and IL-21-
/- mice by day 200 post-infection. There are a variety of differences in experimental 
approaches that could account for this discrepancy. These include the bacterial strains 
used, initial inoculum, housing conditions, and differences in the genetic background of 
the IL-21R-/- and IL-21-/- mice. Regardless, IL-21R-/- mice have a clear phenotype by 
week 16 in our facility.  
 It is possible that reduced CD8+ T cell numbers and increased exhaustion are 
contributing to increased bacterial burden, but we also noted a sharp decline in CD4+ T 
cells at week 16. IL-21 can direct the differentiation of TH17 and Tfh cells, though it is 
not considered essential for their generation in vivo. Still, studies of chronic T. gondii 
infection indicate a decline in Tfh cell at later time points, suggesting IL-21 maintains 
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this population of CD4+ T cells in some settings (83). During tuberculosis, Tfh-like 
CD4+CXCR5+ cells are associated with ectopic lymphoid structures in the lungs that 
contain well-organized B cell follicles (89). The precise role of these pulmonary B cell 
follicles is unclear, but they are associated with better control of bacterial growth in non-
human primate models. Specifically, CD4+CXCR5+ Tfh-like cells preferentially migrate 
to these areas during infection and activate infected macrophages. IL-21 was even 
demonstrated to promote the formation of these pulmonary B cell follicles during murine 
tuberculosis (89). Thus, one hypothesis for the increased susceptibility of IL-21R-/- is a 
decrease in pulmonary B cell follicle formation concomitant with reduced Tfh cells. This 
could result in disorganized lung lesions and reduced bacterial killing. This is obviously 
one of many conceivable explanations, and future studies will address these 
possibilities in IL-21R-/- mice.  
 We have uncovered an essential role for IL-21 during tuberculosis. Our data 
indicate it is a necessity for CD8+ T cells and has other effects on immunity during 
chronic disease. We believe IL-21 has promise as a therapeutic intervention and has 
the potential to augment vaccine efficacy. Future experiments must be designed to test 
these exciting possibilities.  
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Materials and methods 
 
Mice  
C57BL/6 (WT), CD45.1 (B6.SJL-PtprcaPepcb/BoyJ), CD90.1 (B6.PL-Thy1a/CyJ), 
and IL-21R-/- (B6N.129-Il21rtm1Kopf/J) (98) mice were purchased from Jackson 
Laboratories (Bar Harbor, ME). Mice were 6 to 10 weeks old at the start of all 
experiments. All animal experiments were performed in accordance with National and 
European Commission guidelines for the care and handling of laboratory animals and 
were approved by the National Veterinary Directorate and by the local Animal Ethical 
Committee or Institutional Animal Care and Use Committee (Animal Welfare Assurance 
no. A3023-01 [DFCI] or A3306-01 [UMMS]), under Public Health Service assurance of 
Office of Laboratory Animal Welfare guidelines). Mice infected with M. tuberculosis were 
housed in a biosafety level 3 facility under specific pathogen-free conditions at DFCI or 
at UMMS. 
 
Generation of mouse bone marrow chimeras 
1:1 mixed bone barrow chimeras were made by lethally irradiating CD90.1+ 
recipients (2 doses of 600 rads separated by three hours). Bone marrow was flushed 
from the femurs, tibia, and humeri of donor mice and RBC lysed. Bone marrow cells 
were then enumerated and groups were combined in a 1:1 ratio. Each recipient mouse 
received a total of 107 bone marrow cells (5×106 of WT and 5×106 of KO) via lateral tail 
vein injection and was kept on antibiotic-treated water for 5 weeks following irradiation. 
Mice were checked for reconstitution by retro-orbital bleeding to assess the ratio of 
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donor cells in the peripheral blood by flow cytometry. Bone marrow chimeras were 
infected with Mtb 8-10 weeks after transfer of the bone marrow cells.  
 
Generation of retrogenic mice  
TCR retroviral constructs were generated as 2A-linked single open reading 
frames using PCR and cloned into a murine stem cell virus-based retroviral vector with 
a GFP marker as previously described (99). Details of cloning strategies and primer 
sequences are available upon request (Samuel.behar@umassmed.edu). Retroviral-
mediated stem cell gene transfer was performed as previously described (99). 
 
Experimental infection and bacterial quantification 
Infection with M. tuberculosis (Erdman strain) was performed via the aerosol 
route, and mice received a day 1 inoculum of 50-200 CFU. A bacterial aliquot was 
thawed, sonicated twice for 10 seconds in a cup horn sonicator, and then diluted in 
0.9% NaCl–0.02% Tween 80. A 15 ml suspension of M. tuberculosis was loaded into a 
nebulizer (MiniHEART nebulizer; Vortran Medical Technologies) and mice were infected 
using a nose-only exposure unit (Intox Products). Alternatively, the bacterial aliquot was 
diluted in a final volume of 5ml, and mice were infected using a Glas-Col aerosol-
generation device. At different times post-infection, mice were euthanized by carbon 
dioxide inhalation, organs were aseptically removed, individually homogenized and 
viable bacteria were enumerated by plating 10-fold serial dilutions of organ 
homogenates onto 7H11 agar plates. Plates were incubated at 37ºC and M. 
tuberculosis colonies were counted after 21 days. 
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FACS analysis 
Cell suspensions from lung, spleen and lymph nodes were prepared by gentle 
disruption of the organs through a 70µm nylon strainer (Fisher) or using the GentleMacs 
apparatus (Miltenyi Biotec, Germany) according to the manufacturer’s instructions. For 
lung preparations, tissue was digested for 30-60 min at 37°C in cRPMI with 300U/ml 
collagenase (Sigma) prior to straining. Erythrocytes were lysed using a hemolytic 
solution (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM sodium EDTA pH 7.2) and, after 
washing, cells were resuspended in supplemented RPMI (cRPMI - 10% heat inactivated 
FCS, 10 mM HEPES, 1 mM sodium pyruvate, 2 mM L-glutamine, 50 mg/ml 
streptomycin and 50 U/ml penicillin, all from Invitrogen) or MACS buffer (Miltenyi Biotec, 
Germany). Cells were enumerated in 4% trypan blue on a hemocytometer or using a 
MACSQuant flow cytometer (Miltenyi Biotec, Germany). Surface staining was 
performed with antibodies specific for mouse CD3 (clone 17A2), CD3ε (clone 145-
2C11), CD4 (clone GK1.5), CD8 (clone 53-6.7), CD19 (clone 6D5), CD44 (clone IM7), 
CD62L (clone MEL-14), CD45.1 (clone A20), CD45.2 (clone 104), CD90.1 (clone OX-7), 
CD90.2 (clone 53-2.1), CD127 (clone A7R34), KLRG1 (clone 2F1/KLRG1) and Va2 
(clone B20.1), (from Biolegend, CA, USA, or from BD Pharmingen, CA, USA). The 
tetramers of TB10.44–11-loaded H-2 Kb were obtained from the National Institutes of 
Health Tetramer Core Facility (Emory University Vaccine Center, Atlanta, GA, USA). All 
staining was performed for 20 min at 4°C and, unless otherwise stated, cells were fixed 
before acquisition with 1% formaldehyde in PBS for 30-60 min. Cell analysis was 
performed on a FACS Canto (Becton Dickinson, NJ, USA) or on a MACSQuant flow 
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cytometer (Miltenyi Biotec, Germany). Data were analyzed using FlowJo Software (Tree 
Star, OR, USA). For FACS analysis, single-lymphocyte events were gated by forward 
scatter versus height and side scatter for size and granularity. 
 
Intracellular cytokine staining 
5×105-1×106 cells were plated in each well of a round bottom 96-well plate and 
incubated in the presence of TB10.44-11 peptide (10 µM; New England Peptide). 
Incubation in the presence of αCD3/αCD28 (1 µg/mL; BioLegend) or in the absence of 
stimuli were used as positive and negative controls, respectively. Cells were incubated 
for 1 hours at 37ºC, at which point GolgiPlug solution (BD Pharmingen, CA, USA) was 
added to each well for the remaining 4 hours. Cells were collected after the 5 hours 
stimulation and then surface stained with the antibodies described above, followed by 
intracellular staining for IFN-γ (clone XMG1.2), TNF (clone MPX6-T22), or granzyme B 
(clone gb11) using the BD Permwash Kit (BD Pharmingen, CA, USA) as per 
manufacturer’s instructions. 
 
Adoptive T cell transfer 
Single cell suspensions of pools of spleens and lymph nodes from naive 
retrogenic mice (6 to 12 weeks post reconstitution) were prepared. CD8+ T cells were 
purified from each suspension using the CD8+ T cell isolation kit and magnetic 
separation (STEMCELL Technologies Inc, Canada). After purification, cells were 
counted and transferred via the tail vein into congenically marked recipients (CD45.1 or 
CD90.1), which had been infected 7 days earlier with virulent Mtb (Erdman) via the 
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aerosol route. For all experiments, 3×104 -5×104 cells of each group were transferred 
into each recipient.  
 
Measurement of cell proliferation 
For analysis of cell proliferation of retrogenic cells after adoptive transfer, bead-
purified naïve Rg cells (see above) were labeled with 5 µM cell proliferation dye efluor 
450 (eBiosciences) in PBS for 20 min at room temperature, followed by extensive 
washing. 
 
Cell isolation and microarray analysis 
Female C57BL/6 mice were infected with Mtb Erdman as described above. At 
the indicated time points, mice were euthanized by cervical dislocation and lungs were 
harvested after perfusion with collagenase containing media. Lungs were allowed to 
digest in collagenase-containing media for 15 minutes before being homogenized into 
single cell suspensions. At this point, the lungs from 3 individual mice were combined 
into a single sample. T cells were then purified by negative magnetic bead selection 
(Miltenyi Biotec, Germany). Purified cells were stained to distinguish CD4+ and CD8+ T 
cells (CD19, CD3, CD4, CD8). For cell sorting, stained cells were suspended in MACS 
buffer (Miltenyi Biotec, Germany) and deposited in collection tubes using a BD Canto 
flow cytometer (Becton Dickinson, NJ, USA). 50,000 CD19-CD3+CD4+ or CD19-
CD3+CD8+ cells were sorted directly into TRIzol Reagent (Life Technologies, California) 
and immediately frozen. RNA extraction, microarray hybridization (Affymetrix MoGene 
1.0ST array) and data processing were done at the ImmGen Project processing center. 
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Details of the data analysis and quality control can be found at (www.immgen.org). 
 
Statistical analysis 
All data are represented as mean with SEM. Comparisons of two groups within 
1:1 mixed bone marrow chimeras were done with a paired student’s t-test. All other 
comparisons were done with an unpaired student’s t-test and are indicated in the figure 
legends. Comparisons of more than two groups were done using Holm-Šídák multiple 
comparisons testing following two-way ANOVA. Significance was represented by the 
following symbols: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, and ‡P < 0.0001. 
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Summary of findings 
 
  
As an experimental tool, 1:1 mixed bone marrow chimeras are particularly useful 
for examining the effects of cytokine receptors on T cell subsets. The main advantage of 
this system is that it allows for the direct comparison of WT and KO cells within the 
same inflammatory environment. We used 1:1 mixed bone marrow chimeras to examine 
the effects of four key cytokines on CD8+ T cell function during tuberculosis: IL-12, IL-
21, IL-27, and type 1 IFN. Given that all of these cytokines are induced during 
tuberculosis, it is easy to imagine they have redundant roles during infection. We were 
surprised to learn that every cytokine supported CD8+ T cell expansion, albeit to varying 
degrees. This suggests that CD8+ T cells respond to the entire inflammatory milieu 
present in the lungs with each cytokine making some contribution to the overall 
response. The bacterial pathogen Listeria monocytogenes is similar in this regard, as 
CD8+ T cells respond to both IL-12 and type 1 IFN during this infection (1). However, 
CD8+ T cells do not require IL-21 to respond to L. monocytogenes (2), indicating the 
cytokine networks regulating CD8+ T cells during tuberculosis are even more complex. 
In addition to expansion, all of these cytokines were required for the efficient 
induction of granzyme B. This observation was consistent across every model used (1:1 
chimeras, 4:1 chimers, and retrogenic cells), and led us to hypothesize that each signal 
was required for optimal cytolytic activity. In vivo CTL assays were performed and 
revealed that only the loss of IL-12 reduced the specific killing of target cells. Further 
analysis indicated that this reduction in killing was likely the result of diminished CTL 
numbers, not the cytotoxicity of the individual CD8+ T cells. These findings caution 
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against the use of granzyme B as a surrogate for cytolytic function. Indeed, there are 
multiple pathways of cytolysis, and it is likely that a reduction in granzyme B alone fails 
to have a dramatic effect. These observations suggest that CTL activity is robust during 
tuberculosis and is likely supported by redundant cytokine signals. We have not 
examined the effect of IL-21 on cytolytic activity, but other data indicate IL-21 promotes 
perforin expression and cytolysis in vitro (Nunes-Alves C, unpublished observation) (3). 
Thus, it is possible that IL-21 will have a greater impact on cytolytic activity, but this 
remains to be tested.  
 Of the cytokines examined, type 1 IFN and IL-27 had the least dramatic effects 
overall. Both are dispensable in the lymph node, suggesting these cytokines do not 
support priming. It is possible they are not present in the lymph node during priming, 
and we are now conducting experiments to examine their expression at early time 
points after infection. In the lungs, type 1 IFN augments the expansion of CD8+ T cells, 
but has no significant influence on CD8+ T cell differentiation or IFN-γ production. IL-27 
appears to have the smallest impact on expansion and was also dispensable for IFN-γ 
production. This latter finding was surprising, because IL-27 is required to promote IFN-
γ expression in other infections (4). As for differentiation, IL-27 suppresses CD127 
expression without promoting the accumulation of SLECs. This suggests it is 
dispensable for the terminal differentiation of effector cells during tuberculosis but may 
limit the accumulation of memory precursors. Overall, these observations are 
interesting, because both type 1 IFN and IL-27 suppress TH1 responses in vivo (5-8). 
Thus, cytokines that dampen CD4+ T cell responses can simultaneously expand CD8+ T 
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cells. Balancing inflammation is essential during tuberculosis, and these cytokines may 
serve to fine tune inflammation in the lungs.  
 IL-12 and IL-21 had the greatest impact on CD8+ T cell expansion in the lungs of 
1:1 chimeras. Additionally, both cytokines are necessary to expand retrogenic CD8+ T 
cells in the lymph node and act as signal 3 cytokines during tuberculosis. Given the 
general importance of IL-12, it is logical that it supports CD8+ T cells, and these data 
indicated IL-12 is essential for the overall αβ T cell response to Mtb. However, both 
CD8+ T cell priming and expansion occur in the absence of IL-12, indicating it is not 
absolutely required to generate a CD8+ T cell response. It is possible that other signals 
can compensate for the loss of IL-12, and we plan to examine CD8+ T cells deficient for 
both IL-12R and IFNAR. 
The results with IL-21 are unexpected and, in some ways, contradict 
observations made in other infections. IL-21 is essential for CD8+ T cell responses 
during chronic infections; however, it is not typically needed during priming (9-13). In our 
experiments, IL-21 is required after day 13 of infection, which is shortly after the 
initiation of CD8+ T cell expansion in the lymph node. Thus, Mtb is unique among 
chronic pathogens in that CD8+ T cells require IL-21 throughout the infection.  
The requirements for IL-12 and IL-21 are somewhat different in the lymph node 
following low-dose aerosol infection. We observed that IL-12R-/- CD8+ T cells 
underperform relative to WT cells at all time points and do not dilute their proliferation 
dye as quickly. This suggests IL-12 is immediately needed for efficient CD8+ T cell 
priming, and IL-12 likely supports CD8+ T cell expansion at all time points. Activated 
	   159	  
DCs are the primary source of IL-12 in the lymph node, thus this cytokine should be 
present as soon as antigen is presented to naïve cells.  
In contrast, naïve IL-21R-/- CD8+ T cells efficiently dilute their proliferation dye by 
day 11 and only start to lag behind WT cells by day 13. Because IL-21 is derived from 
CD4+ T cells rather than DCs, it is logical that T cell priming must first occur for IL-21 to 
accumulate in the lymph node. This may explain the delayed role for IL-21 and suggests 
CD4+ T cells directly support CD8+ T cell priming. Based on our data, it is unclear if IL-
21 is supporting cell division or cell survival, and future experiment will need to address 
this issue. It is thought that signal 3 cytokines facilitate the continued expansion of cells 
directly following priming (14); however, IL-21 is also associated with preventing cell 
death in the early stages of vaccinia virus infection (15). In response to Mtb, it is 
possible IL-12 promotes cell division during priming while IL-21 maintains cell survival, 
but this hypothesis remains to be tested.  
In addition to supporting priming, IL-12 and IL-21 also promote IFN-γ production. 
During tuberculosis, IFN-γ+ CD8+ T cells are predominantly KLRG1hi in WT mice (Booty 
MG, unpublished observation), and we observe that IL-12 is essential for the 
differentiation of KLRG1hi SLECs. This indicates that IL-12 drives both terminal 
differentiation and effector function during tuberculosis, and this link is frequently seen 
in other infections (1). In contrast, IL-21 differs from other signal 3 cytokines, because it 
has a mild effect on CD8+ T cell differentiation, yet is essential for expansion and 
cytokine production. In the absence of IL-21, the percentage of SLECs actually 
increases, suggesting this cytokine limits the accumulation of SLECs. Thus, IL-21 
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supports expansion and effector function without promoting the terminal differentiation 
of effector cells.  
Beyond the initiation of the adaptive immune response, IL-21 is essential to 
prevent CD8+ T cell exhaustion during tuberculosis. This observation was made in IL-
21R-/- mice at 16 weeks post-infection. We observed that IL-21R-/- CD8+ T cells had 
dramatically increased levels of PD-1 expression and fail to produce TNF at this time. 
The precise role of CD8+ T cell exhaustion during tuberculosis in unclear, buy many 
speculate that it may limit bactericidal activity during chronic infection (16). Thus, it is 
exciting to identify a cytokine that prevents CD8+ T cell exhaustion during Mtb infection. 
Though IL-21R-/- mice had unaltered numbers of CD4+ T cells at week 4, CD4+ T cells 
declined sharply by week 16. This indicates that IL-21 has multiple effects during 
chronic disease. Finally, IL-21R-/- mice eventually fail to control bacterial growth; 
indicating IL-21 is an important mediator of resistance to tuberculosis. The loss of 
bacterial growth is likely related to the reduced number of both CD4+ and CD8+ T cells, 
but this possibility will require further examination. 
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Implications and future directions 
 
 Infection with Mtb induces a considerable amount of inflammation, and in many 
ways, the CD8+ T cell response reflects this. In general, increased levels of 
inflammation enhance the accumulation of effector CD8+ T cells (17), and we observed 
that multiple inflammatory cytokines support CD8+ T cell expansion during tuberculosis. 
However, this increase in the effector cell response can negatively impact the number of 
cells that will adopt a memory phenotype (17). This has been clearly demonstrated in L. 
monocytogenes infection. Pre-treatment of mice with antibiotics dampens inflammation 
during infection and results in a diminished effector CD8+ T cell response (18). 
However, the CD8+ T cells primed in this less inflammatory environment are prone to 
adopt a memory phenotype and respond more robustly to rechallenge. This experiment 
clearly illustrates how the generation of a potent effector response can be at odds with 
memory development. 
 Following Mtb infection, we observed that WT CD8+ T cells overwhelmingly adopt 
a SLEC phenotype. Thus, it appears that high levels of inflammation, largely driven by 
IL-12, are promoting the terminal differentiation of CD8+ T cells. This likely has profound 
effects on memory formation. There is little evidence suggesting people develop 
protective memory to tuberculosis. In fact, people who have been treated for 
tuberculosis are at a higher risk of developing disease again (19-23). These 
observations could be the result of recurrent disease, but it still raises the question of 
whether memory formation is undermined during the course of Mtb infection.  
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 For the purposes of vaccine design, it is essential to consider the role of 
inflammation. Our research focused on the effects of IL-12, IL-21, IL-27, and type 1 IFN 
on primary CD8+ T responses, but the data have implications for vaccine-elicited cells 
and potentially memory responses. Our results indicate that IL-12 is potent driver of 
CD8+ T cell expansion and effector function during tuberculosis. Thus, adjuvant-induced 
IL-12 will generate a vigorous primary response to vaccination; however, it will also 
favor the production of terminally differentiated SLECs. IL-12 is undoubtedly essential 
for a robust CD8+ T cell response, but too much will likely undermine the goal of 
generating long-lived memory lives. 
 IL-27 and type 1 IFN are also unlikely candidates to augment vaccine efficacy. 
During infection, they played minor roles in promoting expansion and appeared to have 
little effect on effector function. Furthermore, IL-27 actually inhibits CD127 expression, 
suggesting it may limit memory formation. Indeed, it would be interesting to determine of 
IL-27R-/- memory CD8+ T cells respond better to rechallenge with Mtb. We have 
preliminary data in which we’ve antibiotic treated WT:IL-27R-/- 1:1 mixed bone marrow 
chimeras following infection. In these mice, a greater percentage of IL-27R-/- CD8+ T 
cells adopt a central memory phenotype after 12 weeks of antibiotic treatment. Thus, 
the absence of IL-27 signaling may promote memory formation during tuberculosis. 
 Of all the cytokines tested, IL-21 appears to be the best candidate for enhancing 
vaccine efficacy. In primary infection, IL-21 promotes the expansion of CD8+ T cells and 
their acquisition of effector functions. Most importantly, IL-21 does not promote the 
accumulation of SLECs, potentially making it an ideal cytokine to facilitate memory 
formation. If IL-21 can enhance the primary response to vaccination without terminally 
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differentiating CD8+ T cells, it may generate a larger memory pool. In tumor vaccination 
models, IL-21 has already been demonstrated to enhance CD8+ T cell function (24). 
Therefore, vaccine strategies that incorporate IL-21 should be examined in tuberculosis. 
Our experiments did not directly address vaccination, but we believe our data regarding 
the role of inflammation during disease may prove valuable in this regard.  
 We demonstrated a significant role for IL-21 in regulating CD8+ T cells during 
tuberculosis as well as mediating resistance to disease. There are still many 
unanswered questions regarding the effects of IL-21 and research in this area will likely 
generate more exciting discoveries. First, the effects of IL-21 on CTL function should be 
fully addressed. Specifically, the effects of IL-21 on perforin expression should be 
examined during tuberculosis, and the cytolytic capacity of IL-21R-/- CD8+ T cells needs 
to be assessed, either in vivo or in vitro.  
 The role of IL-21 in preventing exhaustion also requires intense examination. 
Following aerosol infection, C57BL/6 mice are able to control infection for over a year 
but inevitably succumb to disease. We still do not understand the events that lead to 
mortality in these mice, but many have questioned if the adaptive immune response 
fails late during infection. Could T cell exhaustion lead to unrestricted bacterial growth? 
CD8+ T cell depletion only increases susceptibility after 200 days of infection, 
suggesting CD8+ T cells mediate their protective effects later during disease. Therefore, 
IL-21 may be essential to maintain these protective effector functions at later time 
points. This is one of many possible interpretations of these observations, but it will be 
interesting to measure IL-21 levels in the lungs of infected mice over the extended 
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course of disease. Any significant decline in IL-21 concentrations in the lungs could 
trigger CD8+ T cell exhaustion.  
 There are likely many mechanisms contributing to the increased susceptibility 
observed in IL-21R-/- mice. By week 16 of infection, both CD4+ and CD8+ T cells are 
reduced in the lungs, indicating a substantial decline in the overall T cell response. At 
present, the reasons for this decline in CD4+ T cell numbers are unclear. IL-21 is not 
typically associated with maintaining CD4+ T cells in other infections, but it does make 
an important contribution to the generation of TH17 and Tfh cells. In the discussion 
section of chapter 3, we propose a role for IL-21 in promoting Tfh cell responses during 
chronic disease. IL-21 is not essential for the differentiation of Tfh cells, but in T. gondii 
infection, it does maintain Tfh cells during chronic disease (12). During tuberculosis, 
Tfh-like cells are associated with protection and, in particular, may serve to maintain 
organized lesions in the lungs (25). In future experiments, we will address the numbers 
of Tfh cells in the lungs of WT and IL-21R-/- mice throughout infection.  
Across all infections examined, IL-21 is essential for the generation of plasma 
cells and the production of IgG (12,13,26-28). During tuberculosis, mice that cannot 
secrete antibodies (AID-/- µS-/-) have a limited ability to control bacterial growth at later 
time points and succumb early to disease (29). Thus it is possible that absence of 
functional plasma cells is also contributing to susceptibility. All of these possibilities will 
require examination as we continue to explore the roles of IL-21 in immunity to Mtb.  
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Abstract 
 
 Prostanoids are a diverse family of lipid signaling molecules generated by 
cyclooxygenases (COX-1 and COX-2) and are important mediators of inflammation. In 
particular, the prostanoid prostaglandin E2 (PGE2) is associated with multiple protective 
effects during Mycobacterium tuberculosis infection; however, mice deficient in PGE2 
production are only mildly susceptible to disease. To more completely address the role 
of prostanoid production during tuberculosis, we examine the susceptibility of mice 
deficient in either COX-1 or COX-2. We determined that COX-2 is essential for 
resistance, while COX-1 is largely dispensable. Mice lacking COX-2 initially control 
bacterial growth in the lungs, but show signs of increased inflammation and bacterial 
burden during chronic disease. Through the use of bone marrow chimeras, we 
determine if COX-2 is needed in hematopoietic or nonhematopoietic cells. Surprisingly, 
COX-2 expression is required in both groups of cells for optimal host resistance. Mice 
lacking COX-2 in either hematopoietic or nonhematopoietic cells have increased 
bacterial burden concurrent with increased immunopathology. These data implicate 
COX-2 as an important mediator of resistance and highlight a vital role for 
nonhematopoietic cells in the host response to tuberculosis.  
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Introduction 
 
Overview of eicosanoids 
 Eicosanoids are a diverse family of signaling molecules derived from arachidonic 
acid (AA) that encompasses prostaglandins, thromboxanes, leukotrienes, and lipoxins. 
Together, prostaglandins and thromboxanes are included in a group of molecules 
referred to as prostanoids. Among their many functions, these lipid mediators play vital 
roles in regulating both innate and adaptive immune responses. Eicosanoid production 
is rapidly induced in innate immune cells in response to a number of stimuli, including 
bacterial infection, and these signals exert their effects in both an autocrine and 
paracrine manner (1). Though the effect of each eicosanoid is context dependent, 
leukotrienes are largely pro-inflammatory while lipoxins are involved in resolving 
inflammation (2). It is more challenging to generalize the effects of prostaglandins, 
which vary considerably.  
All eicosanoids are made from arachidonic acid, which is generated from 
membrane phospholipids by the action of phospholipase A2 enzymes (PLA2). 
Arachidonic acid is then further metabolized in one of three main biosynthetic pathways 
involving cyclooxygenases, lipoxygenases, or P-450 epoxygenase (1). Prostanoids are 
generated by cyclooxygenases, which exist in two forms: COX-1, which is constitutively 
expressed in most mammalian tissues; and COX-2, which is induced in response to a 
number of proinflammatory stimuli (3). Both cyclooxygenases catalyze the conversion of 
arachidonic acid into PGH2, which is the metabolic precursor of all prostanoids. 
Lipoxygenases are a larger group of enzymes, whose coordinated action can generate 
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multiple molecules including lipoxin A4 (LXA4), lipoxin B4 (LXB4), and a variety of 
leukotrienes. The effects of eicosanoids are diverse and have profound implications on 
balancing inflammatory processes in a number of settings.  
 
The opposing roles of PGE2 and LXA4 on macrophage cell death 
During tuberculosis, eicosanoids impact bacterial virulence through several 
mechanisms and are particularly important regulators of cell death. Indeed, the cell 
death modality of the infected macrophage can have profound effects on bacterial 
control and the outcome of disease. In general, apoptosis is thought to favor the host, 
and this form of cell death is frequently associated with reduced bacterial growth (4,5). 
We demonstrated that uninfected macrophages can kill Mtb by engulfing apoptotic cells 
containing bacteria, suggesting a mechanism to link apoptosis and bacterial control (6). 
During necrotic death, there is a breakdown of the cell’s plasma membrane, and this is 
thought to facilitate the spread of bacteria. Several groups have reported that virulent 
H37Rv induces necrosis in infected macrophages while avirulent strains, including 
H37Ra, induce apoptosis (7-10).  
H37Rv and H37Ra also differ in the eicosanoid species they elicit in infected 
macrophages, and this difference is relevant to the modality of cell death. Macrophages 
infected with avirulent H37Ra primarily produce prostaglandin E2 (PGE2); however, 
infection with virulent H37Rv predominantly induces lipoxin A4 (LXA4) (7-9,11). LXA4 
directly inhibits PGE2 production during H37Rv infection by limiting the expression of 
COX-2, the inducible enzyme required to produce all prostaglandins. The role of 
eicosanoids in cell death was determined by adding exogenous PGE2 and LXA4 to 
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infected macrophages. The addition of PGE2 to H37Rv-infected cells inhibits necrosis, 
and in avirulent H37Ra infection, the addition of LXA4 drives down PGE2 production and 
promotes necrotic death (11).  
These results were confirmed using knockout mice lacking 5-lipoxygenase (5-LO-
/- or Alox5-/-), which is necessary for LXA4 production, as well as mice lacking 
prostaglandin E synthase (PTGES-/-), which is necessary to produce PGE2. When 
infected with H37Rv, macrophages from 5-LO-/- mice predominantly die by apoptosis 
and almost no bacterial growth is seen by day seven post-infection (12). Conversely, 
PTGES-/- macrophages predominantly die by necrosis.  
The ability of H37Rv to induce necrosis may be linked to its ability to cause 
membrane damage, including plasma membrane damage. Plasma membrane lesions 
are repaired by a process of lysosome exocytosis that is dependent on synaptotagmin-7 
(Syt-7), a Ca2+ sensor located on lysosomes (13,14). Syt-7 facilitates the fusion of 
lysosomal membranes with the damaged plasma membrane and repair can be 
assessed by the accumulation of lysosomal markers, including LAMP-1 and Syt-7, on 
the cell surface. Upon infection with H37Ra, both LAMP-1 and Syt-7 translocate to the 
cell surface; however, evidence of membrane repair is not observed during H37Rv 
infection (12). These results suggest H37Rv is inducing membrane damage and 
inhibiting lysosome-mediated repair pathways. 
The ability of eicosanoids to overcome this block in membrane repair was 
examined by administering exogenous PGE2 to macrophages infected with H37Rv. 
PGE2 increased the expression of Syt-7 and was able to enhance plasma membrane 
repair during H37Rv infection (12). Macrophages from PTGES-/- mice fail to initiate 
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membrane repair in response to H37Ra, indicating that PGE2 is required for Syt-7-
mediated membrane repair during mycobacterial infection. Membrane repair is also 
related to cell death, because knocking down Syt-7 causes cells to undergo necrosis 
during H37Ra infection. These data suggest that the inhibition of PGE2-driven 
membrane repair contributes to necrosis during infection with H37Rv.   
PGE2 functions by signaling through four distinct G-protein coupled receptors, 
EP1-EP4. We have established a role for both EP2 and EP4 signaling in protecting 
against necrosis. EP2 signaling primarily activates protein kinase A (PKA), and EP4 
primarily signals through phosphatidylinositol-3 kinase (PI3K) (15). Pharmacological 
inhibition of PI3K inhibits PGE2-driven membrane repair, suggesting this process is 
mediated by EP4 signaling (12). EP2 signaling also appears to inhibit necrosis, as EP2 
is required for PGE2 to protect against mitochondrial damage during infection with Mtb 
(11). Thus, PGE2 and LXA4 establish an axis that regulates macrophage cell death 
during tuberculosis.  
 
The opposing roles of PGE2 and LXA4 on host susceptibility 
There is considerable in vivo evidence to support this dichotomy of PGE2 and 
LXA4; however, these molecules have broad effects on inflammation. Thus, their actions 
in vivo cannot be reduced to only influencing macrophage cell death. In particular, 
lipoxins are potent anti-inflammatory mediators during infection and lipoxin production 
enhances the virulence of several pathogens (16,17). Both Toxoplasma gondii and 
Pseudomonas aeruginosa secrete enzymes with lipoxygenase activity and can directly 
generate lipoxins from host-derived substrates (18,19). These observations suggest that 
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manipulating lipoxin levels may be an important virulence strategy for multiple 
pathogens.  
LXA4 can be detrimental to adaptive immune response during tuberculosis 
through several mechanisms. By influence the cell death modality of infected cells, it 
delays cross presentation and, subsequently delays CD8+ T cell priming (20). 
Additionally, LXA4 directly inhibits IL-12 production by dendritic cells (DCs) (21). 5-LO-/- 
mice are more resistant to aerosol infection and have a decreased bacterial burden in 
the lungs (22). This resistance is associated with an enhanced TH1 response resulting 
from increased IL-12 levels. Through these mechanisms, Mtb-elicited LXA4 directly 
limits the host’s ability to mount a protective adaptive immune response. 
 Studies using a zebrafish model of Mycobacterium marinum infection have 
identified additional consequences of increased LXA4 signaling. Silencing an enzyme 
involved in leukotriene metabolism, leukotriene-A4 hyrdolase (LTA4H), results in the 
excess accumulation of LXA4 and renders zebrafish larvae more susceptible to M. 
marinum infection (23). Further analysis, revealed that LTA4H is an important mediator 
of inflammation during mycobacterial infection through its ability to influence TNF levels. 
Reductions in LTA4H activity result in increased LXA4 that directly limits TNF production 
and increases susceptibility. Conversely, heightened LTA4H activity results in increased 
levels of leukotriene B4 (LTB4), which promotes TNF production and immunopathology 
(17,23,24). Thus, LTA4H regulates a delicate balance of inflammation that must be 
maintained for optimal host resistance. 
 The negative effects of lipoxin and leukotriene production are also supported in 
human studies. Variants in the gene encoding 5-LO (ALOX5) are associated with 
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increased susceptibility to active pulmonary tuberculosis (25). Though this study did not 
directly address 5-LO functionality in patients with tuberculosis, several of the variants 
were hypothesized to increase 5-LO expression. Polymorphisms in LTA4H are also 
associated with susceptibility to mycobacterial disease. In particular, heterozygosity of 
certain LTA4H single nucleotide polymorphisms (SNPs) is associated with protection 
from extra-pulmonary tuberculosis and severe forms of leprosy (23). Heterozygous 
individuals are hypothesized to produce intermediate amount of LTB4, which balances 
inflammatory responses. This intermediate level of inflammation is thought to optimize 
bacterial control without generating immunopathology.  The relevance of these finding in 
pulmonary tuberculosis is questionable (26,27), but this work underscores the 
importance of lipid mediators during human mycobacterial diseases. 
 Precisely defining the protective effects of PGE2 in vivo during tuberculosis has 
proven challenging. We observed that PTGES-/- mice succumb more quickly to low dose 
aerosol infection and have a higher bacterial burden in the lungs at 5 weeks post-
infection (Figure A-1). However, this increase in bacterial burden was transient and was 
not observed at later time points. Additionally, the susceptibility phenotype of PTGES-/- -
mice takes over 200 days to manifest itself, suggesting PGE2 is not strictly required 
during the early stages of infection. Of course, knocking out PTGES has broader effects 
than simply eliminating PGE2 levels. Research indicates that blocking PTGES activity 
does not reduce overall prostanoid production, but rather shifts the particular 
prostanoids generated in response to stimulation (28). PTGES-/- macrophages fail to 
produce PGE2 in response to LPS stimulation but instead respond with increased levels  
	   176	  
 
 
Figure A-1. PTGES-/- mice are less resistant to tuberculosis. 
 
(Left) Bacterial burden in the lungs of WT and PTGES-/- mice 5 week after low dose 
aerosol infection. (n=5 mice per group) This increase in bacterial burden was 
transient and not observed at later time point during infection. (Right) Survival of WT 
and PTGES-/- mice following low dose aerosol infection (n=8-10 mice per group). 
Each point represents a single mouse and lines represent the mean. Data represent 
a single experiment. 
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of PGD2 production. Thus, it possible that overproduction of other prostanoids 
confounds the interpretation of experiments involving PTGES-/- mice.  
 Recently, the protective effects of PGE2 were demonstrated in vivo during 
tuberculosis. Interleukin-1 alpha and beta (IL-1α/β) are necessary for host resistance 
during tuberculosis, and both IL-1α-/- and IL-1β-/- mice succumb early to disease (29,30). 
It is now apparent that PGE2 is a major mediator of the protective effects of IL-1 (31). IL-
1 stimulation of infected macrophages directly promotes PGE2 production, and 
intranasal treatment with PGE2 increases the control of bacterial growth in highly 
susceptible IL-1α-/-,IL-1β-/- (double knockout) mice. PGE2 promotes bacterial control and 
protection by directly suppressing detrimental type 1 IFN production during disease 
(31). Overall, PGE2 has a positive influence on host resistance and appears to act 
through a number of mechanisms in vivo.  
 
Rationale for current studies 
 Given the protective roles of PGE2 both in vitro and in vivo, it is puzzling that 
PTGES-/- mice are only mildly susceptible to tuberculosis. We speculate that the 
accumulation of other prostanoids in PTGES-/- mice is masking a susceptibility 
phenotype and seek to address the role of prostanoids in host resistance. We 
hypothesize that broadly limiting prostanoid production will increase susceptibility to 
tuberculosis. To this end, we examine the susceptibility of mice deficient in either COX-
1 or COX-2, the upstream enzymes required for prostanoid production.  
Initial studies indicated that COX-1 is dispensable for host resistance, but the 
absence of COX-2 dramatically increases susceptibility. Despite succumbing to 
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disease, COX-2-/- mice are capable of controlling bacterial growth at early time points 
and appear to mount a robust adaptive immune response. Thus, it appears unlikely that 
defects in the initial host immune response are contributing to susceptibility. COX-2-/- 
mice do have higher bacterial burdens at later time points, and this appears to directly 
precede their demise. To determine the requirements of COX-2 expression in 
hematopoietic and nonhematopoietic cell lineages, we generated a series of bone 
marrow chimeras and assessed their susceptibility. Surprisingly, optimal host resistance 
requires COX-2 expression in both hematopoietic and nonhematopoietic cells. Mice 
lacking COX-2 in a single compartment survive longer than mice lacking COX-2 in all 
cells; however, they have higher bacterial burden and increased immunopathology.  
These data indicate that COX-2 expression is required in a variety of cell types to 
mediate resistance to tuberculosis. Additionally, COX-2 is unnecessary to control early 
bacterial growth and is dispensable for the initial immune response to Mtb. We 
hypothesize that COX-2 is necessary to maintain the proper balance of inflammation 
during chronic disease and promotes host survival by limiting immunopathology. 
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Results 
 
Prelude: lessons from B6;129 Cox-2-/- mice 
 To begin understanding the full impact of prostanoids during Mtb infection, we 
examined the susceptibility of mice deficient in either cyclooxygenase 1 or 2 (COX-1-/- or 
COX-2-/-). Currently, the only commercially available COX-1-/- and COX-2-/- mice are on 
a mixed genetic background (B6;129). This is because transferring the COX-2 null allele 
to a pure C57BL/6 background greatly reduces the viability these mice (32). 
Additionally, COX-2-/- females are infertile; so all breeding must be done with 
heterozygous animals. For this reason, all survival experiments utilized B6;129 
littermates as controls. Furthermore, mice doubly deficient for COX-1 and COX-2 die 
shortly after birth, so the loss of both enzymes cannot be directly examined.  
To assess susceptibility, COX-1-/-, COX-2-/-, and WT (B6;129) mice were infected 
with 90 CFU of virulent Mtb (Erdman strain) via the aerosol route and survival was 
monitored (Figure A-2). COX-2-/- mice exhibited a significant decrease in survival 
(median survival = 28 days) compared to WT and COX-1-/- mice (median survival >125 
days). Encouraged by these findings, we set out to characterize the heightened 
susceptibility of COX-2-/- mice. Due to a technical problem, the mice in the follow-up 
experiment received a very low inoculum (approximately 5 CFU); however, this was 
fortuitous as it allowed us to examine COX-2-/- mice at much later time points. At this 
lower infectious dose, both COX-2-/- and WT mice survived and presented no overt 
signs of illness (data not shown). In place of monitoring survival, we examined bacterial 
burden and immune function in these mice at days 35 and 90. In the lungs, the data  
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Figure A-2. COX-2, but not COX-1, is necessary for resistance to tuberculosis. 
 
Survival of WT, COX-1-/-, and COX-2-/- mice following aerosol infection with 90 CFU 
of Mtb (Erdman strain). All mice are on the B6;129 mixed genetic background. (n=5 
mice per group) Data represent a single experiment.  
 
Figure A-3. At a lower inoculum, COX-2-/- mice survive following aerosol 
infection, but fail to control bacterial growth. 
 
Bacterial burden in the lungs and spleens of WT and COX-2-/- mice (B6;129 
background) following an extremely low dose aerosol infection (5 CFU). Each point 
represents the mean ± SEM (n=5 mice per group) *P < 0.05 and **P < 0.01 (unpaired 
Student’s t-test). Data represent a single experiment.  
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were too variable to be conclusive, but the bacterial burden did appear higher in COX-2-
/- mice (Figure A-3). In the spleens, COX-2-/- mice failed to control bacterial growth at 
both time points and burden was significantly increased.  Other than bacterial burden, 
we identified no other differences between WT and COX-2-/- mice. COX-2-/- mice had 
comparable numbers of B, CD4+ T, and CD8+ T cells at both time points (data not 
shown). These data are the first to suggest COX-2 is required to control bacterial growth 
during tuberculosis, but provide few clues regarding the mechanism of this control.  
Because COX-2 can be induced in nearly every cell type, we next determined if 
the enhanced susceptibility of COX-2-/- mice results from a loss of prostanoid production 
by hematopoietic cells. Bone marrow chimeras were made by transferring either WT or 
COX-2-/- bone marrow into lethally irradiated B6;129 F2 recipients. To assess 
susceptibility, chimeras were infected via intravenous injection, as this model of 
infection typically shortens the amount of time required to observe a survival phenotype. 
Surprisingly, COX-2-/- chimeras were actually more resistant to both low and high 
intravenous doses of virulent Mtb (Figure A-4). Bacterial burden was assessed in bone 
marrow chimeras three weeks after IV infection with a low inoculum (Day 1 = 70,000 
CFU/spleen). At this time point, COX-2-/- bone marrow chimeras had significantly 
reduced bacterial burdens in the lungs and spleen (Figure A-5). It is likely that IV 
infection induces greater inflammation, and these data lead us to hypothesize that the 
loss of hematopoietic COX-2 reduced inflammation and prolonged survival during IV 
infection.  In support of this, lung histology showed fewer infiltrating polymorphonuclear 
cells in the COX-2-/- chimeras (Figure A-6A), and flow cytometry confirmed the presence 
of fewer neutrophils in the lungs when hematopoietc COX-2 was absent (Figure A-6B).  
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Figure A-4. Mice lacking hematopoietic COX-2 are more resistant to IV 
infection. 
 
Survival of WT and COX-2-/- bone marrow chimeras following IV infection with the 
indicated inocula of Mtb (Erdman strain). All recipient mice are WT B6;129 (n=5 mice 
per group). Data are representative of two independent experiments. For IV 
infections, day 1 CFU was assessed in the spleen. 
 
Figure A-5. Following IV infection, mice lacking hematopoietic COX-2 have 
reduced bacterial burdens. 
 
Bacterial burden in the lungs and spleens of WT and COX-2-/- bone marrow chimeras 
(B6;129 background) following IV infection (Day 1 = 70,000 CFU/Spleen) Each point 
represents a single mouse and lines represent the mean (n=5 mice per group) *P < 
0.05 and **P < 0.01 (unpaired Student’s t-test). Data represent a single experiment.  
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Figure A-6. Mice lacking hematopoietic COX-2 have reduced inflammation in 
the lungs following IV infection.  
 
All data are from the indicated bone marrow chimeras 3 weeks after IV infection (Day 
1 = 70,000 CFU/Spleen).  (A) Representative H&E staining in the lungs of the 
indicated bone marrow chimeras. (B) Total number of neutrophils in the lungs 
(neutrophils are defined as F4/80- CD11b+ Gr1hi cells). Total amounts of IFN-γ (C), 
TNF (D) and IL-1β (E) in the lung cell-free homogenates as determined by ELISA. 
Each point represents a single mouse and lines represent the mean (n=5 mice per 
group)  *P < 0.05 (unpaired Student’s t-test). Dashed lines represent the limit of 
detection for the ELISAs. Data represent a single experiment.  
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Furthermore, cell-free lung homogenate from COX-2-/- chimeras had significantly 
reduced levels of IFN-γ and IL-1β (Figure A-6C and A-6E). Collectively, these data 
suggest COX-2-/- chimeras incur less inflammation during IV infection, thus a decrease 
in immunopathology likely contributes to their survival advantage in this model.  
The mixed genetic background (B6;129) of the COX-2-/- mice presents a unique 
challenge when working with these animals, as it is well established that mouse strains 
differ in their relative susceptibility to Mtb (33). The C57BL/6J (B6) strain is resistant to 
Mtb infection, while the 129 strain is generally considered more susceptible. Thus, the 
susceptibility of the B6;129 F2 mice was likely variable in our experiments. Indeed, 
variability was often high with these mice, leading us to conclude it was not a viable 
model to continue studying the role of COX-2 during infection. Still, these experiments 
generated several important observations. First, COX-2, but not COX-1, appears to be 
essential for resistance to tuberculosis. Second, studies with the IV infection model 
highlight the importance of hematopoietic COX-2 during inflammation. COX-2 is 
required for resistance, but it can also augment damaging inflammation under certain 
settings (34). Finally, these studies illustrate that IV and aerosol infections can have 
different outcomes, and suggest using caution when comparing these two models.  
 
COX-2 is required for host resistance to tuberculosis 
Fortunately, we were able to obtain COX-2-/- mice backcrossed 10 generations to 
a BALB/c background (35). BALB/c mice are resistant to tuberculosis, thus these mice 
are more suitable to assess COX-2 function.  Following aerosol infection, BALB/c COX-
2-/- mice are more susceptible that WT controls and have a median survival of ~57 days 
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(Figure A-7). This survival phonotype is less dramatic than that of B6;129 mice, but 
nonetheless implicates COX-2 is an important mediator of host resistance. Previous 
studies noted that mice heterozygous for the COX-2 null allele produce intermediate 
amounts of PGE2 in response to stimulation (36). To test for a possible gene dosage 
effect, the survival of heterozygous mice (COX-2+/-) was monitored, but no phenotype 
was noted (data not shown). Given that COX-2-/- is an immediate early gene, we 
reasoned that it plays an important role in the initial innate immune response to Mtb. 
Thus, we hypothesized that unrestricted bacterial growth was leading to the early 
demise of the COX-2-/- mice. Four weeks after infection, bacterial burden was 
comparable in WT mice and groups of mice homozygous and heterozygous for the 
COX-2 null allele (Figure A-8). These data indicate that COX-2-/- mice control bacterial 
growth at early time points, despite being less resistant to disease. 
With the B6;129 mice, we serendipitously noted that COX-2-/- mice survive 
infection with a very low inoculum, but fail to control bacterial growth at later time points. 
In a similar experiment, we infected WT and COX-2-/- BALB/c mice with approximately 5 
CFU of Mtb (Erdman strain). At this low dose, COX-2-/- BALB/c mice survived for at 
least 12 weeks and exhibited no overt signs of illness. At week 12, COX-2-/- mice had 
significantly higher amounts of bacteria in their lungs and spleens (Figure A-9). Though 
COX-2-/- mice control early bacterial replication, it appears that they fail to restrict 
bacterial growth at later time points during chronic disease.   
In an effort to confirm this finding, COX-2-/- mice were infected with the standard 
dose of Mtb (100-200 CFU), and survival was closely monitored. We reasoned that 
increased bacterial growth directly precedes the demise of the mice, and waited until  
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Figure A-7. COX-2 is required for resistance to tuberculosis. 
 
Survival of WT and COX-2-/- BALB/c mice following low dose aerosol infection with 
Mtb (Erdman strain). Data are combined from four independent experiments. Median 
survival is 57 days for COX-2-/- mice and 298 days for WT mice (p < 0.0001). n= 21-
33 mice per group.  
Figure A-8. COX-2 is not required to control bacterial growth at early time 
points. 
 
Bacterial burden in the lungs and spleens of WT, COX-2+/-, and COX-2-/- mice 
(BALB/c background) following low dose aerosol infection. Each point represents a 
single mouse and lines represent the mean (n=5-6 mice per group). Data are 
representative of two independent experiments.  
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Figure A-9. At a lower inoculum, COX-2-/- mice survive following aerosol 
infection, but fail to control bacterial growth. 
 
Bacterial burden in the lungs and spleens of WT and COX-2-/- mice (BALB/c 
background) following extremely low dose aerosol infection (5 CFU). Each point 
represents a single mouse and lines represent the mean (n=5-9 mice per group).  
***P < 0.001 and ****P < 0.0001 (unpaired Student’s t-test). Data represent a single 
experiment.  
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the COX-2-/- group started to succumb to disease. (Figure A-10). At week 9, the mice 
were sacrificed and bacterial burden was assessed. The data indicate that a subset of 
COX-2-/- mice had increased bacterial burden in the lungs, though this was not uniform 
throughout the COX-2-/- group (Figure A-10). We interpret these data to indicate 
bacterial burden precedes host demise in the COX-2-/- mice. Because COX-2-/- mice 
succumb to disease at different rates, it is challenging to capture a window of time in 
which the entire group of COX-2-/- mice have increased bacterial burden. It should also 
be noted that the immune response in COX-2-/- mice was monitored at every time point. 
No difference in the numbers of neutrophils, B cells, CD4+ T cells, or CD8+ T cells was 
ever noted (data not shown).  
 
COX-2 expression is required in both hematopoietic and nonhematopoietic cells to 
mediate resistance to tuberculosis. 
 Because we observed no overt immunological phenotype in infected COX-2-/- 
mice, we hypothesized that COX-2 expression in nonhematopoietic cells may be 
involved in host resistance. To identify the COX-2-expressing cells mediating 
resistance, bone marrow chimeras were generated using BALB/c COX-2-/- mice. As an 
initial assessment, WT and COX-2-/- bone marrow was transferred into lethally irradiated 
WT recipients. Four weeks after infection, these two groups of bone marrow chimeras 
had comparable bacterial burden in the lungs (data not shown). This finding is 
unsurprising given that intact COX-2-/- mice are also comparable to WT controls at week 
four. 
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Figure A-10. Moribund COX-2-/- mice fail to control bacterial growth. 
 
(Top) Survival analysis of the mice used for this experiment. Mice were sacrificed at 
week 9 to assess bacterial burden. This time point was chosen, because animals 
were beginning to succumb to disease. Bacterial burden in the lungs and spleens of 
WT and COX-2-/- mice (BALB/c background) at week 9 following low dose aerosol 
infection. Each point represents a single mouse and lines represent the mean (n=5-
10 mice per group). Data represent a single experiment.  
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 We next generated multiple combinations of bone marrow chimeras: WT bone 
marrow into WT recipients; WT bone marrow into COX-2-/- recipients; COX-2-/- bone 
marrow into WT recipients; and COX-2-/- bone marrow into COX-2-/- recipients. These 
mice were infected via the aerosol route and monitored for survival. COX-2-/- mice 
reconstituted with COX-2-/- bone marrow were the first to succumb and had a median 
survival comparable to intact COX-2-/- mice (Figure A-11). This observation confirmed 
that the process of generating bone marrow chimeras does not dramatically alter the 
susceptibility of these mice. It also indicates that COX-2 expression is required in both 
hematopoietic and nonhematopoietic cells for optimal resistance to tuberculosis. Over 
the course of the experiments, WT recipient mice survived regardless of the donor bone 
marrow received (Figure A-11). Intriguingly, COX-2-/- mice reconstituted with WT bone 
marrow had significantly decreased survival, suggesting non-hematopoietic COX-2 
expression is important for resistance (Figure A-11). 
 At week 15, the surviving bone marrow chimeras were sacrificed and lung 
pathology was assessed. In WT into WT chimeras, lung pathology was minimal and 
consisted mainly of small diffuse myeloid lesions.  In both KO into WT and WT into KO 
chimeras, a significantly larger area of lung tissue was occupied with large diffuse 
myeloid lesions and there were notable areas of necrosis (Figure A-12). Thus, mice 
lacking COX-2 in either hematopoietic or nonhematopoietic cells had significantly worse 
lung pathology. In addition to increased lung pathology, these two groups of chimeras 
had increased bacterial burdens in the lungs at week 15 (Figure A-12). Ultimately, these 
data show that both hematopoietic and nonhematopoietic cells have a role in mediating 
resistance to tuberculosis.  
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Figure A-11. Nonhematopoietic COX-2 mediates resistance to tuberculosis. 
 
Survival of the indicated bone marrow chimeras following low dose aerosol infection 
with Mtb (Erdman strain). Data are combined from three independent experiments. 
Each experiment was terminated by day 110. n= 10-20 mice per group.  
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Figure A-12. COX-2 expression is required in both hematopoietic and non-
hematopoietic cells to control bacterial growth and limit immunopathology.  
 
All data are from the indicated bone marrow chimeras 15 weeks after low dose 
aerosol infection (Top) Representative H&E staining in the lungs of the indicated 
bone marrow chimeras at 2X magnification. (Bottom) Bacterial burden in the lungs of 
the indicated bone marrow chimeras at week 15. Each point represents a single 
mouse and lines represent the mean (n=3-7 mice per group)  *P < 0.05 (one way 
ANOVA followed by Dunnett’s multiple comparisons test). Data are representative of 
three independent experiments.   
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Discussion 
 PGE2 is protective during tuberculosis through a variety of mechanisms, yet mice 
incapable of generating this molecule are only mildly susceptible to disease. We 
hypothesized that other prostanoids contribute to resistance, and examined mice 
deficient in COX-1 and COX-2. These two enzymes are comparable in their ability to 
convert arachidonic acid to PGH2, the precursor of all prostanoids; however, they differ 
considerably in terms of their regulation. COX-1 is constitutively expressed in most cells 
and is generally associated with maintaining homeostatic prostanoid production (3). 
Conversely, COX-2 is rapidly induced following many forms of stress or activation, 
including infection. Based on our initial studies with B6;129 mice, COX-1 appears 
dispensable during tuberculosis, but COX-2 is essential to host resistance. This finding 
has since been replicated in several models. We confirmed the necessity of COX-2 
using knockout mice backcrossed to the resistant BALB/c background, and there is also 
recently published data that supports these findings. Mice carrying a mutation that 
partially inactivates the enzymatic activity of COX-2 also succumb early to aerosol 
infection (31).  Combined, these data provide compelling evidence for the importance of 
COX-2 during tuberculosis. 
Initially, we hypothesized that the loss of COX-2 would impair the innate immune 
response, increase macrophage necrosis, and lead to unrestricted bacterial growth. 
However, COX-2-/- mice are able to control bacterial growth at early time points, 
suggesting the initial response to the invading bacteria is uncompromised. Thus, COX-2 
is likely mediating susceptibility through mechanisms unrelated to the direct control of 
bacteria growth in macrophages.   
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When infected with a very low inoculum (~5 CFU), both B6;129 and BALB/c 
COX-2-/- mice survive much longer, likely because the progression of disease is slowed.  
These infections allowed us to examine bacterial burden at much later time points than 
normally possible, and indicated that COX-2-/- mice eventually fail to control bacterial 
growth. This leads us to speculate that bacterial burden only increases shortly before 
the mice succumb to disease. Indeed, mice infected with the standard inoculum (100-
200 CFU) show signs of increased burden by week 9 post-infection, a time point when 
COX-2-/- mice are dying. This raises the question of whether increased bacterial growth 
is driving susceptibility in COX-2-/- mice or if increased burden is secondary to some 
other event, possibly increased inflammation. 
Because nearly every cell can express COX-2, we sought to narrow down the 
cell types that required COX-2 to promote resistance. To address this, COX-2 bone 
marrow chimeras were generated with all possible combinations of donors and 
recipients. These chimeras were infected with the standard inoculum and monitored for 
survival up to 110 days post infection. COX-2 expression was required in both 
hematopoietic and nonhematopoietic cells to mediate resistance, and the most 
susceptible mice were COX-2-/- recipients with COX-2-/- bone marrow. Furthermore, 
COX-2-/- recipients with WT bone marrow were significantly susceptible to disease, 
while WT mice with COX-2-/- bone marrow survived for the duration of the experiment. 
These observations indicate nonhematopoietic COX-2 expression is essential for host 
survival. Nonhematopoietic cells such as epithelial cells are known to influence the host 
response to tuberculosis (37,38), thus it possible these cells require COX-2 expression 
to promote resistance.  
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At week 15, we examined the surviving bone marrow chimeras and discovered 
that the loss of COX-2 in either hematopoietic cells or non-hematopoietic cells resulted 
in increased bacterial burden. These mice also had increased immunopathology relative 
to control chimeras. These observations suggest COX-2 expression is vital in a variety 
of cell types during tuberculosis.  Additionally, eliminating COX-2 expression in only 
hematopoietic or nonhematopoietic cells increased survival time and allowed us to 
examine much later time points than previously possible. In the end, the week 15 results 
with the bone marrow chimeras were the most consistent and provided the clearest 
differences from WT controls.  
Overall, it appears that immunopathology and bacterial burden are increased 
when COX-2 is absent from either hematopoietic or nonhematopoietic cells. The 
question is whether immunopathology is driving bacterial growth. Based on the data, we 
cannot be certain, but it is intriguing that COX-2-/- mice control bacterial growth during 
the early stages of infection. Because bacterial growth can be controlled in the absence 
of COX-2, we favor the hypothesis that increased immunopathology underpins the 
increased susceptibility of these mice. Prostanoids can have a variety of anti-
inflammatory effects (39), so it is conceivable that they regulate inflammatory responses 
during chronic infection. Additionally, the inhibition of COX-2 can shuttle arachidonic 
acid into pathways generating leuktrienes (40), thus it is possible that the absence of 
COX-2 leads to the accumulation of pro-inflammatory lipid mediators.  Therefore, we 
hypothesize COX-2 expression is required during chronic infection to mediate 
inflammation.  
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Materials and Methods 
 
Mice  
BALB/c (WT),	  B6129SF2/J (WT), COX-1-/- (B6;129S6-Ptgs1tm1Fun/J), and COX-2-
/- (B6;129S-Ptgs2tm1Jed/J) mice were purchased from Jackson Laboratories (Bar Harbor, 
ME). COX-2-/- mice backcrossed on the BALB/c background for 10 generations were 
obtained from Laura Fredenberg (35). Mice were 6 to 10 weeks old at the start of all 
experiments. All animal experiments were performed in accordance with National and 
European Commission guidelines for the care and handling of laboratory animals and 
were approved by the National Veterinary Directorate and by the local Animal Ethical 
Committee or Institutional Animal Care and Use Committee (Animal Welfare Assurance 
no. A3023-01 [DFCI] or A3306-01 [UMMS]), under Public Health Service assurance of 
Office of Laboratory Animal Welfare guidelines). Mice infected with M. tuberculosis were 
housed in a biosafety level 3 facility under specific pathogen-free conditions at DFCI or 
at UMMS. 
 
Generation of mouse bone marrow chimeras 
Bone barrow chimeras were made by lethally irradiating recipients (2 doses of 
500 rads separated by three hours). Bone marrow was flushed from the femurs, tibia, 
and humeri of donor mice and RBC lysed. Each recipient mouse received a total of 107 
bone marrow cells via lateral tail vein injection and was kept on antibiotic-treated water 
for 5 weeks. Bone marrow chimeras were infected with Mtb 10 weeks after transfer of 
the bone marrow cells.  
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Experimental infection and bacterial quantification 
Infection with M. tuberculosis (Erdman strain) was performed via the aerosol 
route, and mice received a day 1 inoculum of 100-200 CFU unless otherwise indicated. 
A bacterial aliquot was thawed, sonicated twice for 10 seconds in a cup horn sonicator, 
and then diluted in 0.9% NaCl–0.02% Tween 80. A 15 ml suspension of M. tuberculosis 
was loaded into a nebulizer (MiniHEART nebulizer; Vortran Medical Technologies) and 
mice were infected using a nose-only exposure unit (Intox Products). Alternatively, the 
bacterial aliquot was diluted in a final volume of 5ml, and mice were infected using a 
Glas-Col aerosol-generation device. At different times post-infection, mice were 
euthanized by carbon dioxide inhalation, organs were aseptically removed, individually 
homogenized and viable bacteria were enumerated by plating 10-fold serial dilutions of 
organ homogenates onto 7H11 agar plates. Plates were incubated at 37ºC and M. 
tuberculosis colonies were counted after 21 days. For intravenous infections, bacteria 
were prepared similarly and injected via the lateral tail vein. The inoculum was 
assessed by plating the spleens of control mice 24 hours after injection.  
 
Tissue histopathology 
Lung tissues were fixed in 10% zinc formalin and embedded in paraffin. Sections 
5 µm thick were stained with hematoxylin and eosin. Images were obtained using a 
microscope (DMLB; Leica) and a digital camera (DFC420; Leica). The images were 
adjusted and assembled in Photoshop (Adobe). 
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Cytokine measurements 
Infected or naive lungs were perfused with 10 ml of sterile RPMI followed by 
digestion with collagenase. Collagenase-treated cells were passed through a 70-µm cell 
strainer in a total volume of 4 ml PBS 1% FCS according to the protocol of Mayer-
Barber et al. (2010). After centrifugation, 100 µl of the cell-free lung suspensions was 
analyzed by ELISA for IFN-γ, TNF, AND IL-1β (from Biolegend, CA, USA,). Absorbance 
was recorded at 450 nm using an ELISA microplate reader (VersaMac; Molecular 
Devices). 
 
FACS analysis 
Cell suspensions from lung, spleen and lymph nodes were prepared by gentle 
disruption of the organs through a 70µm nylon strainer (Fisher) or using the GentleMacs 
apparatus (Miltenyi Biotec, Germany) according to the manufacturer instructions. For 
lung preparations, tissue was digested for 30-60 min at 37°C in cRPMI with 300U/ml 
collagenase (Sigma) prior to straining. Erythrocytes were lysed using a hemolytic 
solution (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM sodium EDTA pH 7.2) and, after 
washing, cells were resuspended in supplemented RPMI (cRPMI - 10% heat inactivated 
FCS, 10 mM HEPES, 1 mM sodium pyruvate, 2 mM L-glutamine, 50 mg/ml 
streptomycin and 50 U/ml penicillin, all from Invitrogen) or MACS buffer (Miltenyi Biotec, 
Germany). Cells were enumerated in 4% trypan blue on a hemocytometer or using a 
MACSQuant flow cytometer (Miltenyi Biotec, Germany). Surface staining was 
performed with antibodies specific for mouse CD3 (clone 17A2), CD3ε (clone 145-
2C11) CD4 (clone GK1.5), CD8 (clone 53-6.7), CD11b (clone M1/70), CD19 (clone 
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6D5), Gr1 (RB6-8C5), and F4/80 (BM8), (from Biolegend, CA, USA, or from BD 
Pharmingen, CA, USA). All staining was performed for 20 min at 4°C and, unless 
otherwise stated, cells were fixed before acquisition with 1% formaldehyde in PBS for 
30-60 min. Cell analysis was performed on a FACS Canto (Becton Dickinson, NJ, USA) 
or on a MACSQuant flow cytometer (Miltenyi Biotec, Germany). Data were analyzed 
using FlowJo Software (Tree Star, OR, USA). For FACS analysis, single-lymphocyte 
events were gated by forward scatter versus height and side scatter for size and 
granularity. 
 
Statistical analysis 
  All data are represented as mean with SEM. All comparisons of two groups were 
done with an unpaired student’s t-test and are indicated in the figure legends. 
Comparisons of more than 2 groups were done by one way ANOVA followed by 
Dunnett’s multiple comparisons. The log-rank (Mantel-Cox) test was used for statistical 
analysis for survival experiments. Significance was represented by the following 
symbols: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.  
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